<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE eSummaryResult PUBLIC "-//NLM//DTD eSummaryResult, 29 October 2004//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/eSummary_041029.dtd">
<eSummaryResult>
<DocSum>
	<Id>20113659</Id>
	<Item Name="PubDate" Type="Date">2009 Nov</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Zhongguo Dang Dai Er Ke Za Zhi</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">He MJ</Item>
		<Item Name="Author" Type="String">Chen Q</Item>
		<Item Name="Author" Type="String">Liu JM</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Liu JM</Item>
	<Item Name="Title" Type="String">[Urinary leukotrience E(4) level in children with asthma].</Item>
	<Item Name="Volume" Type="String">11</Item>
	<Item Name="Issue" Type="String">11</Item>
	<Item Name="Pages" Type="String">909-12</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">Chinese</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">100909956</Item>
	<Item Name="ISSN" Type="String">1008-8830</Item>
	<Item Name="ESSN" Type="String"></Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">1008-8830(2009)11-0909-04</Item>
		<Item Name="pubmed" Type="String">20113659</Item>
		<Item Name="eid" Type="String">20113659</Item>
		<Item Name="rid" Type="String">20113659</Item>
	</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2010/02/02 06:00</Item>
		<Item Name="pubmed" Type="Date">2010/02/02 06:00</Item>
		<Item Name="medline" Type="Date">2010/03/03 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics</Item>
	<Item Name="ELocationID" Type="String"></Item>
	<Item Name="SO" Type="String">2009 Nov;11(11):909-12</Item>
</DocSum>

<DocSum>
	<Id>20074456</Id>
	<Item Name="PubDate" Type="Date">2009 Oct-Dec</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Int J Immunopathol Pharmacol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Chiba Y</Item>
		<Item Name="Author" Type="String">Sato S</Item>
		<Item Name="Author" Type="String">Misawa M</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Misawa M</Item>
	<Item Name="Title" Type="String">GGTI-2133, an inhibitor of geranylgeranyltransferase, inhibits infiltration of inflammatory cells into airways in mouse experimental asthma.</Item>
	<Item Name="Volume" Type="String">22</Item>
	<Item Name="Issue" Type="String">4</Item>
	<Item Name="Pages" Type="String">929-35</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">8911335</Item>
	<Item Name="ISSN" Type="String">0394-6320</Item>
	<Item Name="ESSN" Type="String"></Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">8</Item>
		<Item Name="pubmed" Type="String">20074456</Item>
		<Item Name="eid" Type="String">20074456</Item>
		<Item Name="rid" Type="String">20074456</Item>
	</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2010/01/16 06:00</Item>
		<Item Name="pubmed" Type="Date">2010/01/16 06:00</Item>
		<Item Name="medline" Type="Date">2010/03/23 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">2</Item>
	<Item Name="FullJournalName" Type="String">International journal of immunopathology and pharmacology</Item>
	<Item Name="ELocationID" Type="String"></Item>
	<Item Name="SO" Type="String">2009 Oct-Dec;22(4):929-35</Item>
</DocSum>

<DocSum>
	<Id>20046412</Id>
	<Item Name="PubDate" Type="Date">2009 Dec 31</Item>
	<Item Name="EPubDate" Type="Date">2009 Dec 18</Item>
	<Item Name="Source" Type="String">Yonsei Med J</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Palikhe NS</Item>
		<Item Name="Author" Type="String">Kim JH</Item>
		<Item Name="Author" Type="String">Park HS</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Park HS</Item>
	<Item Name="Title" Type="String">Update on recent advances in the management of aspirin exacerbated respiratory disease.</Item>
	<Item Name="Volume" Type="String">50</Item>
	<Item Name="Issue" Type="String">6</Item>
	<Item Name="Pages" Type="String">744-50</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">0414003</Item>
	<Item Name="ISSN" Type="String">0513-5796</Item>
	<Item Name="ESSN" Type="String">1976-2437</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Review</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="doi" Type="String">10.3349/ymj.2009.50.6.744</Item>
		<Item Name="pubmed" Type="String">20046412</Item>
		<Item Name="pmc" Type="String">PMC2796398</Item>
		<Item Name="eid" Type="String">20046412</Item>
		<Item Name="rid" Type="String">20046412</Item>
		<Item Name="pmcid" Type="String">pmc-id: PMC2796398;</Item>
	</Item>
	<Item Name="DOI" Type="String">10.3349/ymj.2009.50.6.744</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2009/10/16 00:00</Item>
		<Item Name="epublish" Type="Date">2009/12/18 00:00</Item>
		<Item Name="entrez" Type="Date">2010/01/05 06:00</Item>
		<Item Name="pubmed" Type="Date">2010/01/05 06:00</Item>
		<Item Name="medline" Type="Date">2010/04/03 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">5</Item>
	<Item Name="FullJournalName" Type="String">Yonsei medical journal</Item>
	<Item Name="ELocationID" Type="String">doi: 10.3349/ymj.2009.50.6.744</Item>
	<Item Name="SO" Type="String">2009 Dec 31;50(6):744-50</Item>
</DocSum>

<DocSum>
	<Id>20021457</Id>
	<Item Name="PubDate" Type="Date">2009 Jun</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Curr Mol Pharmacol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Mortaz E</Item>
		<Item Name="Author" Type="String">Engels F</Item>
		<Item Name="Author" Type="String">Nijkamp FP</Item>
		<Item Name="Author" Type="String">Redegeld FA</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Redegeld FA</Item>
	<Item Name="Title" Type="String">New insights on the possible role of mast cells in aspirin-induced asthma.</Item>
	<Item Name="Volume" Type="String">2</Item>
	<Item Name="Issue" Type="String">2</Item>
	<Item Name="Pages" Type="String">182-9</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">101467997</Item>
	<Item Name="ISSN" Type="String">1874-4672</Item>
	<Item Name="ESSN" Type="String">1874-4702</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Review</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pubmed" Type="String">20021457</Item>
		<Item Name="eid" Type="String">20021457</Item>
		<Item Name="rid" Type="String">20021457</Item>
	</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/12/22 06:00</Item>
		<Item Name="pubmed" Type="Date">2009/12/22 06:00</Item>
		<Item Name="medline" Type="Date">2010/02/25 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Current molecular pharmacology</Item>
	<Item Name="ELocationID" Type="String"></Item>
	<Item Name="SO" Type="String">2009 Jun;2(2):182-9</Item>
</DocSum>

<DocSum>
	<Id>20008883</Id>
	<Item Name="PubDate" Type="Date">2009 Dec</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Proc Am Thorac Soc</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">O'Byrne PM</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">O'Byrne PM</Item>
	<Item Name="Title" Type="String">Obstructive lung disease from conception to old age: differences in the treatment of adults and children with asthma.</Item>
	<Item Name="Volume" Type="String">6</Item>
	<Item Name="Issue" Type="String">8</Item>
	<Item Name="Pages" Type="String">720-3</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">101203596</Item>
	<Item Name="ISSN" Type="String">1546-3222</Item>
	<Item Name="ESSN" Type="String">1943-5665</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Review</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">6/8/720</Item>
		<Item Name="doi" Type="String">10.1513/pats.200907-059DP</Item>
		<Item Name="pubmed" Type="String">20008883</Item>
		<Item Name="eid" Type="String">20008883</Item>
		<Item Name="rid" Type="String">20008883</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1513/pats.200907-059DP</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/12/17 06:00</Item>
		<Item Name="pubmed" Type="Date">2009/12/17 06:00</Item>
		<Item Name="medline" Type="Date">2010/03/20 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Proceedings of the American Thoracic Society</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1513/pats.200907-059DP</Item>
	<Item Name="SO" Type="String">2009 Dec;6(8):720-3</Item>
</DocSum>

<DocSum>
	<Id>20008181</Id>
	<Item Name="PubDate" Type="Date">2009</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Hematology Am Soc Hematol Educ Program</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Field JJ</Item>
		<Item Name="Author" Type="String">DeBaun MR</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">DeBaun MR</Item>
	<Item Name="Title" Type="String">Asthma and sickle cell disease: two distinct diseases or part of the same process?</Item>
	<Item Name="Volume" Type="String"></Item>
	<Item Name="Issue" Type="String"></Item>
	<Item Name="Pages" Type="String">45-53</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">100890099</Item>
	<Item Name="ISSN" Type="String">1520-4391</Item>
	<Item Name="ESSN" Type="String">1520-4383</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Review</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">2009/1/45</Item>
		<Item Name="doi" Type="String">10.1182/asheducation-2009.1.45</Item>
		<Item Name="pubmed" Type="String">20008181</Item>
		<Item Name="eid" Type="String">20008181</Item>
		<Item Name="rid" Type="String">20008181</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1182/asheducation-2009.1.45</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/12/17 06:00</Item>
		<Item Name="pubmed" Type="Date">2009/12/17 06:00</Item>
		<Item Name="medline" Type="Date">2010/03/17 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">7</Item>
	<Item Name="FullJournalName" Type="String">Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1182/asheducation-2009.1.45</Item>
	<Item Name="SO" Type="String">2009;:45-53</Item>
</DocSum>

<DocSum>
	<Id>19912318</Id>
	<Item Name="PubDate" Type="Date">2010 Feb</Item>
	<Item Name="EPubDate" Type="Date">2009 Nov 12</Item>
	<Item Name="Source" Type="String">Eur J Clin Invest</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Papaioannou AI</Item>
		<Item Name="Author" Type="String">Koutsokera A</Item>
		<Item Name="Author" Type="String">Tanou K</Item>
		<Item Name="Author" Type="String">Kiropoulos TS</Item>
		<Item Name="Author" Type="String">Tsilioni I</Item>
		<Item Name="Author" Type="String">Oikonomidi S</Item>
		<Item Name="Author" Type="String">Liadaki K</Item>
		<Item Name="Author" Type="String">Pournaras S</Item>
		<Item Name="Author" Type="String">Gourgoulianis KI</Item>
		<Item Name="Author" Type="String">Kostikas K</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Kostikas K</Item>
	<Item Name="Title" Type="String">The acute effect of smoking in healthy and asthmatic smokers.</Item>
	<Item Name="Volume" Type="String">40</Item>
	<Item Name="Issue" Type="String">2</Item>
	<Item Name="Pages" Type="String">103-9</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">0245331</Item>
	<Item Name="ISSN" Type="String">0014-2972</Item>
	<Item Name="ESSN" Type="String">1365-2362</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">ECI2221</Item>
		<Item Name="doi" Type="String">10.1111/j.1365-2362.2009.02221.x</Item>
		<Item Name="pubmed" Type="String">19912318</Item>
		<Item Name="eid" Type="String">19912318</Item>
		<Item Name="rid" Type="String">19912318</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1111/j.1365-2362.2009.02221.x</Item>
	<Item Name="History" Type="List">
		<Item Name="aheadofprint" Type="Date">2009/11/12 00:00</Item>
		<Item Name="entrez" Type="Date">2009/11/17 06:00</Item>
		<Item Name="pubmed" Type="Date">2009/11/17 06:00</Item>
		<Item Name="medline" Type="Date">2010/05/12 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">1</Item>
	<Item Name="FullJournalName" Type="String">European journal of clinical investigation</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1111/j.1365-2362.2009.02221.x</Item>
	<Item Name="SO" Type="String">2010 Feb;40(2):103-9</Item>
</DocSum>

<DocSum>
	<Id>19897276</Id>
	<Item Name="PubDate" Type="Date">2010 Jul</Item>
	<Item Name="EPubDate" Type="Date">2009 Nov 7</Item>
	<Item Name="Source" Type="String">Immunobiology</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Mehta AK</Item>
		<Item Name="Author" Type="String">Singh BP</Item>
		<Item Name="Author" Type="String">Arora N</Item>
		<Item Name="Author" Type="String">Gaur SN</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Gaur SN</Item>
	<Item Name="Title" Type="String">Choline attenuates immune inflammation and suppresses oxidative stress in patients with asthma.</Item>
	<Item Name="Volume" Type="String">215</Item>
	<Item Name="Issue" Type="String">7</Item>
	<Item Name="Pages" Type="String">527-34</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">8002742</Item>
	<Item Name="ISSN" Type="String">0171-2985</Item>
	<Item Name="ESSN" Type="String">1878-3279</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">S0171-2985(09)00152-1</Item>
		<Item Name="doi" Type="String">10.1016/j.imbio.2009.09.004</Item>
		<Item Name="pubmed" Type="String">19897276</Item>
		<Item Name="eid" Type="String">19897276</Item>
		<Item Name="rid" Type="String">19897276</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/j.imbio.2009.09.004</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2009/08/13 00:00</Item>
		<Item Name="accepted" Type="Date">2009/09/10 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2009/11/07 00:00</Item>
		<Item Name="entrez" Type="Date">2009/11/10 06:00</Item>
		<Item Name="pubmed" Type="Date">2009/11/10 06:00</Item>
		<Item Name="medline" Type="Date">2010/11/04 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Immunobiology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/j.imbio.2009.09.004</Item>
	<Item Name="SO" Type="String">2010 Jul;215(7):527-34</Item>
</DocSum>

<DocSum>
	<Id>19895589</Id>
	<Item Name="PubDate" Type="Date">2010 Jan</Item>
	<Item Name="EPubDate" Type="Date">2009 Nov 4</Item>
	<Item Name="Source" Type="String">Clin Exp Allergy</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Aggarwal S</Item>
		<Item Name="Author" Type="String">Moodley YP</Item>
		<Item Name="Author" Type="String">Thompson PJ</Item>
		<Item Name="Author" Type="String">Misso NL</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Misso NL</Item>
	<Item Name="Title" Type="String">Prostaglandin E2 and cysteinyl leukotriene concentrations in sputum: association with asthma severity and eosinophilic inflammation.</Item>
	<Item Name="Volume" Type="String">40</Item>
	<Item Name="Issue" Type="String">1</Item>
	<Item Name="Pages" Type="String">85-93</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">8906443</Item>
	<Item Name="ISSN" Type="String">0954-7894</Item>
	<Item Name="ESSN" Type="String">1365-2222</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">CEA3386</Item>
		<Item Name="doi" Type="String">10.1111/j.1365-2222.2009.03386.x</Item>
		<Item Name="pubmed" Type="String">19895589</Item>
		<Item Name="eid" Type="String">19895589</Item>
		<Item Name="rid" Type="String">19895589</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1111/j.1365-2222.2009.03386.x</Item>
	<Item Name="History" Type="List">
		<Item Name="aheadofprint" Type="Date">2009/11/04 00:00</Item>
		<Item Name="entrez" Type="Date">2009/11/10 06:00</Item>
		<Item Name="pubmed" Type="Date">2009/11/10 06:00</Item>
		<Item Name="medline" Type="Date">2010/06/19 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">7</Item>
	<Item Name="FullJournalName" Type="String">Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1111/j.1365-2222.2009.03386.x</Item>
	<Item Name="SO" Type="String">2010 Jan;40(1):85-93</Item>
</DocSum>

<DocSum>
	<Id>19894390</Id>
	<Item Name="PubDate" Type="Date">2009 Sep</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">J Tradit Chin Med</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Li XH</Item>
		<Item Name="Author" Type="String">Tu XY</Item>
		<Item Name="Author" Type="String">Zhang DX</Item>
		<Item Name="Author" Type="String">Xu JF</Item>
		<Item Name="Author" Type="String">Wang WY</Item>
		<Item Name="Author" Type="String">Zhang Y</Item>
		<Item Name="Author" Type="String">Du YM</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Du YM</Item>
	<Item Name="Title" Type="String">Effects of wuwei dilong decoction on inflammatory cells and cytokines in asthma model guinea pigs.</Item>
	<Item Name="Volume" Type="String">29</Item>
	<Item Name="Issue" Type="String">3</Item>
	<Item Name="Pages" Type="String">220-3</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">8211546</Item>
	<Item Name="ISSN" Type="String">0255-2922</Item>
	<Item Name="ESSN" Type="String"></Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pubmed" Type="String">19894390</Item>
		<Item Name="eid" Type="String">19894390</Item>
		<Item Name="rid" Type="String">19894390</Item>
	</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/11/10 06:00</Item>
		<Item Name="pubmed" Type="Date">2009/11/10 06:00</Item>
		<Item Name="medline" Type="Date">2010/01/12 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan / sponsored by All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine</Item>
	<Item Name="ELocationID" Type="String"></Item>
	<Item Name="SO" Type="String">2009 Sep;29(3):220-3</Item>
</DocSum>

<DocSum>
	<Id>19852204</Id>
	<Item Name="PubDate" Type="Date">2009 Oct</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Ann Allergy Asthma Immunol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Kim SH</Item>
		<Item Name="Author" Type="String">Yang EM</Item>
		<Item Name="Author" Type="String">Kim SH</Item>
		<Item Name="Author" Type="String">Park HS</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Park HS</Item>
	<Item Name="Title" Type="String">Regulation of monocyte chemoattractant protein 1 by cysteinyl leukotriene D4 in human lung epithelial A549 cells.</Item>
	<Item Name="Volume" Type="String">103</Item>
	<Item Name="Issue" Type="String">4</Item>
	<Item Name="Pages" Type="String">358-9</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9503580</Item>
	<Item Name="ISSN" Type="String">1081-1206</Item>
	<Item Name="ESSN" Type="String">1534-4436</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Letter</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pubmed" Type="String">19852204</Item>
		<Item Name="pii" Type="String">S1081-1206(10)60540-6</Item>
		<Item Name="doi" Type="String">10.1016/S1081-1206(10)60540-6</Item>
		<Item Name="eid" Type="String">19852204</Item>
		<Item Name="rid" Type="String">19852204</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/S1081-1206(10)60540-6</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/10/27 06:00</Item>
		<Item Name="pubmed" Type="Date">2009/10/27 06:00</Item>
		<Item Name="medline" Type="Date">2009/12/16 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">0</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Annals of allergy, asthma &amp; immunology : official publication of the American College of Allergy, Asthma, &amp; Immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/S1081-1206(10)60540-6</Item>
	<Item Name="SO" Type="String">2009 Oct;103(4):358-9</Item>
</DocSum>

<DocSum>
	<Id>19839969</Id>
	<Item Name="PubDate" Type="Date">2010 May</Item>
	<Item Name="EPubDate" Type="Date">2009 Oct 12</Item>
	<Item Name="Source" Type="String">Allergy</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Sanak M</Item>
		<Item Name="Author" Type="String">Bochenek G</Item>
		<Item Name="Author" Type="String">Faber J</Item>
		<Item Name="Author" Type="String">Plutecka H</Item>
		<Item Name="Author" Type="String">Szczeklik A</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Szczeklik A</Item>
	<Item Name="Title" Type="String">Elevated urinary leukotriene E excretion in asthma: a comparison of HPLC-mass spectrometry and ELISA.</Item>
	<Item Name="Volume" Type="String">65</Item>
	<Item Name="Issue" Type="String">5</Item>
	<Item Name="Pages" Type="String">663-4</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">7804028</Item>
	<Item Name="ISSN" Type="String">0105-4538</Item>
	<Item Name="ESSN" Type="String">1398-9995</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">ALL2206</Item>
		<Item Name="doi" Type="String">10.1111/j.1398-9995.2009.02206.x</Item>
		<Item Name="pubmed" Type="String">19839969</Item>
		<Item Name="eid" Type="String">19839969</Item>
		<Item Name="rid" Type="String">19839969</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1111/j.1398-9995.2009.02206.x</Item>
	<Item Name="History" Type="List">
		<Item Name="aheadofprint" Type="Date">2009/10/12 00:00</Item>
		<Item Name="entrez" Type="Date">2009/10/21 06:00</Item>
		<Item Name="pubmed" Type="Date">2009/10/21 06:00</Item>
		<Item Name="medline" Type="Date">2010/08/21 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">0</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Allergy</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1111/j.1398-9995.2009.02206.x</Item>
	<Item Name="SO" Type="String">2010 May;65(5):663-4</Item>
</DocSum>

<DocSum>
	<Id>19811112</Id>
	<Item Name="PubDate" Type="Date">2009 Dec</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Curr Med Res Opin</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Lindemann J</Item>
		<Item Name="Author" Type="String">David Pampe E</Item>
		<Item Name="Author" Type="String">Peterkin JJ</Item>
		<Item Name="Author" Type="String">Orozco-Cronin P</Item>
		<Item Name="Author" Type="String">Belofsky G</Item>
		<Item Name="Author" Type="String">Stull D</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Stull D</Item>
	<Item Name="Title" Type="String">Clinical study of the effects on asthma-related QOL and asthma management of a medical food in adult asthma patients.</Item>
	<Item Name="Volume" Type="String">25</Item>
	<Item Name="Issue" Type="String">12</Item>
	<Item Name="Pages" Type="String">2865-75</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">0351014</Item>
	<Item Name="ISSN" Type="String">0300-7995</Item>
	<Item Name="ESSN" Type="String">1473-4877</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Randomized Controlled Trial</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="doi" Type="String">10.1185/03007990903316491</Item>
		<Item Name="pubmed" Type="String">19811112</Item>
		<Item Name="eid" Type="String">19811112</Item>
		<Item Name="rid" Type="String">19811112</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1185/03007990903316491</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/10/09 06:00</Item>
		<Item Name="pubmed" Type="Date">2009/10/09 06:00</Item>
		<Item Name="medline" Type="Date">2010/02/23 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">1</Item>
	<Item Name="FullJournalName" Type="String">Current medical research and opinion</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1185/03007990903316491</Item>
	<Item Name="SO" Type="String">2009 Dec;25(12):2865-75</Item>
</DocSum>

<DocSum>
	<Id>19757309</Id>
	<Item Name="PubDate" Type="Date">2009 Oct</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Leuk Lymphoma</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Ramanujam D</Item>
		<Item Name="Author" Type="String">McNicholl F</Item>
		<Item Name="Author" Type="String">Furby D</Item>
		<Item Name="Author" Type="String">Richardson D</Item>
		<Item Name="Author" Type="String">Cuthbert RJ</Item>
		<Item Name="Author" Type="String">McMullin MF</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">McMullin MF</Item>
	<Item Name="Title" Type="String">Dramatic resolution of respiratory symptoms with imatinib mesylate in patients with chronic myeloid leukemia presenting with lower airway symptoms resembling asthma.</Item>
	<Item Name="Volume" Type="String">50</Item>
	<Item Name="Issue" Type="String">10</Item>
	<Item Name="Pages" Type="String">1721-2</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9007422</Item>
	<Item Name="ISSN" Type="String">1042-8194</Item>
	<Item Name="ESSN" Type="String">1029-2403</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Letter</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">914995359</Item>
		<Item Name="doi" Type="String">10.1080/10428190903161059</Item>
		<Item Name="pubmed" Type="String">19757309</Item>
		<Item Name="eid" Type="String">19757309</Item>
		<Item Name="rid" Type="String">19757309</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1080/10428190903161059</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/09/17 06:00</Item>
		<Item Name="pubmed" Type="Date">2009/09/17 06:00</Item>
		<Item Name="medline" Type="Date">2010/03/30 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">0</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Leukemia &amp; lymphoma</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1080/10428190903161059</Item>
	<Item Name="SO" Type="String">2009 Oct;50(10):1721-2</Item>
</DocSum>

<DocSum>
	<Id>19749079</Id>
	<Item Name="PubDate" Type="Date">2009 Dec</Item>
	<Item Name="EPubDate" Type="Date">2009 Sep 11</Item>
	<Item Name="Source" Type="String">J Pharmacol Exp Ther</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Lorrain DS</Item>
		<Item Name="Author" Type="String">Bain G</Item>
		<Item Name="Author" Type="String">Correa LD</Item>
		<Item Name="Author" Type="String">Chapman C</Item>
		<Item Name="Author" Type="String">Broadhead AR</Item>
		<Item Name="Author" Type="String">Santini AM</Item>
		<Item Name="Author" Type="String">Prodanovich P</Item>
		<Item Name="Author" Type="String">Darlington JV</Item>
		<Item Name="Author" Type="String">Hutchinson JH</Item>
		<Item Name="Author" Type="String">King C</Item>
		<Item Name="Author" Type="String">Lee C</Item>
		<Item Name="Author" Type="String">Baccei C</Item>
		<Item Name="Author" Type="String">Li Y</Item>
		<Item Name="Author" Type="String">Arruda JM</Item>
		<Item Name="Author" Type="String">Evans JF</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Evans JF</Item>
	<Item Name="Title" Type="String">Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.</Item>
	<Item Name="Volume" Type="String">331</Item>
	<Item Name="Issue" Type="String">3</Item>
	<Item Name="Pages" Type="String">1042-50</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">0376362</Item>
	<Item Name="ISSN" Type="String">0022-3565</Item>
	<Item Name="ESSN" Type="String">1521-0103</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">jpet.109.158089</Item>
		<Item Name="doi" Type="String">10.1124/jpet.109.158089</Item>
		<Item Name="pubmed" Type="String">19749079</Item>
		<Item Name="eid" Type="String">19749079</Item>
		<Item Name="rid" Type="String">19749079</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1124/jpet.109.158089</Item>
	<Item Name="History" Type="List">
		<Item Name="aheadofprint" Type="Date">2009/09/11 00:00</Item>
		<Item Name="entrez" Type="Date">2009/09/15 06:00</Item>
		<Item Name="pubmed" Type="Date">2009/09/15 06:00</Item>
		<Item Name="medline" Type="Date">2009/12/23 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">1</Item>
	<Item Name="FullJournalName" Type="String">The Journal of pharmacology and experimental therapeutics</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1124/jpet.109.158089</Item>
	<Item Name="SO" Type="String">2009 Dec;331(3):1042-50</Item>
</DocSum>

<DocSum>
	<Id>19739647</Id>
	<Item Name="PubDate" Type="Date">2009 Oct 8</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">J Med Chem</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Hutchinson JH</Item>
		<Item Name="Author" Type="String">Li Y</Item>
		<Item Name="Author" Type="String">Arruda JM</Item>
		<Item Name="Author" Type="String">Baccei C</Item>
		<Item Name="Author" Type="String">Bain G</Item>
		<Item Name="Author" Type="String">Chapman C</Item>
		<Item Name="Author" Type="String">Correa L</Item>
		<Item Name="Author" Type="String">Darlington J</Item>
		<Item Name="Author" Type="String">King CD</Item>
		<Item Name="Author" Type="String">Lee C</Item>
		<Item Name="Author" Type="String">Lorrain D</Item>
		<Item Name="Author" Type="String">Prodanovich P</Item>
		<Item Name="Author" Type="String">Rong H</Item>
		<Item Name="Author" Type="String">Santini A</Item>
		<Item Name="Author" Type="String">Stock N</Item>
		<Item Name="Author" Type="String">Prasit P</Item>
		<Item Name="Author" Type="String">Evans JF</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Evans JF</Item>
	<Item Name="Title" Type="String">5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).</Item>
	<Item Name="Volume" Type="String">52</Item>
	<Item Name="Issue" Type="String">19</Item>
	<Item Name="Pages" Type="String">5803-15</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9716531</Item>
	<Item Name="ISSN" Type="String">0022-2623</Item>
	<Item Name="ESSN" Type="String">1520-4804</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="doi" Type="String">10.1021/jm900945d</Item>
		<Item Name="pubmed" Type="String">19739647</Item>
		<Item Name="eid" Type="String">19739647</Item>
		<Item Name="rid" Type="String">19739647</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1021/jm900945d</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/09/11 06:00</Item>
		<Item Name="pubmed" Type="Date">2009/09/11 06:00</Item>
		<Item Name="medline" Type="Date">2009/11/18 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">3</Item>
	<Item Name="FullJournalName" Type="String">Journal of medicinal chemistry</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1021/jm900945d</Item>
	<Item Name="SO" Type="String">2009 Oct 8;52(19):5803-15</Item>
</DocSum>

<DocSum>
	<Id>19706339</Id>
	<Item Name="PubDate" Type="Date">2009 Oct</Item>
	<Item Name="EPubDate" Type="Date">2009 Aug 23</Item>
	<Item Name="Source" Type="String">Int Immunopharmacol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Muraki M</Item>
		<Item Name="Author" Type="String">Imbe S</Item>
		<Item Name="Author" Type="String">Sato R</Item>
		<Item Name="Author" Type="String">Ikeda Y</Item>
		<Item Name="Author" Type="String">Yamagata S</Item>
		<Item Name="Author" Type="String">Iwanaga T</Item>
		<Item Name="Author" Type="String">Tohda Y</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Tohda Y</Item>
	<Item Name="Title" Type="String">Inhaled montelukast inhibits cysteinyl-leukotriene-induced bronchoconstriction in ovalbumin-sensitized guinea-pigs: the potential as a new asthma medication.</Item>
	<Item Name="Volume" Type="String">9</Item>
	<Item Name="Issue" Type="String">11</Item>
	<Item Name="Pages" Type="String">1337-41</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">100965259</Item>
	<Item Name="ISSN" Type="String">1567-5769</Item>
	<Item Name="ESSN" Type="String">1878-1705</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">S1567-5769(09)00248-3</Item>
		<Item Name="doi" Type="String">10.1016/j.intimp.2009.08.007</Item>
		<Item Name="pubmed" Type="String">19706339</Item>
		<Item Name="eid" Type="String">19706339</Item>
		<Item Name="rid" Type="String">19706339</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/j.intimp.2009.08.007</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2009/08/14 00:00</Item>
		<Item Name="accepted" Type="Date">2009/08/14 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2009/08/23 00:00</Item>
		<Item Name="entrez" Type="Date">2009/08/27 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/08/27 09:00</Item>
		<Item Name="medline" Type="Date">2010/01/06 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">1</Item>
	<Item Name="FullJournalName" Type="String">International immunopharmacology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/j.intimp.2009.08.007</Item>
	<Item Name="SO" Type="String">2009 Oct;9(11):1337-41</Item>
</DocSum>

<DocSum>
	<Id>19665766</Id>
	<Item Name="PubDate" Type="Date">2009 Sep</Item>
	<Item Name="EPubDate" Type="Date">2009 Aug 8</Item>
	<Item Name="Source" Type="String">J Allergy Clin Immunol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Tantisira KG</Item>
		<Item Name="Author" Type="String">Drazen JM</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Drazen JM</Item>
	<Item Name="Title" Type="String">Genetics and pharmacogenetics of the leukotriene pathway.</Item>
	<Item Name="Volume" Type="String">124</Item>
	<Item Name="Issue" Type="String">3</Item>
	<Item Name="Pages" Type="String">422-7</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">1275002</Item>
	<Item Name="ISSN" Type="String">0091-6749</Item>
	<Item Name="ESSN" Type="String">1097-6825</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Review</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">S0091-6749(09)00989-0</Item>
		<Item Name="doi" Type="String">10.1016/j.jaci.2009.06.035</Item>
		<Item Name="pubmed" Type="String">19665766</Item>
		<Item Name="pmc" Type="String">PMC2794036</Item>
		<Item Name="mid" Type="String">NIHMS137999</Item>
		<Item Name="eid" Type="String">19665766</Item>
		<Item Name="rid" Type="String">19665766</Item>
		<Item Name="pmcid" Type="String">pmc-id: PMC2794036;manuscript-id: NIHMS137999;</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/j.jaci.2009.06.035</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2009/04/21 00:00</Item>
		<Item Name="revised" Type="Date">2009/06/25 00:00</Item>
		<Item Name="accepted" Type="Date">2009/06/26 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2009/08/08 00:00</Item>
		<Item Name="entrez" Type="Date">2009/08/12 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/08/12 09:00</Item>
		<Item Name="medline" Type="Date">2009/09/29 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">9</Item>
	<Item Name="FullJournalName" Type="String">The Journal of allergy and clinical immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/j.jaci.2009.06.035</Item>
	<Item Name="SO" Type="String">2009 Sep;124(3):422-7</Item>
</DocSum>

<DocSum>
	<Id>19648384</Id>
	<Item Name="PubDate" Type="Date">2009 Aug</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Mayo Clin Proc</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Tan H</Item>
		<Item Name="Author" Type="String">Sarawate C</Item>
		<Item Name="Author" Type="String">Singer J</Item>
		<Item Name="Author" Type="String">Elward K</Item>
		<Item Name="Author" Type="String">Cohen RI</Item>
		<Item Name="Author" Type="String">Smart BA</Item>
		<Item Name="Author" Type="String">Busk MF</Item>
		<Item Name="Author" Type="String">Lustig J</Item>
		<Item Name="Author" Type="String">O'Brien JD</Item>
		<Item Name="Author" Type="String">Schatz M</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Schatz M</Item>
	<Item Name="Title" Type="String">Impact of asthma controller medications on clinical, economic, and patient-reported outcomes.</Item>
	<Item Name="Volume" Type="String">84</Item>
	<Item Name="Issue" Type="String">8</Item>
	<Item Name="Pages" Type="String">675-84</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">0405543</Item>
	<Item Name="ISSN" Type="String">0025-6196</Item>
	<Item Name="ESSN" Type="String">1942-5546</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Evaluation Studies</Item>
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">S0025-6196(11)60517-X</Item>
		<Item Name="doi" Type="String">10.1016/S0025-6196(11)60517-X</Item>
		<Item Name="pubmed" Type="String">19648384</Item>
		<Item Name="pmc" Type="String">PMC2719520</Item>
		<Item Name="eid" Type="String">19648384</Item>
		<Item Name="rid" Type="String">19648384</Item>
		<Item Name="pmcid" Type="String">pmc-id: PMC2719520;</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/S0025-6196(11)60517-X</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/08/04 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/08/04 09:00</Item>
		<Item Name="medline" Type="Date">2009/08/22 09:00</Item>
	</Item>
	<Item Name="References" Type="List">
		<Item Name="Comment in" Type="String">Mayo Clin Proc. 2009 Aug;84(8):673-4. PMID: 19648383</Item>
	</Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">4</Item>
	<Item Name="FullJournalName" Type="String">Mayo Clinic proceedings. Mayo Clinic</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/S0025-6196(11)60517-X</Item>
	<Item Name="SO" Type="String">2009 Aug;84(8):675-84</Item>
</DocSum>

<DocSum>
	<Id>19647860</Id>
	<Item Name="PubDate" Type="Date">2009 Sep</Item>
	<Item Name="EPubDate" Type="Date">2009 Aug 3</Item>
	<Item Name="Source" Type="String">J Allergy Clin Immunol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Austen KF</Item>
		<Item Name="Author" Type="String">Maekawa A</Item>
		<Item Name="Author" Type="String">Kanaoka Y</Item>
		<Item Name="Author" Type="String">Boyce JA</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Boyce JA</Item>
	<Item Name="Title" Type="String">The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications.</Item>
	<Item Name="Volume" Type="String">124</Item>
	<Item Name="Issue" Type="String">3</Item>
	<Item Name="Pages" Type="String">406-14; quiz 415-6</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">1275002</Item>
	<Item Name="ISSN" Type="String">0091-6749</Item>
	<Item Name="ESSN" Type="String">1097-6825</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Review</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">S0091-6749(09)00948-8</Item>
		<Item Name="doi" Type="String">10.1016/j.jaci.2009.05.046</Item>
		<Item Name="pubmed" Type="String">19647860</Item>
		<Item Name="pmc" Type="String">PMC2739263</Item>
		<Item Name="mid" Type="String">NIHMS128013</Item>
		<Item Name="eid" Type="String">19647860</Item>
		<Item Name="rid" Type="String">19647860</Item>
		<Item Name="pmcid" Type="String">pmc-id: PMC2739263;manuscript-id: NIHMS128013;</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/j.jaci.2009.05.046</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2009/04/10 00:00</Item>
		<Item Name="revised" Type="Date">2009/05/06 00:00</Item>
		<Item Name="accepted" Type="Date">2009/05/06 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2009/08/03 00:00</Item>
		<Item Name="entrez" Type="Date">2009/08/04 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/08/04 09:00</Item>
		<Item Name="medline" Type="Date">2009/09/29 06:00</Item>
	</Item>
	<Item Name="References" Type="List">
		<Item Name="Comment in" Type="String">J Allergy Clin Immunol. 2010 Apr;125(4):950-1; author reply 951. PMID: 20226503</Item>
	</Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">13</Item>
	<Item Name="FullJournalName" Type="String">The Journal of allergy and clinical immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/j.jaci.2009.05.046</Item>
	<Item Name="SO" Type="String">2009 Sep;124(3):406-14; quiz 415-6</Item>
</DocSum>

<DocSum>
	<Id>19616537</Id>
	<Item Name="PubDate" Type="Date">2009 Sep 15</Item>
	<Item Name="EPubDate" Type="Date">2009 Jul 17</Item>
	<Item Name="Source" Type="String">Eur J Pharmacol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Hori M</Item>
		<Item Name="Author" Type="String">Iwama T</Item>
		<Item Name="Author" Type="String">Asakura Y</Item>
		<Item Name="Author" Type="String">Kawanishi M</Item>
		<Item Name="Author" Type="String">Kamon J</Item>
		<Item Name="Author" Type="String">Hoshino A</Item>
		<Item Name="Author" Type="String">Takahashi S</Item>
		<Item Name="Author" Type="String">Takahashi K</Item>
		<Item Name="Author" Type="String">Nakaike S</Item>
		<Item Name="Author" Type="String">Tsuruzoe N</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Tsuruzoe N</Item>
	<Item Name="Title" Type="String">NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase 3 inhibitor, suppress the asthmatic response in guinea pigs, with both bronchodilating and anti-inflammatory effects.</Item>
	<Item Name="Volume" Type="String">618</Item>
	<Item Name="Issue" Type="String">1-3</Item>
	<Item Name="Pages" Type="String">63-9</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">1254354</Item>
	<Item Name="ISSN" Type="String">0014-2999</Item>
	<Item Name="ESSN" Type="String">1879-0712</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">S0014-2999(09)00597-4</Item>
		<Item Name="doi" Type="String">10.1016/j.ejphar.2009.07.005</Item>
		<Item Name="pubmed" Type="String">19616537</Item>
		<Item Name="eid" Type="String">19616537</Item>
		<Item Name="rid" Type="String">19616537</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/j.ejphar.2009.07.005</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2009/02/06 00:00</Item>
		<Item Name="revised" Type="Date">2009/06/26 00:00</Item>
		<Item Name="accepted" Type="Date">2009/07/09 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2009/07/17 00:00</Item>
		<Item Name="entrez" Type="Date">2009/07/21 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/07/21 09:00</Item>
		<Item Name="medline" Type="Date">2010/01/06 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">European journal of pharmacology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/j.ejphar.2009.07.005</Item>
	<Item Name="SO" Type="String">2009 Sep 15;618(1-3):63-9</Item>
</DocSum>

<DocSum>
	<Id>19608262</Id>
	<Item Name="PubDate" Type="Date">2009 Sep</Item>
	<Item Name="EPubDate" Type="Date">2009 Jul 16</Item>
	<Item Name="Source" Type="String">J Allergy Clin Immunol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">O'Byrne PM</Item>
		<Item Name="Author" Type="String">Gauvreau GM</Item>
		<Item Name="Author" Type="String">Murphy DM</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Murphy DM</Item>
	<Item Name="Title" Type="String">Efficacy of leukotriene receptor antagonists and synthesis inhibitors in asthma.</Item>
	<Item Name="Volume" Type="String">124</Item>
	<Item Name="Issue" Type="String">3</Item>
	<Item Name="Pages" Type="String">397-403</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">1275002</Item>
	<Item Name="ISSN" Type="String">0091-6749</Item>
	<Item Name="ESSN" Type="String">1097-6825</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">S0091-6749(09)00840-9</Item>
		<Item Name="doi" Type="String">10.1016/j.jaci.2009.05.029</Item>
		<Item Name="pubmed" Type="String">19608262</Item>
		<Item Name="eid" Type="String">19608262</Item>
		<Item Name="rid" Type="String">19608262</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/j.jaci.2009.05.029</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2009/04/27 00:00</Item>
		<Item Name="accepted" Type="Date">2009/05/14 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2009/07/16 00:00</Item>
		<Item Name="entrez" Type="Date">2009/07/18 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/07/18 09:00</Item>
		<Item Name="medline" Type="Date">2009/09/29 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">5</Item>
	<Item Name="FullJournalName" Type="String">The Journal of allergy and clinical immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/j.jaci.2009.05.029</Item>
	<Item Name="SO" Type="String">2009 Sep;124(3):397-403</Item>
</DocSum>

<DocSum>
	<Id>19576119</Id>
	<Item Name="PubDate" Type="Date">2009 Apr</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Zhonghua Nei Ke Za Zhi</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Tan CW</Item>
		<Item Name="Author" Type="String">Liu CT</Item>
		<Item Name="Author" Type="String">Wu YH</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Wu YH</Item>
	<Item Name="Title" Type="String">[The clinical significance of noninvasive inflammatory markers in exhaled breath condensate and induced sputum in persistent asthmatic patients].</Item>
	<Item Name="Volume" Type="String">48</Item>
	<Item Name="Issue" Type="String">4</Item>
	<Item Name="Pages" Type="String">299-303</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">Chinese</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">16210490R</Item>
	<Item Name="ISSN" Type="String">0578-1426</Item>
	<Item Name="ESSN" Type="String"></Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pubmed" Type="String">19576119</Item>
		<Item Name="eid" Type="String">19576119</Item>
		<Item Name="rid" Type="String">19576119</Item>
	</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/07/07 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/07/07 09:00</Item>
		<Item Name="medline" Type="Date">2009/09/04 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Zhonghua nei ke za zhi [Chinese journal of internal medicine]</Item>
	<Item Name="ELocationID" Type="String"></Item>
	<Item Name="SO" Type="String">2009 Apr;48(4):299-303</Item>
</DocSum>

<DocSum>
	<Id>19575935</Id>
	<Item Name="PubDate" Type="Date">2009 Mar</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Zhonghua Jie He He Hu Xi Za Zhi</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Yang HS</Item>
		<Item Name="Author" Type="String">Wang L</Item>
		<Item Name="Author" Type="String">Yang W</Item>
		<Item Name="Author" Type="String">Guan JT</Item>
		<Item Name="Author" Type="String">Ma JY</Item>
		<Item Name="Author" Type="String">Su Y</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Su Y</Item>
	<Item Name="Title" Type="String">[Effects of leukotriene receptor antagonists on vascular endothelial growth factor and its receptors in a sensitized rat model].</Item>
	<Item Name="Volume" Type="String">32</Item>
	<Item Name="Issue" Type="String">3</Item>
	<Item Name="Pages" Type="String">177-81</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">Chinese</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">8712226</Item>
	<Item Name="ISSN" Type="String">1001-0939</Item>
	<Item Name="ESSN" Type="String"></Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pubmed" Type="String">19575935</Item>
		<Item Name="eid" Type="String">19575935</Item>
		<Item Name="rid" Type="String">19575935</Item>
	</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/07/07 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/07/07 09:00</Item>
		<Item Name="medline" Type="Date">2010/08/18 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</Item>
	<Item Name="ELocationID" Type="String"></Item>
	<Item Name="SO" Type="String">2009 Mar;32(3):177-81</Item>
</DocSum>

<DocSum>
	<Id>19562288</Id>
	<Item Name="PubDate" Type="Date">2009</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Wien Klin Wochenschr</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Suskovic S</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Suskovic S</Item>
	<Item Name="Title" Type="String">COPD is not COPD is not allergy.</Item>
	<Item Name="Volume" Type="String">121</Item>
	<Item Name="Issue" Type="String">9-10</Item>
	<Item Name="Pages" Type="String">289-92</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">21620870R</Item>
	<Item Name="ISSN" Type="String">0043-5325</Item>
	<Item Name="ESSN" Type="String">1613-7671</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Editorial</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="doi" Type="String">10.1007/s00508-009-1189-4</Item>
		<Item Name="pubmed" Type="String">19562288</Item>
		<Item Name="eid" Type="String">19562288</Item>
		<Item Name="rid" Type="String">19562288</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1007/s00508-009-1189-4</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/06/30 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/06/30 09:00</Item>
		<Item Name="medline" Type="Date">2009/09/29 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">1</Item>
	<Item Name="FullJournalName" Type="String">Wiener klinische Wochenschrift</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1007/s00508-009-1189-4</Item>
	<Item Name="SO" Type="String">2009;121(9-10):289-92</Item>
</DocSum>

<DocSum>
	<Id>19558806</Id>
	<Item Name="PubDate" Type="Date">2009 Jun</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Zhongguo Dang Dai Er Ke Za Zhi</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Wu JL</Item>
		<Item Name="Author" Type="String">Chen AH</Item>
		<Item Name="Author" Type="String">Peng QY</Item>
		<Item Name="Author" Type="String">Chen RC</Item>
		<Item Name="Author" Type="String">Zhong NS</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Zhong NS</Item>
	<Item Name="Title" Type="String">[Relationship between the efficacy of inhaled corticosteroids and the leukotriene expression in children with asthma].</Item>
	<Item Name="Volume" Type="String">11</Item>
	<Item Name="Issue" Type="String">6</Item>
	<Item Name="Pages" Type="String">441-4</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">Chinese</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">100909956</Item>
	<Item Name="ISSN" Type="String">1008-8830</Item>
	<Item Name="ESSN" Type="String"></Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">1008-8830(2009)06-0441-04</Item>
		<Item Name="pubmed" Type="String">19558806</Item>
		<Item Name="eid" Type="String">19558806</Item>
		<Item Name="rid" Type="String">19558806</Item>
	</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/06/30 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/06/30 09:00</Item>
		<Item Name="medline" Type="Date">2009/08/26 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics</Item>
	<Item Name="ELocationID" Type="String"></Item>
	<Item Name="SO" Type="String">2009 Jun;11(6):441-4</Item>
</DocSum>

<DocSum>
	<Id>19541351</Id>
	<Item Name="PubDate" Type="Date">2009 Sep</Item>
	<Item Name="EPubDate" Type="Date">2009 Jul 9</Item>
	<Item Name="Source" Type="String">J Allergy Clin Immunol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Triggiani M</Item>
		<Item Name="Author" Type="String">Giannattasio G</Item>
		<Item Name="Author" Type="String">Calabrese C</Item>
		<Item Name="Author" Type="String">Loffredo S</Item>
		<Item Name="Author" Type="String">Granata F</Item>
		<Item Name="Author" Type="String">Fiorello A</Item>
		<Item Name="Author" Type="String">Santini M</Item>
		<Item Name="Author" Type="String">Gelb MH</Item>
		<Item Name="Author" Type="String">Marone G</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Marone G</Item>
	<Item Name="Title" Type="String">Lung mast cells are a source of secreted phospholipases A2.</Item>
	<Item Name="Volume" Type="String">124</Item>
	<Item Name="Issue" Type="String">3</Item>
	<Item Name="Pages" Type="String">558-65, 565.e1-3</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">1275002</Item>
	<Item Name="ISSN" Type="String">0091-6749</Item>
	<Item Name="ESSN" Type="String">1097-6825</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">S0091-6749(09)00694-0</Item>
		<Item Name="doi" Type="String">10.1016/j.jaci.2009.04.035</Item>
		<Item Name="pubmed" Type="String">19541351</Item>
		<Item Name="pmc" Type="String">PMC2788562</Item>
		<Item Name="mid" Type="String">NIHMS160499</Item>
		<Item Name="eid" Type="String">19541351</Item>
		<Item Name="rid" Type="String">19541351</Item>
		<Item Name="pmcid" Type="String">pmc-id: PMC2788562;manuscript-id: NIHMS160499;</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/j.jaci.2009.04.035</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2008/08/05 00:00</Item>
		<Item Name="revised" Type="Date">2009/03/20 00:00</Item>
		<Item Name="accepted" Type="Date">2009/04/29 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2009/07/09 00:00</Item>
		<Item Name="entrez" Type="Date">2009/06/23 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/06/23 09:00</Item>
		<Item Name="medline" Type="Date">2009/09/29 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">8</Item>
	<Item Name="FullJournalName" Type="String">The Journal of allergy and clinical immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/j.jaci.2009.04.035</Item>
	<Item Name="SO" Type="String">2009 Sep;124(3):558-65, 565.e1-3</Item>
</DocSum>

<DocSum>
	<Id>19524426</Id>
	<Item Name="PubDate" Type="Date">2009 Jul</Item>
	<Item Name="EPubDate" Type="Date">2009 Jun 12</Item>
	<Item Name="Source" Type="String">Prostaglandins Leukot Essent Fatty Acids</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Bizzintino JA</Item>
		<Item Name="Author" Type="String">Khoo SK</Item>
		<Item Name="Author" Type="String">Zhang G</Item>
		<Item Name="Author" Type="String">Martin AC</Item>
		<Item Name="Author" Type="String">Rueter K</Item>
		<Item Name="Author" Type="String">Geelhoed GC</Item>
		<Item Name="Author" Type="String">Goldblatt J</Item>
		<Item Name="Author" Type="String">Laing IA</Item>
		<Item Name="Author" Type="String">Le Souf PN</Item>
		<Item Name="Author" Type="String">Hayden CM</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Hayden CM</Item>
	<Item Name="Title" Type="String">Leukotriene pathway polymorphisms are associated with altered cysteinyl leukotriene production in children with acute asthma.</Item>
	<Item Name="Volume" Type="String">81</Item>
	<Item Name="Issue" Type="String">1</Item>
	<Item Name="Pages" Type="String">9-15</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">8802730</Item>
	<Item Name="ISSN" Type="String">0952-3278</Item>
	<Item Name="ESSN" Type="String">1532-2823</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">S0952-3278(09)00103-3</Item>
		<Item Name="doi" Type="String">10.1016/j.plefa.2009.05.022</Item>
		<Item Name="pubmed" Type="String">19524426</Item>
		<Item Name="eid" Type="String">19524426</Item>
		<Item Name="rid" Type="String">19524426</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/j.plefa.2009.05.022</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2008/09/08 00:00</Item>
		<Item Name="revised" Type="Date">2009/05/12 00:00</Item>
		<Item Name="accepted" Type="Date">2009/05/21 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2009/06/12 00:00</Item>
		<Item Name="entrez" Type="Date">2009/06/16 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/06/16 09:00</Item>
		<Item Name="medline" Type="Date">2009/09/04 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Prostaglandins, leukotrienes, and essential fatty acids</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/j.plefa.2009.05.022</Item>
	<Item Name="SO" Type="String">2009 Jul;81(1):9-15</Item>
</DocSum>

<DocSum>
	<Id>19494502</Id>
	<Item Name="PubDate" Type="Date">2009</Item>
	<Item Name="EPubDate" Type="Date">2009 Jun 3</Item>
	<Item Name="Source" Type="String">Int Arch Allergy Immunol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Mori M</Item>
		<Item Name="Author" Type="String">Takaku Y</Item>
		<Item Name="Author" Type="String">Kobayashi T</Item>
		<Item Name="Author" Type="String">Hagiwara K</Item>
		<Item Name="Author" Type="String">Kanazawa M</Item>
		<Item Name="Author" Type="String">Nagata M</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Nagata M</Item>
	<Item Name="Title" Type="String">Eosinophil superoxide anion generation induced by adhesion molecules and leukotriene D4.</Item>
	<Item Name="Volume" Type="String">149 Suppl 1</Item>
	<Item Name="Issue" Type="String"></Item>
	<Item Name="Pages" Type="String">31-8</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9211652</Item>
	<Item Name="ISSN" Type="String">1018-2438</Item>
	<Item Name="ESSN" Type="String">1423-0097</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">000210651</Item>
		<Item Name="doi" Type="String">10.1159/000210651</Item>
		<Item Name="pubmed" Type="String">19494502</Item>
		<Item Name="eid" Type="String">19494502</Item>
		<Item Name="rid" Type="String">19494502</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1159/000210651</Item>
	<Item Name="History" Type="List">
		<Item Name="aheadofprint" Type="Date">2009/06/03 00:00</Item>
		<Item Name="entrez" Type="Date">2009/06/05 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/06/12 09:00</Item>
		<Item Name="medline" Type="Date">2009/07/21 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">2</Item>
	<Item Name="FullJournalName" Type="String">International archives of allergy and immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1159/000210651</Item>
	<Item Name="SO" Type="String">2009;149 Suppl 1:31-8</Item>
</DocSum>

<DocSum>
	<Id>19505984</Id>
	<Item Name="PubDate" Type="Date">2009 Nov</Item>
	<Item Name="EPubDate" Type="Date">2009 Jun 8</Item>
	<Item Name="Source" Type="String">Chest</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Fernndez-Nieto M</Item>
		<Item Name="Author" Type="String">Sastre B</Item>
		<Item Name="Author" Type="String">Sastre J</Item>
		<Item Name="Author" Type="String">Lahoz C</Item>
		<Item Name="Author" Type="String">Quirce S</Item>
		<Item Name="Author" Type="String">Madero M</Item>
		<Item Name="Author" Type="String">Del Pozo V</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Del Pozo V</Item>
	<Item Name="Title" Type="String">Changes in sputum eicosanoids and inflammatory markers after inhalation challenges with occupational agents.</Item>
	<Item Name="Volume" Type="String">136</Item>
	<Item Name="Issue" Type="String">5</Item>
	<Item Name="Pages" Type="String">1308-15</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">0231335</Item>
	<Item Name="ISSN" Type="String">0012-3692</Item>
	<Item Name="ESSN" Type="String">1931-3543</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">chest.09-0103</Item>
		<Item Name="doi" Type="String">10.1378/chest.09-0103</Item>
		<Item Name="pubmed" Type="String">19505984</Item>
		<Item Name="eid" Type="String">19505984</Item>
		<Item Name="rid" Type="String">19505984</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1378/chest.09-0103</Item>
	<Item Name="History" Type="List">
		<Item Name="aheadofprint" Type="Date">2009/06/08 00:00</Item>
		<Item Name="entrez" Type="Date">2009/06/10 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/06/10 09:00</Item>
		<Item Name="medline" Type="Date">2010/01/07 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Chest</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1378/chest.09-0103</Item>
	<Item Name="SO" Type="String">2009 Nov;136(5):1308-15</Item>
</DocSum>

<DocSum>
	<Id>19501235</Id>
	<Item Name="PubDate" Type="Date">2009 Jun</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">J Allergy Clin Immunol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Sutherland ER</Item>
		<Item Name="Author" Type="String">Lehman EB</Item>
		<Item Name="Author" Type="String">Teodorescu M</Item>
		<Item Name="Author" Type="String">Wechsler ME</Item>
		<Item Name="CollectiveName" Type="String">National Heart, Lung, and Blood Institute's Asthma Clinical Research Network</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Wechsler ME</Item>
	<Item Name="Title" Type="String">Body mass index and phenotype in subjects with mild-to-moderate persistent asthma.</Item>
	<Item Name="Volume" Type="String">123</Item>
	<Item Name="Issue" Type="String">6</Item>
	<Item Name="Pages" Type="String">1328-34.e1</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">1275002</Item>
	<Item Name="ISSN" Type="String">0091-6749</Item>
	<Item Name="ESSN" Type="String">1097-6825</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">S0091-6749(09)00557-0</Item>
		<Item Name="doi" Type="String">10.1016/j.jaci.2009.04.005</Item>
		<Item Name="pubmed" Type="String">19501235</Item>
		<Item Name="pmc" Type="String">PMC2743451</Item>
		<Item Name="mid" Type="String">NIHMS122659</Item>
		<Item Name="eid" Type="String">19501235</Item>
		<Item Name="rid" Type="String">19501235</Item>
		<Item Name="pmcid" Type="String">pmc-id: PMC2743451;manuscript-id: NIHMS122659;</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/j.jaci.2009.04.005</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2009/02/09 00:00</Item>
		<Item Name="revised" Type="Date">2009/03/19 00:00</Item>
		<Item Name="accepted" Type="Date">2009/04/01 00:00</Item>
		<Item Name="entrez" Type="Date">2009/06/09 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/06/09 09:00</Item>
		<Item Name="medline" Type="Date">2009/06/27 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">17</Item>
	<Item Name="FullJournalName" Type="String">The Journal of allergy and clinical immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/j.jaci.2009.04.005</Item>
	<Item Name="SO" Type="String">2009 Jun;123(6):1328-34.e1</Item>
</DocSum>

<DocSum>
	<Id>19486029</Id>
	<Item Name="PubDate" Type="Date">2009 Oct</Item>
	<Item Name="EPubDate" Type="Date">2009 May 22</Item>
	<Item Name="Source" Type="String">Clin Exp Allergy</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Celik GE</Item>
		<Item Name="Author" Type="String">Schroeder JT</Item>
		<Item Name="Author" Type="String">Hamilton RG</Item>
		<Item Name="Author" Type="String">Saini SS</Item>
		<Item Name="Author" Type="String">Adkinson NF</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Adkinson NF</Item>
	<Item Name="Title" Type="String">Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease.</Item>
	<Item Name="Volume" Type="String">39</Item>
	<Item Name="Issue" Type="String">10</Item>
	<Item Name="Pages" Type="String">1522-31</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">8906443</Item>
	<Item Name="ISSN" Type="String">0954-7894</Item>
	<Item Name="ESSN" Type="String">1365-2222</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">CEA3277</Item>
		<Item Name="doi" Type="String">10.1111/j.1365-2222.2009.03277.x</Item>
		<Item Name="pubmed" Type="String">19486029</Item>
		<Item Name="pmc" Type="String">PMC2788679</Item>
		<Item Name="mid" Type="String">NIHMS125987</Item>
		<Item Name="eid" Type="String">19486029</Item>
		<Item Name="rid" Type="String">19486029</Item>
		<Item Name="pmcid" Type="String">pmc-id: PMC2788679;manuscript-id: NIHMS125987;</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1111/j.1365-2222.2009.03277.x</Item>
	<Item Name="History" Type="List">
		<Item Name="aheadofprint" Type="Date">2009/05/22 00:00</Item>
		<Item Name="entrez" Type="Date">2009/06/03 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/06/03 09:00</Item>
		<Item Name="medline" Type="Date">2010/02/18 06:00</Item>
	</Item>
	<Item Name="References" Type="List">
		<Item Name="Comment in" Type="String">Clin Exp Allergy. 2010 Mar;40(3):520; author reply 520-1. PMID: 20082616</Item>
	</Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">4</Item>
	<Item Name="FullJournalName" Type="String">Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1111/j.1365-2222.2009.03277.x</Item>
	<Item Name="SO" Type="String">2009 Oct;39(10):1522-31</Item>
</DocSum>

<DocSum>
	<Id>19482346</Id>
	<Item Name="PubDate" Type="Date">2009 Sep</Item>
	<Item Name="EPubDate" Type="Date">2009 May 30</Item>
	<Item Name="Source" Type="String">J Allergy Clin Immunol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Lee TH</Item>
		<Item Name="Author" Type="String">Woszczek G</Item>
		<Item Name="Author" Type="String">Farooque SP</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Farooque SP</Item>
	<Item Name="Title" Type="String">Leukotriene E4: perspective on the forgotten mediator.</Item>
	<Item Name="Volume" Type="String">124</Item>
	<Item Name="Issue" Type="String">3</Item>
	<Item Name="Pages" Type="String">417-21</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">1275002</Item>
	<Item Name="ISSN" Type="String">0091-6749</Item>
	<Item Name="ESSN" Type="String">1097-6825</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Review</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">S0091-6749(09)00660-5</Item>
		<Item Name="doi" Type="String">10.1016/j.jaci.2009.04.020</Item>
		<Item Name="pubmed" Type="String">19482346</Item>
		<Item Name="eid" Type="String">19482346</Item>
		<Item Name="rid" Type="String">19482346</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/j.jaci.2009.04.020</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2009/03/16 00:00</Item>
		<Item Name="revised" Type="Date">2009/04/02 00:00</Item>
		<Item Name="accepted" Type="Date">2009/04/17 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2009/05/30 00:00</Item>
		<Item Name="entrez" Type="Date">2009/06/02 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/06/02 09:00</Item>
		<Item Name="medline" Type="Date">2009/09/29 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">8</Item>
	<Item Name="FullJournalName" Type="String">The Journal of allergy and clinical immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/j.jaci.2009.04.020</Item>
	<Item Name="SO" Type="String">2009 Sep;124(3):417-21</Item>
</DocSum>

<DocSum>
	<Id>19418204</Id>
	<Item Name="PubDate" Type="Date">2009 Jul</Item>
	<Item Name="EPubDate" Type="Date">2009 May 6</Item>
	<Item Name="Source" Type="String">Inflamm Res</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Chiba Y</Item>
		<Item Name="Author" Type="String">Sato S</Item>
		<Item Name="Author" Type="String">Misawa M</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Misawa M</Item>
	<Item Name="Title" Type="String">Lovastatin inhibits antigen-induced airway eosinophilia without affecting the production of inflammatory mediators in mice.</Item>
	<Item Name="Volume" Type="String">58</Item>
	<Item Name="Issue" Type="String">7</Item>
	<Item Name="Pages" Type="String">363-9</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9508160</Item>
	<Item Name="ISSN" Type="String">1023-3830</Item>
	<Item Name="ESSN" Type="String">1420-908X</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="doi" Type="String">10.1007/s00011-009-0043-5</Item>
		<Item Name="pubmed" Type="String">19418204</Item>
		<Item Name="eid" Type="String">19418204</Item>
		<Item Name="rid" Type="String">19418204</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1007/s00011-009-0043-5</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2008/08/31 00:00</Item>
		<Item Name="accepted" Type="Date">2009/04/09 00:00</Item>
		<Item Name="revised" Type="Date">2009/03/02 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2009/05/06 00:00</Item>
		<Item Name="entrez" Type="Date">2009/05/07 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/05/07 09:00</Item>
		<Item Name="medline" Type="Date">2013/01/01 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">3</Item>
	<Item Name="FullJournalName" Type="String">Inflammation research : official journal of the European Histamine Research Society ... [et al.]</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1007/s00011-009-0043-5</Item>
	<Item Name="SO" Type="String">2009 Jul;58(7):363-9</Item>
</DocSum>

<DocSum>
	<Id>19416143</Id>
	<Item Name="PubDate" Type="Date">2009 Jun</Item>
	<Item Name="EPubDate" Type="Date">2009 Mar 26</Item>
	<Item Name="Source" Type="String">Allergy</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Duroudier NP</Item>
		<Item Name="Author" Type="String">Tulah AS</Item>
		<Item Name="Author" Type="String">Sayers I</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Sayers I</Item>
	<Item Name="Title" Type="String">Leukotriene pathway genetics and pharmacogenetics in allergy.</Item>
	<Item Name="Volume" Type="String">64</Item>
	<Item Name="Issue" Type="String">6</Item>
	<Item Name="Pages" Type="String">823-39</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">7804028</Item>
	<Item Name="ISSN" Type="String">0105-4538</Item>
	<Item Name="ESSN" Type="String">1398-9995</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Review</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">ALL2015</Item>
		<Item Name="doi" Type="String">10.1111/j.1398-9995.2009.02015.x</Item>
		<Item Name="pubmed" Type="String">19416143</Item>
		<Item Name="eid" Type="String">19416143</Item>
		<Item Name="rid" Type="String">19416143</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1111/j.1398-9995.2009.02015.x</Item>
	<Item Name="History" Type="List">
		<Item Name="aheadofprint" Type="Date">2009/03/26 00:00</Item>
		<Item Name="entrez" Type="Date">2009/05/07 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/05/07 09:00</Item>
		<Item Name="medline" Type="Date">2009/06/24 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">15</Item>
	<Item Name="FullJournalName" Type="String">Allergy</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1111/j.1398-9995.2009.02015.x</Item>
	<Item Name="SO" Type="String">2009 Jun;64(6):823-39</Item>
</DocSum>

<DocSum>
	<Id>19355919</Id>
	<Item Name="PubDate" Type="Date">2009 Apr</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Curr Mol Med</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Mehrotra AK</Item>
		<Item Name="Author" Type="String">Henderson WR Jr</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Henderson WR Jr</Item>
	<Item Name="Title" Type="String">The role of leukotrienes in airway remodeling.</Item>
	<Item Name="Volume" Type="String">9</Item>
	<Item Name="Issue" Type="String">3</Item>
	<Item Name="Pages" Type="String">383-91</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">101093076</Item>
	<Item Name="ISSN" Type="String">1566-5240</Item>
	<Item Name="ESSN" Type="String">1875-5666</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Review</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pubmed" Type="String">19355919</Item>
		<Item Name="eid" Type="String">19355919</Item>
		<Item Name="rid" Type="String">19355919</Item>
	</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/04/10 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/04/10 09:00</Item>
		<Item Name="medline" Type="Date">2009/05/27 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">3</Item>
	<Item Name="FullJournalName" Type="String">Current molecular medicine</Item>
	<Item Name="ELocationID" Type="String"></Item>
	<Item Name="SO" Type="String">2009 Apr;9(3):383-91</Item>
</DocSum>

<DocSum>
	<Id>19354073</Id>
	<Item Name="PubDate" Type="Date">2009 Mar</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Ann Allergy Asthma Immunol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Oppenheimer J</Item>
		<Item Name="Author" Type="String">Sorkness CA</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Sorkness CA</Item>
	<Item Name="Title" Type="String">Does exhaled nitric oxide measurement have a role in asthma care?</Item>
	<Item Name="Volume" Type="String">102</Item>
	<Item Name="Issue" Type="String">3</Item>
	<Item Name="Pages" Type="String">253-5</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9503580</Item>
	<Item Name="ISSN" Type="String">1081-1206</Item>
	<Item Name="ESSN" Type="String">1534-4436</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pubmed" Type="String">19354073</Item>
		<Item Name="pii" Type="String">S1081-1206(10)60089-0</Item>
		<Item Name="doi" Type="String">10.1016/S1081-1206(10)60089-0</Item>
		<Item Name="eid" Type="String">19354073</Item>
		<Item Name="rid" Type="String">19354073</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/S1081-1206(10)60089-0</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/04/10 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/04/10 09:00</Item>
		<Item Name="medline" Type="Date">2009/04/25 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">0</Item>
	<Item Name="PmcRefCount" Type="Integer">1</Item>
	<Item Name="FullJournalName" Type="String">Annals of allergy, asthma &amp; immunology : official publication of the American College of Allergy, Asthma, &amp; Immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/S1081-1206(10)60089-0</Item>
	<Item Name="SO" Type="String">2009 Mar;102(3):253-5</Item>
</DocSum>

<DocSum>
	<Id>19294813</Id>
	<Item Name="PubDate" Type="Date">2009 Mar</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Pharmacogenomics</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Kukreti R</Item>
		<Item Name="Author" Type="String">Guleria R</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Guleria R</Item>
	<Item Name="Title" Type="String">Understanding clinical variability in response to asthma treatment.</Item>
	<Item Name="Volume" Type="String">10</Item>
	<Item Name="Issue" Type="String">3</Item>
	<Item Name="Pages" Type="String">327-30</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">100897350</Item>
	<Item Name="ISSN" Type="String">1462-2416</Item>
	<Item Name="ESSN" Type="String">1744-8042</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Editorial</Item>
		<Item Name="PubType" Type="String">Review</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pubmed" Type="String">19294813</Item>
		<Item Name="eid" Type="String">19294813</Item>
		<Item Name="rid" Type="String">19294813</Item>
	</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/03/20 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/03/20 09:00</Item>
		<Item Name="medline" Type="Date">2009/05/21 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">0</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Pharmacogenomics</Item>
	<Item Name="ELocationID" Type="String"></Item>
	<Item Name="SO" Type="String">2009 Mar;10(3):327-30</Item>
</DocSum>

<DocSum>
	<Id>19291727</Id>
	<Item Name="PubDate" Type="Date">2009 Apr</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Am J Hematol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Field JJ</Item>
		<Item Name="Author" Type="String">Strunk RC</Item>
		<Item Name="Author" Type="String">Knight-Perry JE</Item>
		<Item Name="Author" Type="String">Blinder MA</Item>
		<Item Name="Author" Type="String">Townsend RR</Item>
		<Item Name="Author" Type="String">DeBaun MR</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">DeBaun MR</Item>
	<Item Name="Title" Type="String">Urinary cysteinyl leukotriene E4 significantly increases during pain in children and adults with sickle cell disease.</Item>
	<Item Name="Volume" Type="String">84</Item>
	<Item Name="Issue" Type="String">4</Item>
	<Item Name="Pages" Type="String">231-3</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">7610369</Item>
	<Item Name="ISSN" Type="String">0361-8609</Item>
	<Item Name="ESSN" Type="String">1096-8652</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="doi" Type="String">10.1002/ajh.21370</Item>
		<Item Name="pubmed" Type="String">19291727</Item>
		<Item Name="eid" Type="String">19291727</Item>
		<Item Name="rid" Type="String">19291727</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1002/ajh.21370</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/03/18 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/03/18 09:00</Item>
		<Item Name="medline" Type="Date">2009/04/18 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">5</Item>
	<Item Name="FullJournalName" Type="String">American journal of hematology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1002/ajh.21370</Item>
	<Item Name="SO" Type="String">2009 Apr;84(4):231-3</Item>
</DocSum>

<DocSum>
	<Id>19233745</Id>
	<Item Name="PubDate" Type="Date">2009 May 1</Item>
	<Item Name="EPubDate" Type="Date">2009 Feb 2</Item>
	<Item Name="Source" Type="String">J Chromatogr B Analyt Technol Biomed Life Sci</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Montuschi P</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Montuschi P</Item>
	<Item Name="Title" Type="String">LC/MS/MS analysis of leukotriene B4 and other eicosanoids in exhaled breath condensate for assessing lung inflammation.</Item>
	<Item Name="Volume" Type="String">877</Item>
	<Item Name="Issue" Type="String">13</Item>
	<Item Name="Pages" Type="String">1272-80</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">101139554</Item>
	<Item Name="ISSN" Type="String">1570-0232</Item>
	<Item Name="ESSN" Type="String">1873-376X</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Review</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">S1570-0232(09)00061-0</Item>
		<Item Name="doi" Type="String">10.1016/j.jchromb.2009.01.036</Item>
		<Item Name="pubmed" Type="String">19233745</Item>
		<Item Name="eid" Type="String">19233745</Item>
		<Item Name="rid" Type="String">19233745</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/j.jchromb.2009.01.036</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2008/08/12 00:00</Item>
		<Item Name="revised" Type="Date">2009/01/21 00:00</Item>
		<Item Name="accepted" Type="Date">2009/01/22 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2009/02/02 00:00</Item>
		<Item Name="entrez" Type="Date">2009/02/24 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/02/24 09:00</Item>
		<Item Name="medline" Type="Date">2009/05/12 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">6</Item>
	<Item Name="FullJournalName" Type="String">Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/j.jchromb.2009.01.036</Item>
	<Item Name="SO" Type="String">2009 May 1;877(13):1272-80</Item>
</DocSum>

<DocSum>
	<Id>19230459</Id>
	<Item Name="PubDate" Type="Date">2009 Feb</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Ann Allergy Asthma Immunol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Cap P</Item>
		<Item Name="Author" Type="String">Maly M</Item>
		<Item Name="Author" Type="String">Pehal F</Item>
		<Item Name="Author" Type="String">Pelikan Z</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Pelikan Z</Item>
	<Item Name="Title" Type="String">Exhaled leukotrienes and bronchial responsiveness to methacholine in patients with seasonal allergic rhinitis.</Item>
	<Item Name="Volume" Type="String">102</Item>
	<Item Name="Issue" Type="String">2</Item>
	<Item Name="Pages" Type="String">103-9</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9503580</Item>
	<Item Name="ISSN" Type="String">1081-1206</Item>
	<Item Name="ESSN" Type="String">1534-4436</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pubmed" Type="String">19230459</Item>
		<Item Name="pii" Type="String">S1081-1206(10)60238-4</Item>
		<Item Name="doi" Type="String">10.1016/S1081-1206(10)60238-4</Item>
		<Item Name="eid" Type="String">19230459</Item>
		<Item Name="rid" Type="String">19230459</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/S1081-1206(10)60238-4</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/02/24 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/02/24 09:00</Item>
		<Item Name="medline" Type="Date">2009/03/11 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Annals of allergy, asthma &amp; immunology : official publication of the American College of Allergy, Asthma, &amp; Immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/S1081-1206(10)60238-4</Item>
	<Item Name="SO" Type="String">2009 Feb;102(2):103-9</Item>
</DocSum>

<DocSum>
	<Id>19226274</Id>
	<Item Name="PubDate" Type="Date">2009 Apr</Item>
	<Item Name="EPubDate" Type="Date">2009 Feb 10</Item>
	<Item Name="Source" Type="String">Clin Exp Allergy</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Fuentes-Beltrn A</Item>
		<Item Name="Author" Type="String">Montes-Vizuet R</Item>
		<Item Name="Author" Type="String">Valencia-Maqueda E</Item>
		<Item Name="Author" Type="String">Negrete-Garca MC</Item>
		<Item Name="Author" Type="String">Garca-Cruz Mde L</Item>
		<Item Name="Author" Type="String">Teran LM</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Teran LM</Item>
	<Item Name="Title" Type="String">Chemokine CC-ligand 5 production and eosinophil activation into the upper airways of aspirin-sensitive patients.</Item>
	<Item Name="Volume" Type="String">39</Item>
	<Item Name="Issue" Type="String">4</Item>
	<Item Name="Pages" Type="String">491-9</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">8906443</Item>
	<Item Name="ISSN" Type="String">0954-7894</Item>
	<Item Name="ESSN" Type="String">1365-2222</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">CEA3190</Item>
		<Item Name="doi" Type="String">10.1111/j.1365-2222.2008.03190.x</Item>
		<Item Name="pubmed" Type="String">19226274</Item>
		<Item Name="eid" Type="String">19226274</Item>
		<Item Name="rid" Type="String">19226274</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1111/j.1365-2222.2008.03190.x</Item>
	<Item Name="History" Type="List">
		<Item Name="aheadofprint" Type="Date">2009/02/10 00:00</Item>
		<Item Name="entrez" Type="Date">2009/02/20 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/02/20 09:00</Item>
		<Item Name="medline" Type="Date">2009/05/27 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">2</Item>
	<Item Name="FullJournalName" Type="String">Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1111/j.1365-2222.2008.03190.x</Item>
	<Item Name="SO" Type="String">2009 Apr;39(4):491-9</Item>
</DocSum>

<DocSum>
	<Id>19205280</Id>
	<Item Name="PubDate" Type="Date">2009 Jan</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Ann Allergy Asthma Immunol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Boss Y</Item>
		<Item Name="Author" Type="String">Stankova J</Item>
		<Item Name="Author" Type="String">Rola-Pleszczynski M</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Rola-Pleszczynski M</Item>
	<Item Name="Title" Type="String">Cysteinyl-leukotrienes in asthmatic airway smooth muscle cell hyperplasia.</Item>
	<Item Name="Volume" Type="String">102</Item>
	<Item Name="Issue" Type="String">1</Item>
	<Item Name="Pages" Type="String">16-21</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9503580</Item>
	<Item Name="ISSN" Type="String">1081-1206</Item>
	<Item Name="ESSN" Type="String">1534-4436</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Review</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pubmed" Type="String">19205280</Item>
		<Item Name="pii" Type="String">S1081-1206(10)60102-0</Item>
		<Item Name="doi" Type="String">10.1016/S1081-1206(10)60102-0</Item>
		<Item Name="eid" Type="String">19205280</Item>
		<Item Name="rid" Type="String">19205280</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/S1081-1206(10)60102-0</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/02/12 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/02/12 09:00</Item>
		<Item Name="medline" Type="Date">2009/03/04 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">2</Item>
	<Item Name="FullJournalName" Type="String">Annals of allergy, asthma &amp; immunology : official publication of the American College of Allergy, Asthma, &amp; Immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/S1081-1206(10)60102-0</Item>
	<Item Name="SO" Type="String">2009 Jan;102(1):16-21</Item>
</DocSum>

<DocSum>
	<Id>19153534</Id>
	<Item Name="PubDate" Type="Date">2009 Mar</Item>
	<Item Name="EPubDate" Type="Date">2009 Jan 25</Item>
	<Item Name="Source" Type="String">Allergol Int</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Matsunaga K</Item>
		<Item Name="Author" Type="String">Yanagisawa S</Item>
		<Item Name="Author" Type="String">Ichikawa T</Item>
		<Item Name="Author" Type="String">Akamatsu K</Item>
		<Item Name="Author" Type="String">Koarai A</Item>
		<Item Name="Author" Type="String">Hirano T</Item>
		<Item Name="Author" Type="String">Sugiura H</Item>
		<Item Name="Author" Type="String">Minakata Y</Item>
		<Item Name="Author" Type="String">Ichinose M</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Ichinose M</Item>
	<Item Name="Title" Type="String">Molecular mechanism of the additive effects of leukotriene modifier in asthmatic patients receiving steroid therapy.</Item>
	<Item Name="Volume" Type="String">58</Item>
	<Item Name="Issue" Type="String">1</Item>
	<Item Name="Pages" Type="String">89-96</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9616296</Item>
	<Item Name="ISSN" Type="String">1323-8930</Item>
	<Item Name="ESSN" Type="String">1440-1592</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Randomized Controlled Trial</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">058010089</Item>
		<Item Name="doi" Type="String">10.2332/allergolint.08-OA-0014</Item>
		<Item Name="pubmed" Type="String">19153534</Item>
		<Item Name="eid" Type="String">19153534</Item>
		<Item Name="rid" Type="String">19153534</Item>
	</Item>
	<Item Name="DOI" Type="String">10.2332/allergolint.08-OA-0014</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2008/06/10 00:00</Item>
		<Item Name="accepted" Type="Date">2008/07/20 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2009/01/25 00:00</Item>
		<Item Name="entrez" Type="Date">2009/01/21 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/01/21 09:00</Item>
		<Item Name="medline" Type="Date">2009/07/08 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">0</Item>
	<Item Name="FullJournalName" Type="String">Allergology international : official journal of the Japanese Society of Allergology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.2332/allergolint.08-OA-0014</Item>
	<Item Name="SO" Type="String">2009 Mar;58(1):89-96</Item>
</DocSum>

<DocSum>
	<Id>19144047</Id>
	<Item Name="PubDate" Type="Date">2009 Jan</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Respirology</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Altraja S</Item>
		<Item Name="Author" Type="String">Jaama J</Item>
		<Item Name="Author" Type="String">Valk E</Item>
		<Item Name="Author" Type="String">Altraja A</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Altraja A</Item>
	<Item Name="Title" Type="String">Changes in the proteome of human bronchial epithelial cells following stimulation with leucotriene E4 and transforming growth factor-beta1.</Item>
	<Item Name="Volume" Type="String">14</Item>
	<Item Name="Issue" Type="String">1</Item>
	<Item Name="Pages" Type="String">39-45</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9616368</Item>
	<Item Name="ISSN" Type="String">1323-7799</Item>
	<Item Name="ESSN" Type="String">1440-1843</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">RES1414</Item>
		<Item Name="doi" Type="String">10.1111/j.1440-1843.2008.01414.x</Item>
		<Item Name="pubmed" Type="String">19144047</Item>
		<Item Name="eid" Type="String">19144047</Item>
		<Item Name="rid" Type="String">19144047</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1111/j.1440-1843.2008.01414.x</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/01/16 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/01/16 09:00</Item>
		<Item Name="medline" Type="Date">2009/05/09 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">2</Item>
	<Item Name="FullJournalName" Type="String">Respirology (Carlton, Vic.)</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1111/j.1440-1843.2008.01414.x</Item>
	<Item Name="SO" Type="String">2009 Jan;14(1):39-45</Item>
</DocSum>

<DocSum>
	<Id>19130894</Id>
	<Item Name="PubDate" Type="Date">2009 Sep</Item>
	<Item Name="EPubDate" Type="Date">2008 Dec 14</Item>
	<Item Name="Source" Type="String">Prostaglandins Other Lipid Mediat</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Claesson HE</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Claesson HE</Item>
	<Item Name="Title" Type="String">On the biosynthesis and biological role of eoxins and 15-lipoxygenase-1 in airway inflammation and Hodgkin lymphoma.</Item>
	<Item Name="Volume" Type="String">89</Item>
	<Item Name="Issue" Type="String">3-4</Item>
	<Item Name="Pages" Type="String">120-5</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9808648</Item>
	<Item Name="ISSN" Type="String">1098-8823</Item>
	<Item Name="ESSN" Type="String"></Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Review</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">S1098-8823(08)00091-9</Item>
		<Item Name="doi" Type="String">10.1016/j.prostaglandins.2008.12.003</Item>
		<Item Name="pubmed" Type="String">19130894</Item>
		<Item Name="eid" Type="String">19130894</Item>
		<Item Name="rid" Type="String">19130894</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/j.prostaglandins.2008.12.003</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2008/11/11 00:00</Item>
		<Item Name="revised" Type="Date">2008/12/02 00:00</Item>
		<Item Name="accepted" Type="Date">2008/12/06 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2008/12/14 00:00</Item>
		<Item Name="entrez" Type="Date">2009/01/10 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/01/10 09:00</Item>
		<Item Name="medline" Type="Date">2009/12/16 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">1</Item>
	<Item Name="FullJournalName" Type="String">Prostaglandins &amp; other lipid mediators</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/j.prostaglandins.2008.12.003</Item>
	<Item Name="SO" Type="String">2009 Sep;89(3-4):120-5</Item>
</DocSum>

<DocSum>
	<Id>19128354</Id>
	<Item Name="PubDate" Type="Date">2009 Jan</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Clin Exp Allergy</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Ono E</Item>
		<Item Name="Author" Type="String">Taniguchi M</Item>
		<Item Name="Author" Type="String">Mita H</Item>
		<Item Name="Author" Type="String">Fukutomi Y</Item>
		<Item Name="Author" Type="String">Higashi N</Item>
		<Item Name="Author" Type="String">Miyazaki E</Item>
		<Item Name="Author" Type="String">Kumamoto T</Item>
		<Item Name="Author" Type="String">Akiyama K</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Akiyama K</Item>
	<Item Name="Title" Type="String">Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis.</Item>
	<Item Name="Volume" Type="String">39</Item>
	<Item Name="Issue" Type="String">1</Item>
	<Item Name="Pages" Type="String">72-80</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">8906443</Item>
	<Item Name="ISSN" Type="String">0954-7894</Item>
	<Item Name="ESSN" Type="String">1365-2222</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">CEA3104</Item>
		<Item Name="doi" Type="String">10.1111/j.1365-2222.2008.03104.x</Item>
		<Item Name="pubmed" Type="String">19128354</Item>
		<Item Name="eid" Type="String">19128354</Item>
		<Item Name="rid" Type="String">19128354</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1111/j.1365-2222.2008.03104.x</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2009/01/09 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/01/09 09:00</Item>
		<Item Name="medline" Type="Date">2009/02/14 09:00</Item>
	</Item>
	<Item Name="References" Type="List">
		<Item Name="Comment in" Type="String">Clin Exp Allergy. 2009 Jan;39(1):5-7. PMID: 19032357</Item>
	</Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">2</Item>
	<Item Name="FullJournalName" Type="String">Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1111/j.1365-2222.2008.03104.x</Item>
	<Item Name="SO" Type="String">2009 Jan;39(1):72-80</Item>
</DocSum>

<DocSum>
	<Id>19127069</Id>
	<Item Name="PubDate" Type="Date">2009</Item>
	<Item Name="EPubDate" Type="Date">2009 Jan 6</Item>
	<Item Name="Source" Type="String">Int Arch Allergy Immunol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Misso NL</Item>
		<Item Name="Author" Type="String">Aggarwal S</Item>
		<Item Name="Author" Type="String">Thompson PJ</Item>
		<Item Name="Author" Type="String">Vally H</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Vally H</Item>
	<Item Name="Title" Type="String">Increases in urinary 9alpha,11beta-prostaglandin f2 indicate mast cell activation in wine-induced asthma.</Item>
	<Item Name="Volume" Type="String">149</Item>
	<Item Name="Issue" Type="String">2</Item>
	<Item Name="Pages" Type="String">127-32</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9211652</Item>
	<Item Name="ISSN" Type="String">1018-2438</Item>
	<Item Name="ESSN" Type="String">1423-0097</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Randomized Controlled Trial</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">000189195</Item>
		<Item Name="doi" Type="String">10.1159/000189195</Item>
		<Item Name="pubmed" Type="String">19127069</Item>
		<Item Name="eid" Type="String">19127069</Item>
		<Item Name="rid" Type="String">19127069</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1159/000189195</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2008/06/16 00:00</Item>
		<Item Name="accepted" Type="Date">2008/08/11 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2009/01/06 00:00</Item>
		<Item Name="entrez" Type="Date">2009/01/08 09:00</Item>
		<Item Name="pubmed" Type="Date">2009/01/08 09:00</Item>
		<Item Name="medline" Type="Date">2009/06/10 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">1</Item>
	<Item Name="FullJournalName" Type="String">International archives of allergy and immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1159/000189195</Item>
	<Item Name="SO" Type="String">2009;149(2):127-32</Item>
</DocSum>

<DocSum>
	<Id>19110408</Id>
	<Item Name="PubDate" Type="Date">2009 May</Item>
	<Item Name="EPubDate" Type="Date">2008 Dec 24</Item>
	<Item Name="Source" Type="String">Respir Med</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Samitas K</Item>
		<Item Name="Author" Type="String">Chorianopoulos D</Item>
		<Item Name="Author" Type="String">Vittorakis S</Item>
		<Item Name="Author" Type="String">Zervas E</Item>
		<Item Name="Author" Type="String">Economidou E</Item>
		<Item Name="Author" Type="String">Papatheodorou G</Item>
		<Item Name="Author" Type="String">Loukides S</Item>
		<Item Name="Author" Type="String">Gaga M</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Gaga M</Item>
	<Item Name="Title" Type="String">Exhaled cysteinyl-leukotrienes and 8-isoprostane in patients with asthma and their relation to clinical severity.</Item>
	<Item Name="Volume" Type="String">103</Item>
	<Item Name="Issue" Type="String">5</Item>
	<Item Name="Pages" Type="String">750-6</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">8908438</Item>
	<Item Name="ISSN" Type="String">0954-6111</Item>
	<Item Name="ESSN" Type="String">1532-3064</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">S0954-6111(08)00403-4</Item>
		<Item Name="doi" Type="String">10.1016/j.rmed.2008.11.009</Item>
		<Item Name="pubmed" Type="String">19110408</Item>
		<Item Name="eid" Type="String">19110408</Item>
		<Item Name="rid" Type="String">19110408</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/j.rmed.2008.11.009</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2008/07/17 00:00</Item>
		<Item Name="revised" Type="Date">2008/09/28 00:00</Item>
		<Item Name="accepted" Type="Date">2008/11/17 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2008/12/24 00:00</Item>
		<Item Name="entrez" Type="Date">2008/12/27 09:00</Item>
		<Item Name="pubmed" Type="Date">2008/12/27 09:00</Item>
		<Item Name="medline" Type="Date">2010/03/17 06:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">7</Item>
	<Item Name="FullJournalName" Type="String">Respiratory medicine</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/j.rmed.2008.11.009</Item>
	<Item Name="SO" Type="String">2009 May;103(5):750-6</Item>
</DocSum>

<DocSum>
	<Id>19077700</Id>
	<Item Name="PubDate" Type="Date">2009 Jan</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Curr Opin Pulm Med</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Murugan A</Item>
		<Item Name="Author" Type="String">Prys-Picard C</Item>
		<Item Name="Author" Type="String">Calhoun WJ</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Calhoun WJ</Item>
	<Item Name="Title" Type="String">Biomarkers in asthma.</Item>
	<Item Name="Volume" Type="String">15</Item>
	<Item Name="Issue" Type="String">1</Item>
	<Item Name="Pages" Type="String">12-8</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9503765</Item>
	<Item Name="ISSN" Type="String">1070-5287</Item>
	<Item Name="ESSN" Type="String">1531-6971</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Review</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="doi" Type="String">10.1097/MCP.0b013e32831de235</Item>
		<Item Name="pii" Type="String">00063198-200901000-00004</Item>
		<Item Name="pubmed" Type="String">19077700</Item>
		<Item Name="eid" Type="String">19077700</Item>
		<Item Name="rid" Type="String">19077700</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1097/MCP.0b013e32831de235</Item>
	<Item Name="History" Type="List">
		<Item Name="entrez" Type="Date">2008/12/17 09:00</Item>
		<Item Name="pubmed" Type="Date">2008/12/17 09:00</Item>
		<Item Name="medline" Type="Date">2009/02/28 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">1</Item>
	<Item Name="FullJournalName" Type="String">Current opinion in pulmonary medicine</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1097/MCP.0b013e32831de235</Item>
	<Item Name="SO" Type="String">2009 Jan;15(1):12-8</Item>
</DocSum>

<DocSum>
	<Id>19063820</Id>
	<Item Name="PubDate" Type="Date">2009 Jan</Item>
	<Item Name="EPubDate" Type="Date"></Item>
	<Item Name="Source" Type="String">Curr Allergy Asthma Rep</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Hallstrand TS</Item>
		<Item Name="Author" Type="String">Henderson WR Jr</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Henderson WR Jr</Item>
	<Item Name="Title" Type="String">Role of leukotrienes in exercise-induced bronchoconstriction.</Item>
	<Item Name="Volume" Type="String">9</Item>
	<Item Name="Issue" Type="String">1</Item>
	<Item Name="Pages" Type="String">18-25</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">101096440</Item>
	<Item Name="ISSN" Type="String">1529-7322</Item>
	<Item Name="ESSN" Type="String">1534-6315</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pubmed" Type="String">19063820</Item>
		<Item Name="eid" Type="String">19063820</Item>
		<Item Name="rid" Type="String">19063820</Item>
	</Item>
	<Item Name="History" Type="List">
		<Item Name="pubmed" Type="Date">2008/12/10 09:00</Item>
		<Item Name="medline" Type="Date">2009/08/27 09:00</Item>
		<Item Name="entrez" Type="Date">2008/12/10 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">4</Item>
	<Item Name="FullJournalName" Type="String">Current allergy and asthma reports</Item>
	<Item Name="ELocationID" Type="String"></Item>
	<Item Name="SO" Type="String">2009 Jan;9(1):18-25</Item>
</DocSum>

<DocSum>
	<Id>19054597</Id>
	<Item Name="PubDate" Type="Date">2009 Feb</Item>
	<Item Name="EPubDate" Type="Date">2008 Dec 2</Item>
	<Item Name="Source" Type="String">Clin Nutr</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Mickleborough TD</Item>
		<Item Name="Author" Type="String">Tecklenburg SL</Item>
		<Item Name="Author" Type="String">Montgomery GS</Item>
		<Item Name="Author" Type="String">Lindley MR</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Lindley MR</Item>
	<Item Name="Title" Type="String">Eicosapentaenoic acid is more effective than docosahexaenoic acid in inhibiting proinflammatory mediator production and transcription from LPS-induced human asthmatic alveolar macrophage cells.</Item>
	<Item Name="Volume" Type="String">28</Item>
	<Item Name="Issue" Type="String">1</Item>
	<Item Name="Pages" Type="String">71-7</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">8309603</Item>
	<Item Name="ISSN" Type="String">0261-5614</Item>
	<Item Name="ESSN" Type="String">1532-1983</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">S0261-5614(08)00204-5</Item>
		<Item Name="doi" Type="String">10.1016/j.clnu.2008.10.012</Item>
		<Item Name="pubmed" Type="String">19054597</Item>
		<Item Name="eid" Type="String">19054597</Item>
		<Item Name="rid" Type="String">19054597</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1016/j.clnu.2008.10.012</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2008/02/13 00:00</Item>
		<Item Name="revised" Type="Date">2008/09/20 00:00</Item>
		<Item Name="accepted" Type="Date">2008/10/28 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2008/12/02 00:00</Item>
		<Item Name="pubmed" Type="Date">2008/12/05 09:00</Item>
		<Item Name="medline" Type="Date">2009/05/27 09:00</Item>
		<Item Name="entrez" Type="Date">2008/12/05 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">3</Item>
	<Item Name="FullJournalName" Type="String">Clinical nutrition (Edinburgh, Scotland)</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1016/j.clnu.2008.10.012</Item>
	<Item Name="SO" Type="String">2009 Feb;28(1):71-7</Item>
</DocSum>

<DocSum>
	<Id>19038786</Id>
	<Item Name="PubDate" Type="Date">2009 Mar</Item>
	<Item Name="EPubDate" Type="Date">2008 Nov 26</Item>
	<Item Name="Source" Type="String">J Leukoc Biol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Bertram CM</Item>
		<Item Name="Author" Type="String">Misso NL</Item>
		<Item Name="Author" Type="String">Fogel-Petrovic M</Item>
		<Item Name="Author" Type="String">Figueroa CD</Item>
		<Item Name="Author" Type="String">Foster PS</Item>
		<Item Name="Author" Type="String">Thompson PJ</Item>
		<Item Name="Author" Type="String">Bhoola KD</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Bhoola KD</Item>
	<Item Name="Title" Type="String">Expression of kinin receptors on eosinophils: comparison of asthmatic patients and healthy subjects.</Item>
	<Item Name="Volume" Type="String">85</Item>
	<Item Name="Issue" Type="String">3</Item>
	<Item Name="Pages" Type="String">544-52</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">8405628</Item>
	<Item Name="ISSN" Type="String">0741-5400</Item>
	<Item Name="ESSN" Type="String">1938-3673</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">jlb.0508283</Item>
		<Item Name="doi" Type="String">10.1189/jlb.0508283</Item>
		<Item Name="pubmed" Type="String">19038786</Item>
		<Item Name="eid" Type="String">19038786</Item>
		<Item Name="rid" Type="String">19038786</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1189/jlb.0508283</Item>
	<Item Name="History" Type="List">
		<Item Name="aheadofprint" Type="Date">2008/11/26 00:00</Item>
		<Item Name="pubmed" Type="Date">2008/11/29 09:00</Item>
		<Item Name="medline" Type="Date">2009/04/07 09:00</Item>
		<Item Name="entrez" Type="Date">2008/11/29 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">1</Item>
	<Item Name="FullJournalName" Type="String">Journal of leukocyte biology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1189/jlb.0508283</Item>
	<Item Name="SO" Type="String">2009 Mar;85(3):544-52</Item>
</DocSum>

<DocSum>
	<Id>19033733</Id>
	<Item Name="PubDate" Type="Date">2009</Item>
	<Item Name="EPubDate" Type="Date">2008 Nov 26</Item>
	<Item Name="Source" Type="String">Int Arch Allergy Immunol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Bavbek S</Item>
		<Item Name="Author" Type="String">Dursun AB</Item>
		<Item Name="Author" Type="String">Birben E</Item>
		<Item Name="Author" Type="String">Kalayci O</Item>
		<Item Name="Author" Type="String">Misirligil Z</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Misirligil Z</Item>
	<Item Name="Title" Type="String">Cellular allergen stimulation test with acetylsalicylic acid-lysine is not a useful test to discriminate between asthmatic patients with and without acetylsalicylic acid sensitivity.</Item>
	<Item Name="Volume" Type="String">149</Item>
	<Item Name="Issue" Type="String">1</Item>
	<Item Name="Pages" Type="String">58-64</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9211652</Item>
	<Item Name="ISSN" Type="String">1018-2438</Item>
	<Item Name="ESSN" Type="String">1423-0097</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Evaluation Studies</Item>
		<Item Name="PubType" Type="String">Journal Article</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">000176307</Item>
		<Item Name="doi" Type="String">10.1159/000176307</Item>
		<Item Name="pubmed" Type="String">19033733</Item>
		<Item Name="eid" Type="String">19033733</Item>
		<Item Name="rid" Type="String">19033733</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1159/000176307</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2008/02/20 00:00</Item>
		<Item Name="accepted" Type="Date">2008/06/16 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2008/11/26 00:00</Item>
		<Item Name="pubmed" Type="Date">2008/11/27 09:00</Item>
		<Item Name="medline" Type="Date">2009/05/12 09:00</Item>
		<Item Name="entrez" Type="Date">2008/11/27 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">1</Item>
	<Item Name="FullJournalName" Type="String">International archives of allergy and immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1159/000176307</Item>
	<Item Name="SO" Type="String">2009;149(1):58-64</Item>
</DocSum>

<DocSum>
	<Id>19001792</Id>
	<Item Name="PubDate" Type="Date">2009</Item>
	<Item Name="EPubDate" Type="Date">2008 Nov 11</Item>
	<Item Name="Source" Type="String">Int Arch Allergy Immunol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Schubert R</Item>
		<Item Name="Author" Type="String">Kitz R</Item>
		<Item Name="Author" Type="String">Beermann C</Item>
		<Item Name="Author" Type="String">Rose MA</Item>
		<Item Name="Author" Type="String">Lieb A</Item>
		<Item Name="Author" Type="String">Sommerer PC</Item>
		<Item Name="Author" Type="String">Moskovits J</Item>
		<Item Name="Author" Type="String">Alberternst H</Item>
		<Item Name="Author" Type="String">Bhles HJ</Item>
		<Item Name="Author" Type="String">Schulze J</Item>
		<Item Name="Author" Type="String">Zielen S</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Zielen S</Item>
	<Item Name="Title" Type="String">Effect of n-3 polyunsaturated fatty acids in asthma after low-dose allergen challenge.</Item>
	<Item Name="Volume" Type="String">148</Item>
	<Item Name="Issue" Type="String">4</Item>
	<Item Name="Pages" Type="String">321-9</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9211652</Item>
	<Item Name="ISSN" Type="String">1018-2438</Item>
	<Item Name="ESSN" Type="String">1423-0097</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Randomized Controlled Trial</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">000170386</Item>
		<Item Name="doi" Type="String">10.1159/000170386</Item>
		<Item Name="pubmed" Type="String">19001792</Item>
		<Item Name="eid" Type="String">19001792</Item>
		<Item Name="rid" Type="String">19001792</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1159/000170386</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2008/03/25 00:00</Item>
		<Item Name="accepted" Type="Date">2008/06/04 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2008/11/11 00:00</Item>
		<Item Name="pubmed" Type="Date">2008/11/13 09:00</Item>
		<Item Name="medline" Type="Date">2009/04/17 09:00</Item>
		<Item Name="entrez" Type="Date">2008/11/13 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">6</Item>
	<Item Name="FullJournalName" Type="String">International archives of allergy and immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1159/000170386</Item>
	<Item Name="SO" Type="String">2009;148(4):321-9</Item>
</DocSum>

<DocSum>
	<Id>18849616</Id>
	<Item Name="PubDate" Type="Date">2009</Item>
	<Item Name="EPubDate" Type="Date">2008 Oct 10</Item>
	<Item Name="Source" Type="String">Int Arch Allergy Immunol</Item>
	<Item Name="AuthorList" Type="List">
		<Item Name="Author" Type="String">Schubert R</Item>
		<Item Name="Author" Type="String">Eickmeier O</Item>
		<Item Name="Author" Type="String">Garn H</Item>
		<Item Name="Author" Type="String">Baer PC</Item>
		<Item Name="Author" Type="String">Mueller T</Item>
		<Item Name="Author" Type="String">Schulze J</Item>
		<Item Name="Author" Type="String">Rose MA</Item>
		<Item Name="Author" Type="String">Rosewich M</Item>
		<Item Name="Author" Type="String">Renz H</Item>
		<Item Name="Author" Type="String">Zielen S</Item>
	</Item>
	<Item Name="LastAuthor" Type="String">Zielen S</Item>
	<Item Name="Title" Type="String">Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy.</Item>
	<Item Name="Volume" Type="String">148</Item>
	<Item Name="Issue" Type="String">3</Item>
	<Item Name="Pages" Type="String">251-60</Item>
	<Item Name="LangList" Type="List">
		<Item Name="Lang" Type="String">English</Item>
	</Item>
	<Item Name="NlmUniqueID" Type="String">9211652</Item>
	<Item Name="ISSN" Type="String">1018-2438</Item>
	<Item Name="ESSN" Type="String">1423-0097</Item>
	<Item Name="PubTypeList" Type="List">
		<Item Name="PubType" Type="String">Journal Article</Item>
		<Item Name="PubType" Type="String">Randomized Controlled Trial</Item>
	</Item>
	<Item Name="RecordStatus" Type="String">PubMed - indexed for MEDLINE</Item>
	<Item Name="PubStatus" Type="String">ppublish+epublish</Item>
	<Item Name="ArticleIds" Type="List">
		<Item Name="pii" Type="String">000161585</Item>
		<Item Name="doi" Type="String">10.1159/000161585</Item>
		<Item Name="pubmed" Type="String">18849616</Item>
		<Item Name="eid" Type="String">18849616</Item>
		<Item Name="rid" Type="String">18849616</Item>
	</Item>
	<Item Name="DOI" Type="String">10.1159/000161585</Item>
	<Item Name="History" Type="List">
		<Item Name="received" Type="Date">2008/02/27 00:00</Item>
		<Item Name="accepted" Type="Date">2008/06/10 00:00</Item>
		<Item Name="aheadofprint" Type="Date">2008/10/10 00:00</Item>
		<Item Name="pubmed" Type="Date">2008/10/14 09:00</Item>
		<Item Name="medline" Type="Date">2009/03/10 09:00</Item>
		<Item Name="entrez" Type="Date">2008/10/14 09:00</Item>
	</Item>
	<Item Name="References" Type="List"></Item>
	<Item Name="HasAbstract" Type="Integer">1</Item>
	<Item Name="PmcRefCount" Type="Integer">2</Item>
	<Item Name="FullJournalName" Type="String">International archives of allergy and immunology</Item>
	<Item Name="ELocationID" Type="String">doi: 10.1159/000161585</Item>
	<Item Name="SO" Type="String">2009;148(3):251-60</Item>
</DocSum>

</eSummaryResult>
<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st May 2013//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_130501.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20113659</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>02</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>03</Month>
            <Day>02</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1008-8830</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>11</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics</Title>
                <ISOAbbreviation>Zhongguo Dang Dai Er Ke Za Zhi</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Urinary leukotrience E(4) level in children with asthma].</ArticleTitle>
            <Pagination>
                <MedlinePgn>909-12</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Cysteinyl leukotriene (CysLTs) plays an important role in airway inflammation and remodeling in asthma. Measurement of urinary leukotriene E(4) (LTE(4)) is a sensitive and noninvasive method of assaying total body CysLTs level. This study aimed to evaluate the clinical significance of urinary leukotriene E(4) (LTE(4)) in childhood asthma.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Sixty children with acute asthma were randomly divided into montelukast (leukotriene receptor antagonist) treatment and conventional treatment groups (n = 30 each). Urinary LTE(4) levels were measured using ELISA and the airway resistance Rint was assessed by the lung function instrument at the acute and the convalescence phases. Twenty healthy children were used as the control group.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Urinary LTE(4) levels in asthmatic children at the acute and the convalescence phases were significantly higher than those in the control group (p&lt;0.01). The urinary LTE(4) levels at the convalescence phase were significantly reduced compared with those at the acute phase in asthmatic children (p&lt;0.01). More significantly decreased urinary LTE(4) levels were noted in the montelukast treatment group than the conventional treatment group at the convalescence phase (p&lt;0.01). In the acute phase, there was no correlation between urinary LTE4 level and Rint in asthmatic children.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Urinary LTE(4) level is significantly increased in children with acute asthma. Urinary LTE(4) is a useful marker for the diagnosis of asthma and can be as a predictor of asthma control and marker of susceptibility to treatment with leukotriene receptor antagonists.</AbstractText>
            </Abstract>
            <Affiliation>Department of Respiratory Medicine, Jiangxi Children's Hospital, Nanchang 330006, China.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>He</LastName>
                    <ForeName>Mei-Juan</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Qiang</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Jian-Mei</ForeName>
                    <Initials>JM</Initials>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Zhongguo Dang Dai Er Ke Za Zhi</MedlineTA>
            <NlmUniqueID>100909956</NlmUniqueID>
            <ISSNLinking>1008-8830</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>75715-89-8</RegistryNumber>
                <NameOfSubstance>Leukotriene E4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Airway Resistance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="Y">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene E4</DescriptorName>
                <QualifierName MajorTopicYN="Y">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>2</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>2</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>3</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1008-8830(2009)11-0909-04</ArticleId>
            <ArticleId IdType="pubmed">20113659</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20074456</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>01</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>03</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0394-6320</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <MedlineDate>2009 Oct-Dec</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of immunopathology and pharmacology</Title>
                <ISOAbbreviation>Int J Immunopathol Pharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>GGTI-2133, an inhibitor of geranylgeranyltransferase, inhibits infiltration of inflammatory cells into airways in mouse experimental asthma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>929-35</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Statins have been proposed as a novel treatment of respiratory diseases including asthma. Although the mechanism of anti-inflammatory effect of statins is still unclear, an inhibition of protein prenylation by depleting the downstream metabolites of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase might be involved. To test the hypothesis, the effects of GGTI-2133, a direct inhibitor of geran ylgeranyltransferase (GGTase), on antigen-induced airway inflammation were investigated in a murine model of allergic bronchial asthma. Mice were sensitized and repeatedly challenged with ovalbumin antigen (OA). Animals were also treated with GGTI-2133 (5 mg/kg/day, i.p.) once a day before and during the antigen inhalation period. Repeated antigen inhalation caused an infiltration of inflammatory cells, especially eosinophils, into airways. Significant increases in interleukin (IL)-4, IL-13, eotaxin, thymus and activation-regulated chemokine (TARC) and leukotriene B4 (LTB4) in bronchoalveolar lavage fluids and total and OA-specific IgE in sera were also found in the antigen-exposed animals. The systemic treatments with GGTI-2133 inhibited the antigen-induced eosinophil infiltration into airways almost completely. However, interestingly, the GGTI-2133 treatment did not affect the levels of these chemotactic factors and IgE. These findings suggest that selective inhibition of GGTase is effective for eosinophilic airway inflammation such as asthma.</AbstractText>
            </Abstract>
            <Affiliation>Department of Pharmacology, School of Pharmacy, Hoshi University, Tokyo, Japan. chiba@hoshi.ac.jp</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chiba</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sato</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Misawa</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>Int J Immunopathol Pharmacol</MedlineTA>
            <NlmUniqueID>8911335</NlmUniqueID>
            <ISSNLinking>0394-6320</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Asthmatic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Ccl17 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Chemokine CCL17</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>GGTI-2133</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Interleukin-13</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Naphthalenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>207137-56-2</RegistryNumber>
                <NameOfSubstance>Interleukin-4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>37341-29-0</RegistryNumber>
                <NameOfSubstance>Immunoglobulin E</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>61-90-5</RegistryNumber>
                <NameOfSubstance>Leucine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>71160-24-2</RegistryNumber>
                <NameOfSubstance>Leukotriene B4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9006-59-1</RegistryNumber>
                <NameOfSubstance>Ovalbumin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.5.-</RegistryNumber>
                <NameOfSubstance>Alkyl and Aryl Transferases</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Alkyl and Aryl Transferases</DescriptorName>
                <QualifierName MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Asthmatic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchoalveolar Lavage Fluid</DescriptorName>
                <QualifierName MajorTopicYN="N">cytology</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Chemokine CCL17</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Immunoglobulin E</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Injections, Intraperitoneal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Interleukin-13</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Interleukin-4</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leucine</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene B4</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Naphthalenes</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Ovalbumin</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Protein Prenylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pulmonary Eosinophilia</DescriptorName>
                <QualifierName MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>3</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">8</ArticleId>
            <ArticleId IdType="pubmed">20074456</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20046412</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>01</Month>
            <Day>04</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>04</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>05</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1976-2437</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>50</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Dec</Month>
                        <Day>31</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Yonsei medical journal</Title>
                <ISOAbbreviation>Yonsei Med. J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Update on recent advances in the management of aspirin exacerbated respiratory disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>744-50</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3349/ymj.2009.50.6.744</ELocationID>
            <Abstract>
                <AbstractText>Aspirin intolerant asthma (AIA) is frequently characterized as an aspirin (ASA)-exacerbated respiratory disease (AERD). It is a clinical syndrome associated with chronic severe inflammation in the upper and lower airways resulting in chronic rhinitis, sinusitis, recurrent polyposis, and asthma. AERD generally develops secondary to abnormalities in inflammatory mediators and arachidonic acid biosynthesis expression. Upper and lower airway eosinophil infiltration is a key feature of AERD; however, the exact mechanisms of such chronic eosinophilic inflammation are not fully understood. Cysteinyl leukotriene over-production may be a key factor in the induction of eosinophilic activation. Genetic studies have suggested a role for variability of genes in disease susceptibility and response to medication. Potential genetic biomarkers contributing to the AERD phenotype include HLA-DPB1*301, LTC4S, ALOX5, CYSLT, PGE2, TBXA2R, TBX21, MS4A2, IL10 -1082A &gt; G, ACE -262A &gt; T, and CRTH2 -466T &gt; C; the four-locus SNP set was composed of B2ADR 46A &gt; G, CCR3 -520T &gt; G, CysLTR1 -634C &gt; T, and FCER1B -109T &gt; C. Management of AERD is an important issue. Aspirin ingestion may result in significant morbidity and mortality, and patients must be advised regarding aspirin risk. Leukotriene receptor antagonists (LTRA) that inhibit leukotriene pathways have an established role in long-term AERD management and rhinosinusitis. Aspirin desensitization may be required for the relief of upper and lower airway symptoms in AERD patients. Future research should focus on identification of biomarkers for a comprehensive diagnostic approach.</AbstractText>
            </Abstract>
            <Affiliation>Department of Allergy and Rheumatology, Ajou University School of Medicine, Yeongtong-gu, Suwon, Korea.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Palikhe</LastName>
                    <ForeName>Nami Shrestha</ForeName>
                    <Initials>NS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Joo-Hee</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Hae-Sim</ForeName>
                    <Initials>HS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Yonsei Med J</MedlineTA>
            <NlmUniqueID>0414003</NlmUniqueID>
            <ISSNLinking>0513-5796</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotriene Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy Asthma Proc. 2006 Sep-Oct;27(5):341-6</RefSource>
                <PMID Version="1">17063661</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2005 Jun;60(6):760-5</RefSource>
                <PMID Version="1">15876305</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 2006 Jul;36(7):877-83</RefSource>
                <PMID Version="1">16839402</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 2006 Apr;36(4):433-9</RefSource>
                <PMID Version="1">16630147</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Tohoku J Exp Med. 2006 Jan;208(1):49-56</RefSource>
                <PMID Version="1">16340173</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2005 Nov;116(5):970-5</RefSource>
                <PMID Version="1">16275362</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Epidemiol. 1999 Aug;28(4):717-22</RefSource>
                <PMID Version="1">10480701</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 1999 Jul;160(1):291-6</RefSource>
                <PMID Version="1">10390414</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 1997 Apr;27(4):431-7</RefSource>
                <PMID Version="1">9146937</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1608-14</RefSource>
                <PMID Version="1">8970343</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 1995 Jan;25(1):38-40</RefSource>
                <PMID Version="1">7728622</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 1995 Aug;96(2):148-56</RefSource>
                <PMID Version="1">7636051</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Respir J. 1993 Mar;6(3):391-9</RefSource>
                <PMID Version="1">8386106</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 1992 Feb;22(2):283-7</RefSource>
                <PMID Version="1">1571820</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Allergy. 1988 Jan;18(1):15-20</RefSource>
                <PMID Version="1">3127083</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Respir J. 1989 Feb;2(2):127-9</RefSource>
                <PMID Version="1">2703041</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drugs. 2004;64(21):2417-32</RefSource>
                <PMID Version="1">15482000</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 2004 Aug;34(8):1270-5</RefSource>
                <PMID Version="1">15298569</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2004 Mar;113(3):562-4</RefSource>
                <PMID Version="1">15007363</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Res. 2004 Jul;50(1):1-11</RefSource>
                <PMID Version="1">15082024</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Expert Opin Pharmacother. 2004 Mar;5(3):679-86</RefSource>
                <PMID Version="1">15013935</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 2003 Aug;33(8):1103-10</RefSource>
                <PMID Version="1">12911785</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2009 Dec;64(12):1746-52</RefSource>
                <PMID Version="1">19385948</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):391-8</RefSource>
                <PMID Version="1">10673176</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Lung Cell Mol Physiol. 2003 Sep;285(3):L619-27</RefSource>
                <PMID Version="1">12754192</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2009 Sep;124(3):417-21</RefSource>
                <PMID Version="1">19482346</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Postgrad Med. 2000 Sep 15;108(4 Suppl):40-4</RefSource>
                <PMID Version="1">19667532</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2009 Aug;64(8):1221-5</RefSource>
                <PMID Version="1">19222424</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int Arch Allergy Immunol. 2009;149(4):378-84</RefSource>
                <PMID Version="1">19295242</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 2008 Nov;38(11):1727-37</RefSource>
                <PMID Version="1">18727619</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergol Int. 2008 Dec;57(4):313-20</RefSource>
                <PMID Version="1">18946233</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Thorax. 2008 Dec;63(12):1076-82</RefSource>
                <PMID Version="1">18757457</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Respir Med. 2008 Aug;102(8):1132-9</RefSource>
                <PMID Version="1">18595682</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Immunol. 2008 Jul;28(4):336-42</RefSource>
                <PMID Version="1">18379861</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):680-5</RefSource>
                <PMID Version="1">18184802</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2007 Nov 1;357(18):1841-54</RefSource>
                <PMID Version="1">17978293</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics. 2007 Sep;8(9):1143-50</RefSource>
                <PMID Version="1">17924829</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2007 Apr;17(4):295-304</RefSource>
                <PMID Version="1">17496729</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2007 Jan;119(1):157-64</RefSource>
                <PMID Version="1">17208597</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 2002 Dec 1;64(11):1549-57</RefSource>
                <PMID Version="1">12429344</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2002 Nov 7;347(19):1524-6</RefSource>
                <PMID Version="1">12421897</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2002 Nov 7;347(19):1493-9</RefSource>
                <PMID Version="1">12421891</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 2002 Oct;32(10):1491-6</RefSource>
                <PMID Version="1">12372130</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Thorax. 2002 Jul;57(7):569-74</RefSource>
                <PMID Version="1">12096197</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chest. 2002 Jan;121(1):143-50</RefSource>
                <PMID Version="1">11796443</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 2001 Feb;31(2):219-25</RefSource>
                <PMID Version="1">11251623</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Respir J. 2000 Sep;16(3):432-6</RefSource>
                <PMID Version="1">11028656</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2000 Dec;106(6):1201-2</RefSource>
                <PMID Version="1">11112909</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2000 Jan;55(1):11-5</RefSource>
                <PMID Version="1">10696852</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Cell Mol Biol. 2000 Sep;23(3):290-6</RefSource>
                <PMID Version="1">10970818</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2000 Jul;106(1 Pt 1):72-6</RefSource>
                <PMID Version="1">10887308</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2005 Sep;60(9):1139-45</RefSource>
                <PMID Version="1">16076298</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2005 Jul;15(7):483-92</RefSource>
                <PMID Version="1">15970796</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Genet. 2005 Jun;117(1):16-26</RefSource>
                <PMID Version="1">15806396</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 2005 May;35(5):585-90</RefSource>
                <PMID Version="1">15898979</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>EMBO J. 2006 Oct 4;25(19):4615-27</RefSource>
                <PMID Version="1">16990797</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma, Aspirin-Induced</DescriptorName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophils</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Models, Biological</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>59</NumberOfReferences>
        <OtherID Source="NLM">PMC2796398</OtherID>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Aspirin</Keyword>
            <Keyword MajorTopicYN="N">asthma</Keyword>
            <Keyword MajorTopicYN="N">eosinophil</Keyword>
            <Keyword MajorTopicYN="N">genetic polymorphism</Keyword>
            <Keyword MajorTopicYN="N">leukotriene</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3349/ymj.2009.50.6.744</ArticleId>
            <ArticleId IdType="pubmed">20046412</ArticleId>
            <ArticleId IdType="pmc">PMC2796398</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20021457</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>12</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>02</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2011</Year>
            <Month>12</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1874-4702</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Current molecular pharmacology</Title>
                <ISOAbbreviation>Curr Mol Pharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>New insights on the possible role of mast cells in aspirin-induced asthma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>182-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Nonsteroidal anti-inflammatory drugs (NSAIDs) are major drugs used in the treatment of inflammation and pain in a wide variety of disorders. The best-known mechanism of action of NSAIDs is the inhibition of prostaglandin synthesis as a result of their action on cyclooxygenase (COX) enzymes. However, data have been accumulating through the years indicating that NSAIDs also act on other targets in cell signaling. It has been established that NSAIDs induce anti-inflammatory effects independent of COX. Acetylsalicylic acid (ASA) and other inhibitors of COX induce severe bronchospasms and asthmatic attacks in a significant population of asthmatic patients. The etiology of ASA induced asthma is complex and not fully understood, but most evidence points towards an abnormality of arachidonic acid (AA) metabolism. Since doses of ASA necessary to treat chronic inflammatory diseases appeared much higher than those required to inhibit PG synthesis, COX-independent mechanisms of NSAIDs were postulated. Recently, we have shown that NSAIDs induced expression of heat shock proteins specially HSP70. Heat shock proteins (HSPs) are normal intracellular proteins that are produced in greater amounts when cells are subjected to stress or injury. Interestingly, a potential pathogenic role for heat shock proteins in diseases such as autoimmune disease, vascular disease has been reported. Because mast cells have been reported to play a role in the pathogenesis of ASA induced asthma, a link between heat shock proteins and this disease could postulated. In this review, an overview is given on aspirin-induced asthma and the cells and mediators that may play a role therein. Mast cell signaling with regard to interaction with NSAIDs and heat shock proteins (HSPs) and toll-like receptors (TLRs) is further highlighted.</AbstractText>
            </Abstract>
            <Affiliation>Division of Pharmacology and Pathophysiology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands. e.mortaz@uu.nl</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mortaz</LastName>
                    <ForeName>Esmaeil</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Engels</LastName>
                    <ForeName>Ferdi</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nijkamp</LastName>
                    <ForeName>Frans P</ForeName>
                    <Initials>FP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Redegeld</LastName>
                    <ForeName>Frank A</ForeName>
                    <Initials>FA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United Arab Emirates</Country>
            <MedlineTA>Curr Mol Pharmacol</MedlineTA>
            <NlmUniqueID>101467997</NlmUniqueID>
            <ISSNLinking>1874-4672</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>HSP70 Heat-Shock Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Toll-Like Receptors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>27415-26-5</RegistryNumber>
                <NameOfSubstance>8-epi-prostaglandin F2alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>50-78-2</RegistryNumber>
                <NameOfSubstance>Aspirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>506-32-1</RegistryNumber>
                <NameOfSubstance>Arachidonic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>551-11-1</RegistryNumber>
                <NameOfSubstance>Dinoprost</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.99.1</RegistryNumber>
                <NameOfSubstance>Prostaglandin-Endoperoxide Synthases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.3.-</RegistryNumber>
                <NameOfSubstance>Phosphoric Monoester Hydrolases</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Arachidonic Acid</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aspirin</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma, Aspirin-Induced</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dinoprost</DescriptorName>
                <QualifierName MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mast Cells</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Phosphoric Monoester Hydrolases</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Prostaglandin-Endoperoxide Synthases</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Toll-Like Receptors</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>85</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>2</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20021457</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20008883</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>12</Month>
            <Day>17</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>03</Month>
            <Day>19</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1943-5665</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>6</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Proceedings of the American Thoracic Society</Title>
                <ISOAbbreviation>Proc Am Thorac Soc</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Obstructive lung disease from conception to old age: differences in the treatment of adults and children with asthma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>720-3</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1513/pats.200907-059DP</ELocationID>
            <Abstract>
                <AbstractText>Achieving asthma control is the focus of asthma management. Inhaled corticosteroids are the most effective treatment for asthma in children and adults, with no evidence that the magnitude of benefit differs between adults and school-aged children. Leukotriene inhibitors are more widely used in children than in adults. This may be because provoking stimuli, such as environmental allergens and frequent exercise, are more important asthma triggers in children or because parental concerns about the side effects of treatment with ICS. Inhaled corticosteroid/long-acting inhaled beta(2)-agonist combinations may not be as effective in children as in they are adults in improving asthma control and reducing asthma exacerbations.</AbstractText>
            </Abstract>
            <Affiliation>Firestone Institute for Respiratory Health, St. Joseph's Hospital and Department of Medicine, McMaster University, Hamilton, Ontario, Canada. obyrnep@mcmaster.ca</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>O'Byrne</LastName>
                    <ForeName>Paul M</ForeName>
                    <Initials>PM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Proc Am Thorac Soc</MedlineTA>
            <NlmUniqueID>101203596</NlmUniqueID>
            <ISSNLinking>1546-3222</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Adrenal Cortex Hormones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Adrenergic beta-Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Administration, Inhalation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adrenergic beta-Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>51</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>3</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">6/8/720</ArticleId>
            <ArticleId IdType="doi">10.1513/pats.200907-059DP</ArticleId>
            <ArticleId IdType="pubmed">20008883</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20008181</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>12</Month>
            <Day>16</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>03</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2010</Year>
            <Month>11</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1520-4383</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2009</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program</Title>
                <ISOAbbreviation>Hematology Am Soc Hematol Educ Program</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Asthma and sickle cell disease: two distinct diseases or part of the same process?</ArticleTitle>
            <Pagination>
                <MedlinePgn>45-53</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1182/asheducation-2009.1.45</ELocationID>
            <Abstract>
                <AbstractText>A physician diagnosis of asthma in children and adults with sickle cell disease (SCD) has been associated with increased rates of pain and acute chest syndrome (ACS) episodes and premature death. Despite the clinical significance of a doctor's diagnosis of asthma in individuals with SCD, the criteria for a physician diagnosis of asthma are not well defined. Many features of asthma are common in individuals with SCD, including symptoms of wheezing, obstructive lung disease and airway hyper-responsiveness. However, it is not clear if these signs and symptoms of asthma reflect a physician diagnosis of asthma, or if these asthma features are related to SCD. Further complicating the diagnosis of asthma in children with SCD is the significant overlap in clinical manifestations between an asthma exacerbation and an ACS episode. Evidence supporting the concept that asthma and SCD are separate co-morbid conditions includes a similar prevalence of asthma between children with SCD and those in the general population and the observation that asthma is inherited in a familial pattern in the families of children with SCD. In contrast, there is significant evidence that asthma-like features may be associated with SCD without a diagnosis of asthma, including a higher than expected prevalence of airway hyper-responsiveness and obstructive lung disease. Regardless of whether SCD and asthma are distinct or overlapping co-morbid conditions, we recommend a systematic and complete evaluation of asthma when the diagnosis is suspected or when patients have multiple episodes of pain or ACS.</AbstractText>
            </Abstract>
            <Affiliation>Department of Medicine, Division of Hematology, Washington University School of Medicine, St. Louis, MO 63110, USA. jfield@dom.wustl.edu</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Field</LastName>
                    <ForeName>Joshua J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>DeBaun</LastName>
                    <ForeName>Michael R</ForeName>
                    <Initials>MR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hematology Am Soc Hematol Educ Program</MedlineTA>
            <NlmUniqueID>100890099</NlmUniqueID>
            <ISSNLinking>1520-4383</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>10102-43-9</RegistryNumber>
                <NameOfSubstance>Nitric Oxide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Acute Chest Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anemia, Sickle Cell</DescriptorName>
                <QualifierName MajorTopicYN="N">complications</QualifierName>
                <QualifierName MajorTopicYN="N">mortality</QualifierName>
                <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchial Hyperreactivity</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Comorbidity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Nitric Oxide</DescriptorName>
                <QualifierName MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pulmonary Disease, Chronic Obstructive</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Respiratory Sounds</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>64</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>3</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">2009/1/45</ArticleId>
            <ArticleId IdType="doi">10.1182/asheducation-2009.1.45</ArticleId>
            <ArticleId IdType="pubmed">20008181</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19912318</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>01</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>05</Month>
            <Day>11</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2362</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>40</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of clinical investigation</Title>
                <ISOAbbreviation>Eur. J. Clin. Invest.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The acute effect of smoking in healthy and asthmatic smokers.</ArticleTitle>
            <Pagination>
                <MedlinePgn>103-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2362.2009.02221.x</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute exposure to cigarette smoke is related to airway and systemic inflammation and oxidative stress. Little is known about the acute effect of cigarette smoking in smoking asthmatics. The aim of this study was to evaluate the acute effect of smoking in airway and systemic inflammation and oxidative stress in normal smokers and patients with properly treated well-controlled persistent asthma.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Ten normal smokers and 10 smokers with moderate persistent asthma controlled with LABA and ICS were recruited. Subjects refrained from smoking for at least 12 h prior to their inclusion. We compared the effects of smoking of two cigarettes on airway obstruction, airway inflammation and oxidative stress [by measuring fraction of exhaled nitric oxide (FeNO), plus pH and 8-isoprostane in exhaled breath condensate (EBC)] before and 30, 90 and 180 min after smoking. Furthermore, we evaluated systemic oxidative stress, C-reactive protein (CRP) and serum amyloid A (SAA) and urine leukotriene E(4) (LTE(4)) before and 180 min after smoking.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">No differences were observed in EBC pH and 8-isoprostane, FeNO and systemic oxidative stress between the groups at baseline. In asthmatics, EBC pH decreased 30 min and EBC 8-isoprostane increased 90 min after smoking (P = 0.039 and P = 0.029 respectively), which was not evident in smoking controls. Serum oxidative stress increased only in asthmatic smokers at 180 min (P = 0.001). No differences were observed in SAA, CRP and urine LTE(4) levels before and after smoking.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Acute smoking has more deleterious effects in well-controlled properly treated asthmatic smokers compared with matched normal smokers.</AbstractText>
            </Abstract>
            <Affiliation>University of Thessaly Medical School, Larissa, Greece.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Papaioannou</LastName>
                    <ForeName>A I</ForeName>
                    <Initials>AI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koutsokera</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanou</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kiropoulos</LastName>
                    <ForeName>T S</ForeName>
                    <Initials>TS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsilioni</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oikonomidi</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liadaki</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pournaras</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gourgoulianis</LastName>
                    <ForeName>K I</ForeName>
                    <Initials>KI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kostikas</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Eur J Clin Invest</MedlineTA>
            <NlmUniqueID>0245331</NlmUniqueID>
            <ISSNLinking>0014-2972</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Biological Markers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Serum Amyloid A Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>10102-43-9</RegistryNumber>
                <NameOfSubstance>Nitric Oxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>27415-26-5</RegistryNumber>
                <NameOfSubstance>8-epi-prostaglandin F2alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>551-11-1</RegistryNumber>
                <NameOfSubstance>Dinoprost</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75715-89-8</RegistryNumber>
                <NameOfSubstance>Leukotriene E4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-41-4</RegistryNumber>
                <NameOfSubstance>C-Reactive Protein</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Biological Markers</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Breath Tests</DescriptorName>
                <QualifierName MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">C-Reactive Protein</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dinoprost</DescriptorName>
                <QualifierName MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Exhalation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene E4</DescriptorName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Nitric Oxide</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Oxidative Stress</DescriptorName>
                <QualifierName MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Respiratory Function Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Serum Amyloid A Protein</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Smoking</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sputum</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>5</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ECI2221</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1365-2362.2009.02221.x</ArticleId>
            <ArticleId IdType="pubmed">19912318</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19897276</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>06</Month>
            <Day>04</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>11</Month>
            <Day>03</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1878-3279</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>215</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Immunobiology</Title>
                <ISOAbbreviation>Immunobiology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Choline attenuates immune inflammation and suppresses oxidative stress in patients with asthma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>527-34</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.imbio.2009.09.004</ELocationID>
            <Abstract>
                <AbstractText>Asthma is a chronic immune inflammatory disease characterized by variable airflow obstruction and increased bronchial hyperreactivity (BHR). Therapeutic interventions reduce airway inflammation and relieve symptoms but associated with potential side effects that limit their usefulness. The present study was undertaken to assess the effect of choline on immune inflammation and BHR in asthma subjects. The patients of asthma (n=76) were recruited and treated with choline supplement (1500 mg twice) or standard pharmacotherapy for 6 months in two groups. The patients were evaluated by clinical, immunologic and biochemical parameters. The treatment with choline showed significant reduction in symptom/drug score and improvement in PC(20) FEV1 compared to baseline or standard pharmacotherapy (p&lt;0.01). Choline therapy significantly reduced IL-4, IL-5 and TNF-alpha level as compared to baseline or standard pharmacotherapy after 6 months (p&lt;0.01). Blood eosinophil count and total IgE levels were reduced in both the treatment groups. Cysteinyl leukotriene and leukotriene B4 were suppressed significantly by choline treatment (p&lt;0.01). This was accompanied by decreased 8-isoprostanes, a biomarker for oxidative stress after choline treatment (p&lt;0.01). Choline therapy modulates immune inflammation and suppresses oxidative stress in asthma patients. It can be used as an adjunct therapy for asthma patients.</AbstractText>
                <CopyrightInformation>Copyright 2009 Elsevier GmbH. All rights reserved.</CopyrightInformation>
            </Abstract>
            <Affiliation>Allergy and Immunology Section, Institute of Genomics and Integrative Biology, Delhi, India.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mehta</LastName>
                    <ForeName>Amit K</ForeName>
                    <Initials>AK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Bhanu P</ForeName>
                    <Initials>BP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arora</LastName>
                    <ForeName>Naveen</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gaur</LastName>
                    <ForeName>Shailendra N</ForeName>
                    <Initials>SN</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Immunobiology</MedlineTA>
            <NlmUniqueID>8002742</NlmUniqueID>
            <ISSNLinking>0171-2985</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Cytokines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>62-49-7</RegistryNumber>
                <NameOfSubstance>Choline</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchial Hyperreactivity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Choline</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cytokines</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophils</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Forced Expiratory Volume</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Immunosuppression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Inflammation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Oxidative Stress</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Skin Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Th2 Cells</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0171-2985(09)00152-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.imbio.2009.09.004</ArticleId>
            <ArticleId IdType="pubmed">19897276</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19895589</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>03</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>06</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2011</Year>
            <Month>11</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2222</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>40</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</Title>
                <ISOAbbreviation>Clin. Exp. Allergy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prostaglandin E2 and cysteinyl leukotriene concentrations in sputum: association with asthma severity and eosinophilic inflammation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>85-93</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2222.2009.03386.x</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Inflammation of the airways in asthma is associated with the production of cysteinyl leukotrienes (cysLT), prostaglandin (PG)E(2), 8-isoprostane, nitric oxide and other mediators. However, the relationship between asthma severity or eosinophilic inflammation and the concentrations of mediators in sputum is unclear.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess sputum PGE(2), cysLT, 8-isoprostane and nitrate concentrations, as well as urinary leukotriene (LT)E(4) and 9alpha,11beta-prostaglandin (PG)F(2) concentrations, in patients with differing severities of asthma and eosinophilic or non-eosinophilic airway inflammation.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Inflammatory cells in sputum were assessed in 12 patients with mild, 14 with moderate and 12 with severe persistent asthma, as well as in 13 control subjects. Asthmatic patients were categorized into those with eosinophilic or non-eosinophilic airway inflammation. Sputum PGE(2), cysLT and 8-isoprostane, and urinary LTE(4) were extracted on immunoaffinity sorbents, and the concentrations of all mediators were measured using enzyme immunoassays. Sputum nitrate concentrations were measured on a chemiluminescence analyzer.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Sputum PGE(2) concentrations were higher in both moderate (1710 pg/mL) and severe asthmatic (1590 pg/mL) compared with control subjects (827 pg/mL) (P&lt;0.05). CysLT concentrations were higher in moderate asthmatic compared with control or severe asthmatic subjects (P&lt;0.05). Sputum PGE(2) concentrations were lower in patients with eosinophilic (1180 pg/mL) compared with non-eosinophilic airway inflammation (2520 pg/mL) (P=0.02). In contrast, sputum cysLT and urinary LTE(4) concentrations were higher in those with eosinophilic airway inflammation (P&lt;0.05). Forced expiratory volume in 1 s was inversely correlated with sputum eosinophils in all asthmatic patients (r(s)=-0.5, P=0.002). There were no significant differences in sputum 8-isoprostane or nitrate concentrations.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Increased airway concentrations of PGE(2) are consistent with the hypothesis that PGE(2) has a bronchoprotective and anti-inflammatory role in patients with more severe asthma. A reduced PGE(2) to cysLT ratio in the airways may adversely affect lung function and contribute to persistence of symptoms and airway remodelling in patients with eosinophilic airway inflammation.</AbstractText>
            </Abstract>
            <Affiliation>Centre for Asthma, Allergy and Respiratory Research, Lung Institute of Western Australia, The University of Western Australia, Perth, WA, Australia.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Aggarwal</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moodley</LastName>
                    <ForeName>Y P</ForeName>
                    <Initials>YP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thompson</LastName>
                    <ForeName>P J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Misso</LastName>
                    <ForeName>N L</ForeName>
                    <Initials>NL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Clin Exp Allergy</MedlineTA>
            <NlmUniqueID>8906443</NlmUniqueID>
            <ISSNLinking>0954-7894</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Biological Markers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Nitrates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>cysteinyl-leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>363-24-6</RegistryNumber>
                <NameOfSubstance>Dinoprostone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>52-90-4</RegistryNumber>
                <NameOfSubstance>Cysteine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Biological Markers</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cysteine</DescriptorName>
                <QualifierName MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dinoprostone</DescriptorName>
                <QualifierName MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Disease Progression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophils</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Inflammation</DescriptorName>
                <QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukocyte Count</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Luminescent Measurements</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Nitrates</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sputum</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">CEA3386</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1365-2222.2009.03386.x</ArticleId>
            <ArticleId IdType="pubmed">19895589</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19894390</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>11</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>01</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2010</Year>
            <Month>11</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0255-2922</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>29</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan / sponsored by All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine</Title>
                <ISOAbbreviation>J Tradit Chin Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of wuwei dilong decoction on inflammatory cells and cytokines in asthma model guinea pigs.</ArticleTitle>
            <Pagination>
                <MedlinePgn>220-3</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To explore the effects and the mechanism of Wuwei Dilong Decoction (Schisandra Fruit and Earthworm Decoction) for treatment of asthma.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The asthma guinea pig model was established with spray of ovalbumin (OVA). Fifteen days later, the guinea pigs were administered by intra-gastric perfusion of Wuwei Dilong Decoction once a day for 8 consecutive days. Blood samples were taken for testing the total leucocytes, eosinophil (EOS), lymphocytes, interferon-gamma (IFN-gamma) and leukotriene B4 (LTB4).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In the asthma model group, the total leucocytes, EOS and lymphocytes were all increased, with significant differences as compared with the different dosage Wuwei Dilong Decoction groups (P &lt; 0.01 or P &lt; 0.05). The serum LTB4 in the asthma model group was significantly increased and IFN-gamma decreased. After administration of Wuwei Dilong Decoction of the large, medium and small dosages, LTB4 decreased, while IFN-gamma increased (P &lt; 0.05 or P &lt; 0.01).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Wuwei Dilong Decoction can inhibit infiltration and diffusion of the inflammatory cells in the asthma model guinea pigs, and regulate LTB4 and IFN-gamma, which is probably one of the important mechanisms of Wuwei Dilong Decoction for relieving asthma.</AbstractText>
            </Abstract>
            <Affiliation>Medical College of Changliang University, Jingzhou 434000, China.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Xiang-Hua</ForeName>
                    <Initials>XH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tu</LastName>
                    <ForeName>Xian-Yu</ForeName>
                    <Initials>XY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>De-Xin</ForeName>
                    <Initials>DX</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Jia-Feng</ForeName>
                    <Initials>JF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Wen-Ying</ForeName>
                    <Initials>WY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yuan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Du</LastName>
                    <ForeName>Ya-Ming</ForeName>
                    <Initials>YM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>J Tradit Chin Med</MedlineTA>
            <NlmUniqueID>8211546</NlmUniqueID>
            <ISSNLinking>0255-2922</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Drugs, Chinese Herbal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>wuwei dilong</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>71160-24-2</RegistryNumber>
                <NameOfSubstance>Leukotriene B4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>82115-62-6</RegistryNumber>
                <NameOfSubstance>Interferon-gamma</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Analysis of Variance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophils</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Guinea Pigs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Interferon-gamma</DescriptorName>
                <QualifierName MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukocyte Count</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukocytes</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene B4</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Lymphocytes</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Medicine, Chinese Traditional</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Random Allocation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19894390</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19852204</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>10</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>12</Month>
            <Day>04</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1081-1206</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>103</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of allergy, asthma &amp; immunology : official publication of the American College of Allergy, Asthma, &amp; Immunology</Title>
                <ISOAbbreviation>Ann. Allergy Asthma Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Regulation of monocyte chemoattractant protein 1 by cysteinyl leukotriene D4 in human lung epithelial A549 cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>358-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S1081-1206(10)60540-6</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Seung-Hyun</ForeName>
                    <Initials>SH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Eun-Mi</ForeName>
                    <Initials>EM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Seol-Hwa</ForeName>
                    <Initials>SH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Hae-Sim</ForeName>
                    <Initials>HS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Letter</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ann Allergy Asthma Immunol</MedlineTA>
            <NlmUniqueID>9503580</NlmUniqueID>
            <ISSNLinking>1081-1206</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Chemokine CCL2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotriene Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Propionates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Quinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>cysteinyl-leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>115104-28-4</RegistryNumber>
                <NameOfSubstance>verlukast</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>52-90-4</RegistryNumber>
                <NameOfSubstance>Cysteine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>73836-78-9</RegistryNumber>
                <NameOfSubstance>Leukotriene D4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Chemokine CCL2</DescriptorName>
                <QualifierName MajorTopicYN="Y">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cysteine</DescriptorName>
                <QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Epithelial Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene D4</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Propionates</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Quinolines</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19852204</ArticleId>
            <ArticleId IdType="pii">S1081-1206(10)60540-6</ArticleId>
            <ArticleId IdType="doi">10.1016/S1081-1206(10)60540-6</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19839969</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>04</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1398-9995</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>65</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Allergy</Title>
                <ISOAbbreviation>Allergy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Elevated urinary leukotriene E excretion in asthma: a comparison of HPLC-mass spectrometry and ELISA.</ArticleTitle>
            <Pagination>
                <MedlinePgn>663-4</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1398-9995.2009.02206.x</ELocationID>
            <Affiliation>Department of Medicine, Jagiellonian University School of Medicine, Krakow, Poland. mmszczek@cyf-kr.edu.pl</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sanak</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bochenek</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Faber</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Plutecka</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Szczeklik</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Comparative Study</PublicationType>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Denmark</Country>
            <MedlineTA>Allergy</MedlineTA>
            <NlmUniqueID>7804028</NlmUniqueID>
            <ISSNLinking>0105-4538</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>75715-89-8</RegistryNumber>
                <NameOfSubstance>Leukotriene E4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Chromatography, High Pressure Liquid</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Enzyme-Linked Immunosorbent Assay</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene E4</DescriptorName>
                <QualifierName MajorTopicYN="Y">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Mass Spectrometry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Urinalysis</DescriptorName>
                <QualifierName MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ALL2206</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1398-9995.2009.02206.x</ArticleId>
            <ArticleId IdType="pubmed">19839969</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19811112</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>11</Month>
            <Day>17</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>02</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1473-4877</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>25</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Current medical research and opinion</Title>
                <ISOAbbreviation>Curr Med Res Opin</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clinical study of the effects on asthma-related QOL and asthma management of a medical food in adult asthma patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2865-75</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1185/03007990903316491</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Asthma can have a negative impact on quality of life although this is not well correlated with objective evaluations of pulmonary function. A medical food, EFF1009, containing the fatty acids gamma-linolenic acid (GLA) and eicosapentaenoic acid (EPA) decreases leukotriene B(4) synthesis in patients with asthma. Two previous clinical studies with EFF1009 provided preliminary evidence that the medical food improves asthma-related quality of life (ARQOL) and asthma management.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the impact on ARQOL of EFF1009 in adults with asthma.</AbstractText>
                <AbstractText Label="RESEARCH DESIGN AND METHODS" NlmCategory="METHODS">The study was a randomized, prospective, double-blind, placebo-controlled, parallel group study in twenty-one (N = 21 evaluable) subjects with mild to moderate persistent asthma who consumed the medical food emulsion or placebo emulsion daily for 28 days. All participants continued their asthma medications throughout the study. ARQOL, including asthma signs and symptoms, and asthma control were measured using the Mini Asthma Quality of Life Questionnaire (MiniAQLQ) and the Asthma Control Questionnaire (ACQ), administered at baseline, Day 14 and Day 28. Safety and tolerability parameters, including adverse events, were monitored.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline ARQOL scores, forced expiratory volume in one second (FEV(1)) and other characteristics were balanced between both groups. Mean (standard error) total MiniAQLQ scores changed by 0.73 (0.38) and -0.22 (0.36) in the EFF1009 and placebo groups, respectively, (p &lt; 0.05). The MiniAQLQ symptom domain score was improved in the EFF1009 group (p &lt; 0.05). Total scores for the ACQ were not significantly improved in either group. Levels of the fatty acid EPA in plasma increased in the EFF1009 group but not the placebo group (p &lt; 0.03). The medical food was well tolerated and no safety concerns were identified.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The dietary addition of the medical food EFF1009 to asthma management regimens can improve patient perceived, ARQOL and can also improve asthma management as evidenced by reduced asthma symptoms. An additional study of the medical food, with larger subject population and longer treatment duration, is warranted to confirm these findings.</AbstractText>
            </Abstract>
            <Affiliation>Efficas Inc., Boulder, CO, USA. jlindemann@efficas.com</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lindemann</LastName>
                    <ForeName>Julianne</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>David Pampe</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peterkin</LastName>
                    <ForeName>Joanna J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Orozco-Cronin</LastName>
                    <ForeName>Patti</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Belofsky</LastName>
                    <ForeName>Gil</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stull</LastName>
                    <ForeName>Dean</ForeName>
                    <Initials>D</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Randomized Controlled Trial</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Curr Med Res Opin</MedlineTA>
            <NlmUniqueID>0351014</NlmUniqueID>
            <ISSNLinking>0300-7995</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>EFF1009</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Emulsions</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Placebos</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Plant Oils</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>borage oil</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1553-41-9</RegistryNumber>
                <NameOfSubstance>Eicosapentaenoic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>506-26-3</RegistryNumber>
                <NameOfSubstance>gamma-Linolenic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>71160-24-2</RegistryNumber>
                <NameOfSubstance>Leukotriene B4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">diet therapy</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="Y">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eicosapentaenoic Acid</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Emulsions</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Food, Fortified</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene B4</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Placebos</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Plant Oils</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Quality of Life</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Questionnaires</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">gamma-Linolenic Acid</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>2</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1185/03007990903316491</ArticleId>
            <ArticleId IdType="pubmed">19811112</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19757309</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>03</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1029-2403</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>50</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Leukemia &amp; lymphoma</Title>
                <ISOAbbreviation>Leuk. Lymphoma</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dramatic resolution of respiratory symptoms with imatinib mesylate in patients with chronic myeloid leukemia presenting with lower airway symptoms resembling asthma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1721-2</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1080/10428190903161059</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ramanujam</LastName>
                    <ForeName>Deivasikamani</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McNicholl</LastName>
                    <ForeName>Feargal</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Furby</LastName>
                    <ForeName>Darshayani</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Richardson</LastName>
                    <ForeName>Deborah</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cuthbert</LastName>
                    <ForeName>Robert J G</ForeName>
                    <Initials>RJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McMullin</LastName>
                    <ForeName>Mary F</ForeName>
                    <Initials>MF</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Case Reports</PublicationType>
                <PublicationType>Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Leuk Lymphoma</MedlineTA>
            <NlmUniqueID>9007422</NlmUniqueID>
            <ISSNLinking>1026-8022</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Piperazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Protein Kinase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Pyrimidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>72025-60-6</RegistryNumber>
                <NameOfSubstance>Leukotriene C4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>BKJ8M8G5HI</RegistryNumber>
                <NameOfSubstance>imatinib</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma, Exercise-Induced</DescriptorName>
                <QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">B-Lymphocytes</DescriptorName>
                <QualifierName MajorTopicYN="N">secretion</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cough</DescriptorName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Diagnostic Errors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dyspnea</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Exercise</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukemia, Myeloid, Chronic-Phase</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="Y">complications</QualifierName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene C4</DescriptorName>
                <QualifierName MajorTopicYN="N">secretion</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Paraneoplastic Syndromes</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Piperazines</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pyrimidines</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Remission Induction</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>3</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">914995359</ArticleId>
            <ArticleId IdType="doi">10.1080/10428190903161059</ArticleId>
            <ArticleId IdType="pubmed">19757309</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19749079</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>11</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>12</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1521-0103</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>331</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of pharmacology and experimental therapeutics</Title>
                <ISOAbbreviation>J. Pharmacol. Exp. Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1042-50</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1124/jpet.109.158089</ELocationID>
            <Abstract>
                <AbstractText>Leukotrienes (LTs) are proinflammatory lipid mediators synthesized by the conversion of arachidonic acid (AA) to LTA(4) by the enzyme 5-lipoxygenase (5-LO) in the presence of 5-LO-activating protein (FLAP). 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103) is a novel selective FLAP inhibitor in development for the treatment of respiratory conditions such as asthma. In a rat ex vivo whole-blood calcium ionophore-induced LTB(4) assay, AM103 (administered orally at 1 mg/kg) displayed &gt;50% inhibition for up to 6 h with a calculated EC(50) of approximately 60 nM. When rat lung was challenged in vivo with calcium ionophore, AM103 inhibited LTB(4) and cysteinyl leukotriene (CysLT) production with ED(50) values of 0.8 and 1 mg/kg, respectively. In this model, the EC(50) derived from plasma AM103 was approximately 330 nM for inhibition of both LTB(4) and CysLT. In an acute inflammation setting, AM103 displayed dose-dependent inhibition of LTB(4), CysLT, and plasma protein extravasation induced by peritoneal zymosan injection. In a model of chronic lung inflammation using ovalbumin-primed and challenged BALB/c mice, AM103 reduced the concentrations of eosinophil peroxidase, CysLTs, and interleukin-5 in the bronchoalveolar lavage fluid. Finally, AM103 increased survival time in mice exposed to a lethal intravenous injection of platelet-activating factor. In summary, AM103 is a novel, potent and selective FLAP inhibitor that has excellent pharmacodynamic properties in vivo and is effective in animal models of acute and chronic inflammation and in a model of lethal shock.</AbstractText>
            </Abstract>
            <Affiliation>Amira Pharmaceuticals, San Diego, California 92121, USA. dan.lorrain@amirapharm.com</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lorrain</LastName>
                    <ForeName>Daniel S</ForeName>
                    <Initials>DS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bain</LastName>
                    <ForeName>Gretchen</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Correa</LastName>
                    <ForeName>Lucia D</ForeName>
                    <Initials>LD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chapman</LastName>
                    <ForeName>Charles</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Broadhead</LastName>
                    <ForeName>Alex R</ForeName>
                    <Initials>AR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santini</LastName>
                    <ForeName>Angelina M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Prodanovich</LastName>
                    <ForeName>Pat</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Darlington</LastName>
                    <ForeName>Janice V</ForeName>
                    <Initials>JV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hutchinson</LastName>
                    <ForeName>John H</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>King</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Catherine</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baccei</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yiwei</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arruda</LastName>
                    <ForeName>Jeannie M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Evans</LastName>
                    <ForeName>Jilly F</ForeName>
                    <Initials>JF</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>09</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Pharmacol Exp Ther</MedlineTA>
            <NlmUniqueID>0376362</NlmUniqueID>
            <ISSNLinking>0022-3565</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>3-(3-tert-butylsulfanyl-1-(4-(6-methoxypyridin-3-yl)benzyl)-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl)-2,2-dimethylpropionic acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>5-Lipoxygenase-Activating Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>ALOX5AP protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Alox5ap protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Alox5ap protein, rat</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Carrier Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Indoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Membrane Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Propionates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>71160-24-2</RegistryNumber>
                <NameOfSubstance>Leukotriene B4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9010-72-4</RegistryNumber>
                <NameOfSubstance>Zymosan</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">5-Lipoxygenase-Activating Proteins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Acute Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Carrier Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Chronic Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Extravasation of Diagnostic and Therapeutic Materials</DescriptorName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Indoles</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Inflammation</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene B4</DescriptorName>
                <QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Membrane Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pneumonia</DescriptorName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Propionates</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Zymosan</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jpet.109.158089</ArticleId>
            <ArticleId IdType="doi">10.1124/jpet.109.158089</ArticleId>
            <ArticleId IdType="pubmed">19749079</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19739647</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>11</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1520-4804</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>52</Volume>
                    <Issue>19</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Oct</Month>
                        <Day>8</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medicinal chemistry</Title>
                <ISOAbbreviation>J. Med. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).</ArticleTitle>
            <Pagination>
                <MedlinePgn>5803-15</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1021/jm900945d</ELocationID>
            <Abstract>
                <AbstractText>The potent and selective 5-lipoxygenase-activating protein leukotriene synthesis inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (11j) is described. Lead optimization was designed to afford compounds with superior in vitro and in vivo inhibition of leukotriene synthesis in addition to having excellent pharmacokinetics and safety in rats and dogs. The key structural features of these new compounds are incorporation of heterocycles on the indole N-benzyl substituent and replacement of the quinoline group resulting in compounds with excellent in vitro and in vivo activities, superior pharmacokinetics, and improved physical properties. The methoxypyridine derivative 11j has an IC(50) of 4.2 nM in a 5-lipoxygenase-activating protein (FLAP) binding assay, an IC(50) of 349 nM in the human blood LTB(4) inhibition assay, and is efficacious in a murine ovalbumin model of allergen-induced asthma. Compound 11j was selected for clinical development and has successfully completed phase 1 trials in healthy volunteers.</AbstractText>
            </Abstract>
            <Affiliation>Departments of Chemistry, Amira Pharmaceuticals, San Diego, California 92121, USA. john.hutchinson@amirapharm.com</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hutchinson</LastName>
                    <ForeName>John H</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yiwei</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arruda</LastName>
                    <ForeName>Jeannie M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baccei</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bain</LastName>
                    <ForeName>Gretchen</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chapman</LastName>
                    <ForeName>Charles</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Correa</LastName>
                    <ForeName>Lucia</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Darlington</LastName>
                    <ForeName>Janice</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>King</LastName>
                    <ForeName>Christopher D</ForeName>
                    <Initials>CD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Catherine</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lorrain</LastName>
                    <ForeName>Dan</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Prodanovich</LastName>
                    <ForeName>Pat</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rong</LastName>
                    <ForeName>Haojing</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santini</LastName>
                    <ForeName>Angelina</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stock</LastName>
                    <ForeName>Nicholas</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Prasit</LastName>
                    <ForeName>Peppi</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Evans</LastName>
                    <ForeName>Jilly F</ForeName>
                    <Initials>JF</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Med Chem</MedlineTA>
            <NlmUniqueID>9716531</NlmUniqueID>
            <ISSNLinking>0022-2623</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>3-(3-tert-butylsulfanyl-1-(4-(6-methoxypyridin-3-yl)benzyl)-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl)-2,2-dimethylpropionic acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>5-Lipoxygenase-Activating Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>ALOX5AP protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Alox5ap protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Carrier Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Heterocyclic Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Indoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Membrane Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Propionates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>71160-24-2</RegistryNumber>
                <NameOfSubstance>Leukotriene B4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">5-Lipoxygenase-Activating Proteins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Carrier Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dogs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Toxicity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Heterocyclic Compounds</DescriptorName>
                <QualifierName MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Indoles</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene B4</DescriptorName>
                <QualifierName MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Membrane Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Propionates</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Protein Binding</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm900945d</ArticleId>
            <ArticleId IdType="pubmed">19739647</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19706339</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>01</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1878-1705</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>International immunopharmacology</Title>
                <ISOAbbreviation>Int. Immunopharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhaled montelukast inhibits cysteinyl-leukotriene-induced bronchoconstriction in ovalbumin-sensitized guinea-pigs: the potential as a new asthma medication.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1337-41</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2009.08.007</ELocationID>
            <Abstract>
                <AbstractText>Oral cysteinyl-leukotriene (LT) receptor antagonists such as montelukast are used for reducing airway inflammation and exacerbations. However, inhaled therapy using LT receptor antagonists has not been studied. In the present study, the effect of inhaled montelukast was investigated on airway hyperresponsiveness measured by cysteinyl-LT induced bronchoconstriction in an animal model of asthma. Bronchoconstriction responses were induced by inhaled LTC4 and LTD4 (0.2 microg/ml each) or three doses of intravenous LTC4 and LTD4 (0.3, 1, 3 microg/kg) in ovalbumin (OVA)-sensitized Hartley male guinea-pigs. The response was measured by the change in peak pressure of airway opening (Pao). The effect of montelukast was evaluated by the comparison of bronchoconstriction responses between the groups of animals pre-treated with 15-min inhalation of 10mg/ml montelukast and saline. To evaluate the tissue injury which might be caused by montelukast inhalation, lung tissues were examined for the histology. The broncoconstriction responses induced by inhaled LTC4 and LTD4 were enhanced by OVA sensitization in the guinea-pigs. In sensitized animals, the significant increases in peak Pao were 18.5+/-2.1 cmH(2)O by LTC4 inhalation and 25.0+/-1.6 cmH(2)O by LTD4 inhalation on average. Prior treatment of inhaled montelukast potently suppressed the peak Pao increases induced by both inhaled and intravenous LTC4 and LTD4 (all P&lt;0.01 vs. saline control). Moreover, the suppression of inhaled montelukast against LTD4-induced bronchoconstriction was observed for at least up to 24h. According to the histological examination, montelukast inhalation produced no injury to the lung tissue. Inhaled montelukast, a cysteinyl-LT receptor antagonist, was effective in inhibiting cysteinyl-LT-induced acute bronchoconstriction, and may have the potential for clinical use as a new asthma drug.</AbstractText>
            </Abstract>
            <Affiliation>Department of Respiratory Medicine and Allergology, Kinki University School of Medicine, Japan. muraki@ko-arena.med.kindai.ac.jp</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Muraki</LastName>
                    <ForeName>Masato</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Imbe</LastName>
                    <ForeName>Shu</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sato</LastName>
                    <ForeName>Ryuji</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ikeda</LastName>
                    <ForeName>Yoko</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamagata</LastName>
                    <ForeName>Shigeyoshi</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iwanaga</LastName>
                    <ForeName>Takashi</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tohda</LastName>
                    <ForeName>Yuji</ForeName>
                    <Initials>Y</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>08</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Int Immunopharmacol</MedlineTA>
            <NlmUniqueID>100965259</NlmUniqueID>
            <ISSNLinking>1567-5769</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Acetates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Immunologic Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotriene Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Quinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>cysteinyl-leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>52-90-4</RegistryNumber>
                <NameOfSubstance>Cysteine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>72025-60-6</RegistryNumber>
                <NameOfSubstance>Leukotriene C4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>73836-78-9</RegistryNumber>
                <NameOfSubstance>Leukotriene D4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9006-59-1</RegistryNumber>
                <NameOfSubstance>Ovalbumin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>MHM278SD3E</RegistryNumber>
                <NameOfSubstance>montelukast</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Acetates</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Administration, Inhalation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchial Hyperreactivity</DescriptorName>
                <QualifierName MajorTopicYN="N">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchoconstriction</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cysteine</DescriptorName>
                <QualifierName MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Guinea Pigs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Immunologic Factors</DescriptorName>
                <QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene C4</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene D4</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Lung</DescriptorName>
                <QualifierName MajorTopicYN="N">anatomy &amp; histology</QualifierName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Ovalbumin</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Quinolines</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1567-5769(09)00248-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.intimp.2009.08.007</ArticleId>
            <ArticleId IdType="pubmed">19706339</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19665766</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-6825</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>124</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of allergy and clinical immunology</Title>
                <ISOAbbreviation>J. Allergy Clin. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genetics and pharmacogenetics of the leukotriene pathway.</ArticleTitle>
            <Pagination>
                <MedlinePgn>422-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaci.2009.06.035</ELocationID>
            <Abstract>
                <AbstractText>Leukotrienes are now established contributors to the inflammatory process in asthma, and leukotriene modifiers are mainstays in the therapy of asthma. This review focuses on published association studies implicating the role of leukotriene pathway genes in asthma pathogenesis and treatment response, specifically focusing on those genetic variants associated with asthma affection status, the development of aspirin-exacerbated respiratory disease, and pharmacogenetic response. Although published studies have been limited by small sample sizes and a lack of independent replication, multiple loci within multiple leukotriene pathway genes have now been associated in more than 1 study related to asthma or asthma treatment response. Those specific variants include 2 variants in the 5-lipoxygenase gene (ALOX5) that are both associated with response to 5-lipoxygenase inhibition and to leukotriene receptor antagonists, variants in genes encoding the 2 established cysteinyl leukotriene receptor antagonists (CYSLTR1 and CYSLTR2) that are both associated with asthma susceptibility in at least 2 independent populations, and a leukotriene C(4) synthase promoter polymorphism (LTC4s) that has been associated with asthma affection status and asthma-exacerbated respiratory disease. Despite these successes, genetic investigations into this pathway remain in their formative stages. Future studies aimed at providing a broader scope of investigation through increased sample sizes and through genome-wide approaches are needed.</AbstractText>
            </Abstract>
            <Affiliation>Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 02115, USA. rekgt@channing.harvard.edu</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tantisira</LastName>
                    <ForeName>Kelan G</ForeName>
                    <Initials>KG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Drazen</LastName>
                    <ForeName>Jeffrey M</ForeName>
                    <Initials>JM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>K23 HG003983-03</GrantID>
                    <Acronym>HG</Acronym>
                    <Agency>NHGRI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>K23:HG3983</GrantID>
                    <Acronym>HG</Acronym>
                    <Agency>NHGRI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL092197-01A1</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL092197-04</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01:HL92197</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 HL065899-07</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01:HL65899</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>08</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Allergy Clin Immunol</MedlineTA>
            <NlmUniqueID>1275002</NlmUniqueID>
            <ISSNLinking>0091-6749</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Asthmatic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotriene Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Receptors, Leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.13.11.34</RegistryNumber>
                <NameOfSubstance>Arachidonate 5-Lipoxygenase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2009 Mar;19(3):244-7</RefSource>
                <PMID Version="1">19214143</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br Med Bull. 2000;56(4):1054-70</RefSource>
                <PMID Version="1">11359637</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2002 Jun;109(6):936-42</RefSource>
                <PMID Version="1">12063521</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Genet. 2004 Mar;114(4):337-44</RefSource>
                <PMID Version="1">14749922</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2004 May;59(5):469-78</RefSource>
                <PMID Version="1">15080825</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2004 May;113(5):889-95</RefSource>
                <PMID Version="1">15131571</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenetics. 2004 Sep;14(9):627-33</RefSource>
                <PMID Version="1">15475736</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 1975 Sep;56(3):215-21</RefSource>
                <PMID Version="1">1151014</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am Rev Respir Dis. 1993 Dec;148(6 Pt 1):1447-51</RefSource>
                <PMID Version="1">8256883</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 1999 Jun;22(2):168-70</RefSource>
                <PMID Version="1">10369259</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2005 Feb;115(2):233-42</RefSource>
                <PMID Version="1">15696076</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2005 Jul;15(7):483-92</RefSource>
                <PMID Version="1">15970796</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2006 Jan;61(1):97-103</RefSource>
                <PMID Version="1">16364163</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Ther. 2006 Dec;112(3):701-18</RefSource>
                <PMID Version="1">16837050</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2007 Jul;17(7):539-49</RefSource>
                <PMID Version="1">17558309</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics. 2007 Jul;8(7):787-802</RefSource>
                <PMID Version="1">18240907</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Respir Med. 2008 Jun;102(6):857-61</RefSource>
                <PMID Version="1">18339529</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2008 Aug;63(8):1046-53</RefSource>
                <PMID Version="1">18547289</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Respir J. 2009 Jan;33(1):42-8</RefSource>
                <PMID Version="1">18829683</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2009 Feb;19(2):129-38</RefSource>
                <PMID Version="1">19151602</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 2006 Apr;36(4):433-9</RefSource>
                <PMID Version="1">16630147</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2006 Feb 15;173(4):379-85</RefSource>
                <PMID Version="1">16293801</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2007 Mar;17(3):189-96</RefSource>
                <PMID Version="1">17460547</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Asthmatic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Arachidonate 5-Lipoxygenase</DescriptorName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptors, Leukotriene</DescriptorName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>24</NumberOfReferences>
        <OtherID Source="NLM">NIHMS137999</OtherID>
        <OtherID Source="NLM">PMC2794036</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0091-6749(09)00989-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jaci.2009.06.035</ArticleId>
            <ArticleId IdType="pubmed">19665766</ArticleId>
            <ArticleId IdType="pmc">PMC2794036</ArticleId>
            <ArticleId IdType="mid">NIHMS137999</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19648384</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>08</Month>
            <Day>03</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1942-5546</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>84</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Mayo Clinic proceedings. Mayo Clinic</Title>
                <ISOAbbreviation>Mayo Clin. Proc.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Impact of asthma controller medications on clinical, economic, and patient-reported outcomes.</ArticleTitle>
            <Pagination>
                <MedlinePgn>675-84</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S0025-6196(11)60517-X</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To comprehensively evaluate clinical, economic, and patient-reported outcomes associated with various therapeutic classes of asthma controller medications.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">This observational study, which used administrative claims data from US commercial health plans, included patients with asthma aged 18 through 64 years who filled a prescription for at least 1 asthma controller medication from September 1, 2003, through August 31, 2005. Outcome metrics included the use of short-acting beta-agonists (SABAs), the use of oral corticosteroids, inpatient (INP)/emergency department (ED) visits, and asthma-related health care costs. A subset of 5000 patients was randomly selected for a survey using the Mini-Asthma Quality of Life Questionnaire, the Work Productivity and Activity Impairment questionnaire, and the Asthma Therapy Assessment Questionnaire.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 56,168 eligible patients, 823 returned completed questionnaires. Compared with inhaled corticosteroids (ICSs), leukotriene modifiers (LMs) were associated with lower odds of INP/ED visits (odds ratio [OR], 0.80; P&lt;.001), lower odds of using 6 or more SABA canisters (OR, 0.81; P&lt;.001), and higher annual cost ($193; P&lt;.001). In the subgroup analysis of adherent patients, LMs were associated with higher odds of INP/ED visits (OR, 1.74; P=.04), lower odds of using 6 or more SABA canisters (OR, 0.46; P&lt;.001), and higher annual cost ($235; P&lt;.001). Inhaled corticosteroids and LMs had a comparable impact on all patient-reported outcomes. For combination therapy, ICS plus a long-acting beta-agonist consistently showed at least equivalent or better outcomes in the use of SABAs and oral corticosteroids, the risk of INP/ED visits, cost, asthma control level, quality of life, and impairment in productivity and activity.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Inhaled corticosteroids were associated with a lower risk of INP/ED visits, and a lower cost if adherence was achieved. When adherence cannot be achieved, LMs may be a reasonable alternative. Combination therapy with ICS plus a long-acting beta-agonist was associated with better or equivalent clinical, economic, and patient-reported outcomes.</AbstractText>
            </Abstract>
            <Affiliation>Health Outcomes Research, HealthCore, Wilmington, DE 19801, USA. jtan@healthcore.com</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tan</LastName>
                    <ForeName>Hiangkiat</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sarawate</LastName>
                    <ForeName>Chaitanya</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singer</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elward</LastName>
                    <ForeName>Kurt</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cohen</LastName>
                    <ForeName>Rubin I</ForeName>
                    <Initials>RI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smart</LastName>
                    <ForeName>Brian A</ForeName>
                    <Initials>BA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Busk</LastName>
                    <ForeName>Michael F</ForeName>
                    <Initials>MF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lustig</LastName>
                    <ForeName>James</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Brien</LastName>
                    <ForeName>Jeana D</ForeName>
                    <Initials>JD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schatz</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Comparative Study</PublicationType>
                <PublicationType>Evaluation Studies</PublicationType>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mayo Clin Proc</MedlineTA>
            <NlmUniqueID>0405543</NlmUniqueID>
            <ISSNLinking>0025-6196</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Adrenal Cortex Hormones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Asthmatic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1647-52</RefSource>
                <PMID Version="1">10556135</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Ther. 2008 Mar;30(3):560-71</RefSource>
                <PMID Version="1">18405796</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chest. 2000 Feb;117(2):542-50</RefSource>
                <PMID Version="1">10669701</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacotherapy. 2002 Feb;22(2):166-74</RefSource>
                <PMID Version="1">11837555</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2002 Mar;109(3):433-9</RefSource>
                <PMID Version="1">11897987</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chest. 2002 Apr;121(4):1028-35</RefSource>
                <PMID Version="1">11948029</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>MMWR Surveill Summ. 2002 Mar 29;51(1):1-13</RefSource>
                <PMID Version="1">12420904</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy Asthma Proc. 2003 Jan-Feb;24(1):43-51</RefSource>
                <PMID Version="1">12635577</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Asthma. 2003 Feb;40(1):93-101</RefSource>
                <PMID Version="1">12699217</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Manag Care. 2004 Jan;10(1):25-32</RefSource>
                <PMID Version="1">14738184</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cochrane Database Syst Rev. 2004;(2):CD002314</RefSource>
                <PMID Version="1">15106175</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Allergy Asthma Immunol. 2004 May;92(5):523-9</RefSource>
                <PMID Version="1">15191020</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Med Res Opin. 2004 Aug;20(8):1209-20</RefSource>
                <PMID Version="1">15324523</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacoeconomics. 1993 Nov;4(5):353-65</RefSource>
                <PMID Version="1">10146874</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 1999 Jun 9;281(22):2119-26</RefSource>
                <PMID Version="1">10367823</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Respir J. 1999 Jul;14(1):32-8</RefSource>
                <PMID Version="1">10489826</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Allergy Asthma Immunol. 2004 Oct;93(4):373-80</RefSource>
                <PMID Version="1">15521374</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2004 Dec;114(6):1288-93</RefSource>
                <PMID Version="1">15577825</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Asthma. 2005 Jun;42(5):385-93</RefSource>
                <PMID Version="1">16036414</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2005 Aug 4;353(5):487-97</RefSource>
                <PMID Version="1">16079372</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacotherapy. 2005 Dec;25(12):1752-60</RefSource>
                <PMID Version="1">16305295</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Med Res Opin. 2006 Mar;22(3):453-61</RefSource>
                <PMID Version="1">16574029</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Manag Care Pharm. 2006 May;12(4):310-21</RefSource>
                <PMID Version="1">16792437</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Allergy Asthma Immunol. 2006 Aug;97(2):236-43</RefSource>
                <PMID Version="1">16937758</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cochrane Database Syst Rev. 2006;(4):CD003137</RefSource>
                <PMID Version="1">17054161</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Respir Res. 2007;8:46</RefSource>
                <PMID Version="1">17610727</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Value Health. 2008 Mar-Apr;11(2):231-9</RefSource>
                <PMID Version="1">18380635</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2008 Apr;121(4):885-92.e5</RefSource>
                <PMID Version="1">18313133</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Mayo Clin Proc. 2009 Aug;84(8):673-4</RefSource>
                <PMID Version="1">19648383</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Administration, Inhalation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
                <QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N">economics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Asthmatic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y">economics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">economics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Cost of Illness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Utilization</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N">economics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Linear Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Multivariate Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Odds Ratio</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Office Visits</DescriptorName>
                <QualifierName MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Patient Participation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Probability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Questionnaires</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Severity of Illness Index</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC2719520</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0025-6196(11)60517-X</ArticleId>
            <ArticleId IdType="doi">10.1016/S0025-6196(11)60517-X</ArticleId>
            <ArticleId IdType="pubmed">19648384</ArticleId>
            <ArticleId IdType="pmc">PMC2719520</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19647860</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-6825</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>124</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of allergy and clinical immunology</Title>
                <ISOAbbreviation>J. Allergy Clin. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications.</ArticleTitle>
            <Pagination>
                <MedlinePgn>406-14; quiz 415-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaci.2009.05.046</ELocationID>
            <Abstract>
                <AbstractText>The intracellular parent of the cysteinyl leukotrienes (cysLTs), leukotriene (LT) C(4), is formed by conjugation of LTA(4) and reduced glutathione by LTC(4) synthase in mast cells, eosinophils, basophils, and macrophages. After extracellular export, LTC(4) is converted to LTD(4) and LTE(4) through sequential enzymatic removal of glutamic acid and then glycine. Only LTE(4) is sufficiently stable to be prominent in biologic fluids, such as urine or bronchoalveolar lavage fluid, of asthmatic individuals and at sites of inflammation in animal models. LTE(4) has received little attention because it binds poorly to the classical type 1 and 2 cysLT receptors and is much less active on normal airways than LTC(4) or LTD(4). However, early studies indicated that LTE(4) caused skin swelling in human subjects as potently as LTC(4) and LTD(4), that airways of asthmatic subjects (particularly those that were aspirin sensitive) were selectively hyperresponsive to LTE(4), and that a potential distinct LTE(4) receptor was present in guinea pig trachea. Recent studies have begun to uncover receptors selective for LTE(4): P2Y(12), an adenosine diphosphate receptor, and CysLT(E)R, which was observed functionally in the skin of mice lacking the type 1 and 2 cysLT receptors. These findings prompt a renewed focus on LTE(4) receptors as therapeutic targets that are not currently addressed by available receptor antagonists.</AbstractText>
            </Abstract>
            <Affiliation>Department of Medicine, Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Mass 02115, USA. fausten@rics.bwh.harvard.edu</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Austen</LastName>
                    <ForeName>K Frank</ForeName>
                    <Initials>KF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maekawa</LastName>
                    <ForeName>Akiko</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanaoka</LastName>
                    <ForeName>Yoshihide</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boyce</LastName>
                    <ForeName>Joshua A</ForeName>
                    <Initials>JA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P01 AI031599-17</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P01 HL036110-24</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AI052353-07</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AI052353-07S1</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AI052353-07S2</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AI052353-10</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AI078908</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AI078908-01A1</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R56 AI052353-06A1</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>08</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Allergy Clin Immunol</MedlineTA>
            <NlmUniqueID>1275002</NlmUniqueID>
            <ISSNLinking>0091-6749</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotriene Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Receptors, Leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Receptors, Purinergic P2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>72025-60-6</RegistryNumber>
                <NameOfSubstance>Leukotriene C4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>73836-78-9</RegistryNumber>
                <NameOfSubstance>Leukotriene D4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75715-89-8</RegistryNumber>
                <NameOfSubstance>Leukotriene E4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1980 Jul;77(7):4354-8</RefSource>
                <PMID Version="1">6933488</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16394-9</RefSource>
                <PMID Version="1">17050692</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostaglandins. 1980 Nov;20(5):863-86</RefSource>
                <PMID Version="1">6110221</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1982 Apr 9;216(4542):196-8</RefSource>
                <PMID Version="1">7063880</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am Rev Respir Dis. 1982 Mar;125(3):290-4</RefSource>
                <PMID Version="1">6279000</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1982 Jul;79(13):4166-70</RefSource>
                <PMID Version="1">6955794</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Invest Dermatol. 1983 Feb;80(2):115-9</RefSource>
                <PMID Version="1">6296237</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1983 Feb 24;308(8):436-9</RefSource>
                <PMID Version="1">6823253</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 1983 Apr;71(4):909-15</RefSource>
                <PMID Version="1">6300193</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 1983 May 27;249(20):2814-7</RefSource>
                <PMID Version="1">6842792</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 2007 Aug 1;405(3):379-95</RefSource>
                <PMID Version="1">17623009</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 2007 Nov 1;110(9):3263-70</RefSource>
                <PMID Version="1">17693579</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2008 Jun 13;283(24):16477-87</RefSource>
                <PMID Version="1">18411276</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16695-700</RefSource>
                <PMID Version="1">18931305</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 1980 Sep 16;96(1):271-7</RefSource>
                <PMID Version="1">6254506</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2000 Sep 29;275(39):30531-6</RefSource>
                <PMID Version="1">10851239</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2001 Jun 22;276(25):22608-13</RefSource>
                <PMID Version="1">11319240</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7964-9</RefSource>
                <PMID Version="1">11438743</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1495-500</RefSource>
                <PMID Version="1">11704602</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2002 Jun 7;277(23):20820-4</RefSource>
                <PMID Version="1">11932261</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11589-93</RefSource>
                <PMID Version="1">13679572</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2004 Oct 29;279(44):46129-34</RefSource>
                <PMID Version="1">15328359</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1973 Mar;110(3):760-70</RefSource>
                <PMID Version="1">4347478</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1979 Sep;76(9):4275-9</RefSource>
                <PMID Version="1">41240</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prostaglandins. 1980 Feb;19(2):185-201</RefSource>
                <PMID Version="1">6104346</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1983 Dec 25;258(24):15004-10</RefSource>
                <PMID Version="1">6317683</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1984 Aug;81(15):4922-5</RefSource>
                <PMID Version="1">6087352</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am Rev Respir Dis. 1987 Feb;135(2):333-7</RefSource>
                <PMID Version="1">3028218</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 1988 Mar;81(3):866-71</RefSource>
                <PMID Version="1">3343345</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1990 Dec 15;265(35):21771-8</RefSource>
                <PMID Version="1">2174886</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1991 Dec 25;266(36):24763-72</RefSource>
                <PMID Version="1">1761571</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Respir J. 1993 Nov;6(10):1468-73</RefSource>
                <PMID Version="1">8112440</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7663-7</RefSource>
                <PMID Version="1">8052639</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Biochem. 1996 Jun 15;238(3):606-12</RefSource>
                <PMID Version="1">8706658</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1999 Jun 24;399(6738):789-93</RefSource>
                <PMID Version="1">10391245</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2004 Dec 15;173(12):7539-47</RefSource>
                <PMID Version="1">15585881</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2005 Mar 11;280(10):8722-32</RefSource>
                <PMID Version="1">15590629</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2005 Nov 11;337(1):281-8</RefSource>
                <PMID Version="1">16185654</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 2005 Dec 19;71(1-2):115-25</RefSource>
                <PMID Version="1">16280122</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2006 Sep 1;177(5):2755-9</RefSource>
                <PMID Version="1">16920908</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>J Allergy Clin Immunol. 2010 Apr;125(4):950-1; author reply 951</RefSource>
                <PMID Version="1">20226503</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Guinea Pigs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene C4</DescriptorName>
                <QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene D4</DescriptorName>
                <QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene E4</DescriptorName>
                <QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptors, Leukotriene</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptors, Purinergic P2</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Skin</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>43</NumberOfReferences>
        <OtherID Source="NLM">NIHMS128013</OtherID>
        <OtherID Source="NLM">PMC2739263</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0091-6749(09)00948-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jaci.2009.05.046</ArticleId>
            <ArticleId IdType="pubmed">19647860</ArticleId>
            <ArticleId IdType="pmc">PMC2739263</ArticleId>
            <ArticleId IdType="mid">NIHMS128013</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19616537</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>01</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2010</Year>
            <Month>11</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0712</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>618</Volume>
                    <Issue>1-3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Sep</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of pharmacology</Title>
                <ISOAbbreviation>Eur. J. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase 3 inhibitor, suppress the asthmatic response in guinea pigs, with both bronchodilating and anti-inflammatory effects.</ArticleTitle>
            <Pagination>
                <MedlinePgn>63-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejphar.2009.07.005</ELocationID>
            <Abstract>
                <AbstractText>We evaluated the effects of NT-702 (parogrelil hydrochloride, NM-702, 4-bromo-6-[3-(4-chlorophenyl) propoxy]-5-[(pyridine-3-ylmethyl) amino] pyridazin-3(2H)-one hydrochloride), a selective phosphodiesterase 3 inhibitor, on the asthmatic response in guinea pigs. NT-702 at a concentration of 1 x 10(-7)M elevated the cyclic adenosine monophosphate content in prostaglandin E(2)-treated guinea pig tracheal smooth muscle cells. Leukotriene (LT) D(4)- and histamine-induced contraction of isolated guinea pig tracheal strips was inhibited by NT-702, with EC(50) values of 3.2 x 10(-7) and 2.5 x 10(-7)M, respectively. In an in vivo study, NT-702 suppressed LTD(4)-induced bronchoconstriction and the ovalbumin-induced immediate asthmatic response in guinea pigs through its bronchodilating effect. Furthermore, NT-702 also suppressed the ovalbumin-induced late asthmatic response, airway hyperresponsiveness, and the accumulation of inflammatory cells in the bronchoalveolar lavage fluid. These results suggest that NT-702 has an anti-inflammatory effect as well as a bronchodilating effect and might be useful as a novel potent therapeutic agent for the treatment of bronchial asthma, a new type of agent with both a bronchodilating and an anti-inflammatory effect.</AbstractText>
            </Abstract>
            <Affiliation>Department of Pharmacology, Molecular Function and Pharmacology Laboratories, Taisho Pharmaceutical Co Ltd, Saitama, Japan. miyuki.hori@po.rd.taisho.co.jp</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hori</LastName>
                    <ForeName>Miyuki</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iwama</LastName>
                    <ForeName>Takehisa</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asakura</LastName>
                    <ForeName>Yumiko</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawanishi</LastName>
                    <ForeName>Masafumi</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kamon</LastName>
                    <ForeName>Junji</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoshino</LastName>
                    <ForeName>Akihiko</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takahashi</LastName>
                    <ForeName>Shuya</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takahashi</LastName>
                    <ForeName>Kenzo</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakaike</LastName>
                    <ForeName>Shiro</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsuruzoe</LastName>
                    <ForeName>Nobutomo</ForeName>
                    <Initials>N</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>In Vitro</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>07</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Eur J Pharmacol</MedlineTA>
            <NlmUniqueID>1254354</NlmUniqueID>
            <ISSNLinking>0014-2999</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone hydrochloride</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Inflammatory Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antigens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Bronchodilator Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Phosphodiesterase 3 Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Pyridazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>363-24-6</RegistryNumber>
                <NameOfSubstance>Dinoprostone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>51-45-6</RegistryNumber>
                <NameOfSubstance>Histamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>60-92-4</RegistryNumber>
                <NameOfSubstance>Cyclic AMP</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>73836-78-9</RegistryNumber>
                <NameOfSubstance>Leukotriene D4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antigens</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchoconstriction</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchodilator Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cell Movement</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cyclic AMP</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dinoprostone</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Guinea Pigs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Histamine</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene D4</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Lung</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Muscle Contraction</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Muscle, Smooth</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Phosphodiesterase 3 Inhibitors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pyridazines</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Trachea</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0014-2999(09)00597-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejphar.2009.07.005</ArticleId>
            <ArticleId IdType="pubmed">19616537</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19608262</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>28</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-6825</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>124</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of allergy and clinical immunology</Title>
                <ISOAbbreviation>J. Allergy Clin. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Efficacy of leukotriene receptor antagonists and synthesis inhibitors in asthma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>397-403</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaci.2009.05.029</ELocationID>
            <Abstract>
                <AbstractText>Cysteinyl leukotrienes are important mediators of asthmatic responses. They are the most potent bronchoconstrictors known; their release is triggered by exposure to inhaled allergens after exercise and after aspirin ingestion by subjects with aspirin-sensitive asthma. The cysteinyl leukotrienes promote inflammatory cell migration into the airways, as well as bone marrow eosinophilopoiesis after allergen inhalation. Leukotriene inhibitors are effective at attenuating asthmatic responses to all of these stimuli and are also effective at treating persistent asthma. These drugs are a viable alternative to low-dose inhaled corticosteroid (ICS) treatment but should be reserved for patients who cannot or will not use ICSs, often because of concerns about potential side effects of ICS treatment, which limits their use, particularly in children. Leukotriene receptor antagonists are also alternatives to long-acting inhaled beta(2)-agonists as add-on therapy to ICSs, but their efficacy together with ICSs is less than that of ICS/long-acting inhaled beta(2)-agonist combinations. Leukotriene receptor antagonists have an excellent safety profile.</AbstractText>
            </Abstract>
            <Affiliation>Department of Medicine, McMaster University, Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, Ontario, Canada. obyrnep@mcmaster.ca</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>O'Byrne</LastName>
                    <ForeName>Paul M</ForeName>
                    <Initials>PM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gauvreau</LastName>
                    <ForeName>Gail M</ForeName>
                    <Initials>GM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murphy</LastName>
                    <ForeName>Desmond M</ForeName>
                    <Initials>DM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>07</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Allergy Clin Immunol</MedlineTA>
            <NlmUniqueID>1275002</NlmUniqueID>
            <ISSNLinking>0091-6749</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Adrenal Cortex Hormones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Allergens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Asthmatic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Immunologic Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotriene Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>cysteinyl-leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>52-90-4</RegistryNumber>
                <NameOfSubstance>Cysteine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Allergens</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Asthmatic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cysteine</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophils</DescriptorName>
                <QualifierName MajorTopicYN="N">cytology</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Immunologic Factors</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0091-6749(09)00840-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jaci.2009.05.029</ArticleId>
            <ArticleId IdType="pubmed">19608262</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19576119</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>07</Month>
            <Day>06</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>03</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0578-1426</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>48</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Zhonghua nei ke za zhi [Chinese journal of internal medicine]</Title>
                <ISOAbbreviation>Zhonghua Nei Ke Za Zhi</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[The clinical significance of noninvasive inflammatory markers in exhaled breath condensate and induced sputum in persistent asthmatic patients].</ArticleTitle>
            <Pagination>
                <MedlinePgn>299-303</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the clinical significance of three different noninvasive airway inflammatory indices in induced sputum and exhaled breath condensate (EBC) from persistent asthmatic patients.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Moderate and severe asthmatic patients were prescribed inhaled corticosteroids combined with long-acting beta(2) agonists for a month. The symptom scores and percentage of predicted value of forced expiratory volume in one second (FEV(1)) (FEV(1)%pred) were measured while the concentrations of H(2)O(2), NO(3)(-)/NO(2)(-), and cysteinyl-leukotriene E(4) (LTE(4)) in induced sputum and EBC were detected before and after therapy.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of twenty-five subjects with moderate and severe asthma were enrolled. By combined therapy for one month the asthma symptoms relieved and FEV(1)%pred improved significantly (P &lt; 0.01). The concentrations of H(2)O(2), NO(3)(-)/NO(2)(-) and LTE(4) in induced sputum and EBC declined significantly (P &lt; 0.01) although the concentrations were still higher than those at normal baseline. More marked reduction of H(2)O(2) and NO(3)(-)/NO(2)(-) compared to LTE(4) was observed. It was revealed that the concentrations of H(2)O(2)and NO(3)(-)/NO(2)(-) but not of LTE(4) in EBC were negatively correlated with FEV(1)%pred (P &lt; 0.01) and positively with symptom scores. Such correlations were also found in H(2)O(2) in induced sputum with FEV(1)%pred and symptom scores as well as NO(3)(-)/NO(2)(-) in induced sputum with FEV(1)%pred. The improvement of FEV(1)%pred after treatment was positively correlated with the reduction of H(2)O(2) and NO(3)(-)/NO(2)(-) both in induced sputum and EBC. Correlation analysis also demonstrated three inflammatory indices were equivalent in induced sputum and EBC (correlation coefficient of H(2)O(2), NO(3)(-)/NO(2)(-) and LTE(4), 0.759, 0.826 and 0.653, respectively. P &lt; 0.01).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">(1) Combined therapy with inhaled corticosteroid plus long-acting beta(2) agonist significantly improves the clinical symptoms and lung function of patients with moderate and severe asthma companies with marked suppression of airway inflammation. (2) Both of EBC and induced sputum sampling are valuable noninvasive procedures for detecting asthma airway inflammation, however, EBC technique is superior in safety and reproducibility. (3) H(2)O(2) and NO(3)(-)/NO(2)(-) seem to be more sensitive indices in diagnosis and monitoring asthma compared to LTE(4).</AbstractText>
            </Abstract>
            <Affiliation>Department of Respiratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tan</LastName>
                    <ForeName>Cheng-Wu</ForeName>
                    <Initials>CW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Chun-Tao</ForeName>
                    <Initials>CT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Yong-Hong</ForeName>
                    <Initials>YH</Initials>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Zhonghua Nei Ke Za Zhi</MedlineTA>
            <NlmUniqueID>16210490R</NlmUniqueID>
            <ISSNLinking>0578-1426</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Biological Markers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>10102-43-9</RegistryNumber>
                <NameOfSubstance>Nitric Oxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75715-89-8</RegistryNumber>
                <NameOfSubstance>Leukotriene E4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7722-84-1</RegistryNumber>
                <NameOfSubstance>Hydrogen Peroxide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Biological Markers</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Breath Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Forced Expiratory Volume</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Inflammation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene E4</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Nitric Oxide</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sputum</DescriptorName>
                <QualifierName MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19576119</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19575935</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>07</Month>
            <Day>06</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>08</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1001-0939</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>32</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</Title>
                <ISOAbbreviation>Zhonghua Jie He He Hu Xi Za Zhi</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Effects of leukotriene receptor antagonists on vascular endothelial growth factor and its receptors in a sensitized rat model].</ArticleTitle>
            <Pagination>
                <MedlinePgn>177-81</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the effect of montelukast (MK) on airway inflammation and remodeling in asthmatic rats, and to explore the regulating role of MK on vascular endothelial growth factor (VEGF) and its receptors.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-four male Sprague-Dawley rats were randomly divided into 3 groups, a control group (n = 8), an asthmatic group (n = 8) and a MK treated group (n = 8). The rats were sensitized with ovalbumin and AL (OH3), and repeatedly exposed to aerosolized ovalbumin. Airway reactivity of the animals were measured by animal lung function meter. VEGF levels and leukotriene D(4) (LTD(4)) in serum were measured by enzyme linked-immunosorbent assay (ELISA). The pathologic changes of bronchi and the lung tissue were evaluated, and the expression of VEGF and its acceptors was analyzed with immunohistochemistry. The vascular counts and vascular smooth muscle thickness were measured by using image analysis system.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The bronchial provocation test showed that, in the asthmatic group, the average expiratory resistance increased remarkably. The serum levels of VEGF and LTD(4) in the asthmatic group were 31 +/- 6 and 11 +/- 4 respectively, significantly higher than those in the control group (17 +/- 5 and 6.1 +/- 0.7) respectively and in the MK group (15 +/- 4 and 9.8 +/- 1.6) respectively. (F 63.78, 39.56 all P &lt; 0.01). Immunohistochemistry showed that, the expression of VEGF, VEGFR(1) and VEGFR(2) in the asthmatic group were increased, as compared to those in the control group and the treated group. The vascular counts were 14 +/- 2, 22 +/- 2 and 16 +/- 4 in the control, the asthmatic, and the treated groups.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">VEGF and its receptors were over-expressed in the sensitized rat model, and involved in angiogenesis and airway remodeling. MK may be effective in reducing allergic airway inflammation and airway remodeling through VEGF and VEGFR.</AbstractText>
            </Abstract>
            <Affiliation>Department of Respirology, the Second Affiliated Hospital of Hebei Medical University, Shijiazhuang 050000, China. yhs4546@sohu.com.cn</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Hong-Shen</ForeName>
                    <Initials>HS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Lai</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guan</LastName>
                    <ForeName>Ji-Tao</ForeName>
                    <Initials>JT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Jun-Yi</ForeName>
                    <Initials>JY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Su</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Zhonghua Jie He He Hu Xi Za Zhi</MedlineTA>
            <NlmUniqueID>8712226</NlmUniqueID>
            <ISSNLinking>1001-0939</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Acetates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotriene Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Quinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Vascular Endothelial Growth Factor A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>vascular endothelial growth factor A, rat</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>73836-78-9</RegistryNumber>
                <NameOfSubstance>Leukotriene D4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance>Receptors, Vascular Endothelial Growth Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>MHM278SD3E</RegistryNumber>
                <NameOfSubstance>montelukast</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Acetates</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Airway Remodeling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene D4</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Quinolines</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptors, Vascular Endothelial Growth Factor</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>8</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19575935</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19562288</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>06</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>28</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0043-5325</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>121</Volume>
                    <Issue>9-10</Issue>
                    <PubDate>
                        <Year>2009</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Wiener klinische Wochenschrift</Title>
                <ISOAbbreviation>Wien. Klin. Wochenschr.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>COPD is not COPD is not allergy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>289-92</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00508-009-1189-4</ELocationID>
            <Abstract>
                <AbstractText>Chronic obstructive pulmonary disease (COPD) is still a poorly understood disease. Its pathogenesis is excitingly complex and has systemic consequences caused not only by increased production of certain cytokines but also by neurohumoral activation, chronic bacterial infection, muscle wasting and cachexia. Asthma and COPD have many overlapping clinical features so it should not be surprising that in the pathogenesis of COPD mediators such as leukotrienes, complement activation, atopic or even autoimmune processes are possibly involved. The pathogenesis of cardiovascular system involvement in COPD is also multifaceted and includes chronic heart hypoxia, damage by smoking and pulmonary hypertension; it must also be viewed as a consequence of systemic inflammation and neurohormonal activation. COPD is among the leading causes of morbidity and mortality worldwide and therefore it should be studied intensively beyond the lung itself. Treatments directed at neurohumoral activation in COPD have not been fully addressed; this aspect of COPD should be better understood, as it may direct novel therapeutic approaches.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Suskovic</LastName>
                    <ForeName>Stanislav</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Editorial</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Austria</Country>
            <MedlineTA>Wien Klin Wochenschr</MedlineTA>
            <NlmUniqueID>21620870R</NlmUniqueID>
            <ISSNLinking>0043-5325</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Inflammation Mediators</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Neurotransmitter Agents</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Autoimmune Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N">complications</QualifierName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Complement Activation</DescriptorName>
                <QualifierName MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hypersensitivity</DescriptorName>
                <QualifierName MajorTopicYN="N">complications</QualifierName>
                <QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Inflammation Mediators</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Neurotransmitter Agents</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pulmonary Disease, Chronic Obstructive</DescriptorName>
                <QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Smoking</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00508-009-1189-4</ArticleId>
            <ArticleId IdType="pubmed">19562288</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19558806</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>06</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1008-8830</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>11</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics</Title>
                <ISOAbbreviation>Zhongguo Dang Dai Er Ke Za Zhi</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Relationship between the efficacy of inhaled corticosteroids and the leukotriene expression in children with asthma].</ArticleTitle>
            <Pagination>
                <MedlinePgn>441-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the relationship between leukotriene expression in blood polymorphonuclear leukocytes (PMNL) and the efficacy of inhaled corticosteroids (ICS) in children with asthma.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-two children with asthma (5-12 years) and ten healthy children (control group) were enrolled. The asthmatic children were subdivided into ICS well-controlled and ICS poorly-controlled groups based on their clinical symptoms and lung function. The level of leukotriene C4 synthase (LTC4S) mRNA in PMNL was detected by fluorescence quantitative polymerase chain reaction. The level of LTC4S mRNA was expressed by the value of qCt, and the value of qCt was diversely correlated with the level of LTC4S mRNA expression. The concentration of urinary leukotriene E4 (LTE4) was measured using ELISA.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The expression of LTC4S mRNA in PMNL was significantly higher in children with asthma (qCt: 1.12+/-0.27) than that in the control group (qCt: 1.42+/-0.12; P&lt; 0.05). The expression of LTC4S mRNA in PMNL in the ICS poorly-controlled group (qCt: 1.03+/-0.17) was significantly higher than that in the ICS well-controlled group (qCt: 1.24+/-0.33; P&lt; 0.05) and the control group(1.42+/-0.12; P&lt; 0.01). There was no significant difference in the level of urinary LTE4 among the the ICS poorly-controlled, the ICS well-controlled and the control groups.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">LTC4S mRNA expression in PMNL in asthmatic children increases, and the LTC4S mRNA expression in the ICS poorly-controlled group is higher than that in the ICS well-controlled group. This suggests that an increased leukotriene expression might be associated with poorly-controlled asthma.</AbstractText>
            </Abstract>
            <Affiliation>Guangzhou Institute of Respiratory Disease, First Hospital Affiliated to Guangzhou Medical College, Guangzhou 510120, China.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Jie-Ling</ForeName>
                    <Initials>JL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Ai-Huan</ForeName>
                    <Initials>AH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Qiu-Ying</ForeName>
                    <Initials>QY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Rong-Chang</ForeName>
                    <Initials>RC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhong</LastName>
                    <ForeName>Nan-Shan</ForeName>
                    <Initials>NS</Initials>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Zhongguo Dang Dai Er Ke Za Zhi</MedlineTA>
            <NlmUniqueID>100909956</NlmUniqueID>
            <ISSNLinking>1008-8830</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Adrenal Cortex Hormones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75715-89-8</RegistryNumber>
                <NameOfSubstance>Leukotriene E4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.5.1.18</RegistryNumber>
                <NameOfSubstance>Glutathione Transferase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 4.4.1.20</RegistryNumber>
                <NameOfSubstance>leukotriene-C4 synthase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Administration, Inhalation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
                <QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glutathione Transferase</DescriptorName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene E4</DescriptorName>
                <QualifierName MajorTopicYN="Y">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1008-8830(2009)06-0441-04</ArticleId>
            <ArticleId IdType="pubmed">19558806</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19541351</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>01</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-6825</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>124</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of allergy and clinical immunology</Title>
                <ISOAbbreviation>J. Allergy Clin. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Lung mast cells are a source of secreted phospholipases A2.</ArticleTitle>
            <Pagination>
                <MedlinePgn>558-65, 565.e1-3</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaci.2009.04.035</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Secreted phospholipases A(2) (sPLA(2)s) are released in plasma and other biologic fluids of patients with inflammatory, autoimmune, and allergic diseases.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We sought to evaluate sPLA(2) activity in the bronchoalveolar lavage fluid (BALF) of asthmatic patients and to examine the expression and release of sPLA(2)s from primary human lung mast cells (HLMCs).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">sPLA(2) activity was measured in BALF and supernatants of either unstimulated or anti-IgE-activated HLMCs as hydrolysis of oleic acid from radiolabeled Escherichia coli membranes. Expression of sPLA(2)s was examined by using RT-PCR. The release of cysteinyl leukotriene (LT) C(4) was measured by means of enzyme immunoassay.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Phospholipase A(2) (PLA(2)) activity was higher in the BALF of asthmatic patients than in the control group. BALF PLA(2) activity was blocked by the sPLA(2) inhibitors dithiothreitol and Me-Indoxam but not by the cytosolic PLA(2) inhibitor AZ-1. HLMCs spontaneously released a PLA(2) activity that was increased on stimulation with anti-IgE. This PLA(2) activity was blocked by dithiothreitol and Me-Indoxam but not by AZ-1. HLMCs constitutively express mRNA for group IB, IIA, IID, IIE, IIF, III, V, X, XIIA, and XIIB sPLA(2)s. Anti-IgE did not modify the expression of sPLA(2)s. The cell-impermeable inhibitor Me-Indoxam significantly reduced (up to 40%) the production of LTC(4) from anti-IgE-stimulated HLMCs.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">sPLA(2) activity is increased in the airways of asthmatic patients. HLMCs express multiple sPLA(2)s and release 1 or more of them when activated by anti-IgE. The sPLA(2)s released by mast cells contribute to LTC(4) production by acting in an autocrine fashion. Mast cells can be a source of sPLA(2)s in the airways of asthmatic patients.</AbstractText>
            </Abstract>
            <Affiliation>Department of Clinical Immunology and Allergy and the Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy. triggian@unina.it</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Triggiani</LastName>
                    <ForeName>Massimo</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Giannattasio</LastName>
                    <ForeName>Giorgio</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Calabrese</LastName>
                    <ForeName>Cecilia</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loffredo</LastName>
                    <ForeName>Stefania</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Granata</LastName>
                    <ForeName>Francescopaolo</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fiorello</LastName>
                    <ForeName>Alfonso</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santini</LastName>
                    <ForeName>Mario</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gelb</LastName>
                    <ForeName>Michael H</ForeName>
                    <Initials>MH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marone</LastName>
                    <ForeName>Gianni</ForeName>
                    <Initials>G</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>HL36235</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL50040</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R37 HL036235-24</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>07</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Allergy Clin Immunol</MedlineTA>
            <NlmUniqueID>1275002</NlmUniqueID>
            <ISSNLinking>0091-6749</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>2-aziridin-1-yl-3-((2-((2-(3-aziridin-1-yl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)thio)ethoxy)ethyl)thio)naphthoquinone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antibodies, Anti-Idiotypic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Aziridines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Carbamates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Indolizines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Naphthoquinones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>anti-IgE antibodies</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>indoxam</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3483-12-3</RegistryNumber>
                <NameOfSubstance>Dithiothreitol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>37341-29-0</RegistryNumber>
                <NameOfSubstance>Immunoglobulin E</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>72025-60-6</RegistryNumber>
                <NameOfSubstance>Leukotriene C4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.1.4</RegistryNumber>
                <NameOfSubstance>Phospholipases A2, Secretory</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 1997 Feb;155(2):421-5</RefSource>
                <PMID Version="1">9032172</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 1997 Jul;156(1):94-100</RefSource>
                <PMID Version="1">9230731</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1998 Mar;284(3):847-57</RefSource>
                <PMID Version="1">9495842</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 1998 Apr 15;91(8):3037-43</RefSource>
                <PMID Version="1">9531617</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Rheum Dis. 1998 Sep;57(9):550-8</RefSource>
                <PMID Version="1">9849315</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 1999 Sep;104(5):611-8</RefSource>
                <PMID Version="1">10487775</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunol Rev. 2000 Feb;173:131-40</RefSource>
                <PMID Version="1">10719674</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2000 May;105(5):847-59</RefSource>
                <PMID Version="1">10808163</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2000 Sep 1;165(5):2773-82</RefSource>
                <PMID Version="1">10946309</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2000 Oct 1;165(7):4007-14</RefSource>
                <PMID Version="1">11034411</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Chem Lab Med. 2000 Dec;38(12):1231-6</RefSource>
                <PMID Version="1">11205686</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochim Biophys Acta. 2001 Jan 15;1530(1):67-76</RefSource>
                <PMID Version="1">11341959</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2002 Feb 22;277(8):5849-57</RefSource>
                <PMID Version="1">11694541</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2002 Feb 15;277(7):5061-73</RefSource>
                <PMID Version="1">11741884</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Respir Res. 2002;3:4</RefSource>
                <PMID Version="1">11806839</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Chem. 2002 Mar 14;45(6):1348-62</RefSource>
                <PMID Version="1">11882004</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2002 Apr 5;292(3):689-96</RefSource>
                <PMID Version="1">11922621</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochim Biophys Acta. 2002 May 23;1582(1-3):168-74</RefSource>
                <PMID Version="1">12069825</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2002 Dec 13;277(50):48535-49</RefSource>
                <PMID Version="1">12359733</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2003 Jan 17;300(3):731-7</RefSource>
                <PMID Version="1">12507511</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2003 Mar 15;170(6):3279-88</RefSource>
                <PMID Version="1">12626587</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int Arch Allergy Immunol. 2003 Jul;131(3):153-63</RefSource>
                <PMID Version="1">12876405</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochim Biophys Acta. 2003 Nov 30;1635(1):37-47</RefSource>
                <PMID Version="1">14642775</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2004 Apr 16;279(16):16488-94</RefSource>
                <PMID Version="1">14761945</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 2004 Feb;34(2):241-9</RefSource>
                <PMID Version="1">14987304</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2004 Jun 11;279(24):25024-38</RefSource>
                <PMID Version="1">15007070</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 2005 Apr 1;387(Pt 1):27-38</RefSource>
                <PMID Version="1">15509193</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2004 Nov 15;173(10):6433-9</RefSource>
                <PMID Version="1">15528384</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2005 Jan 1;174(1):464-74</RefSource>
                <PMID Version="1">15611272</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2005 Oct 1;172(7):807-16</RefSource>
                <PMID Version="1">16020805</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2005 Nov 15;175(10):6786-91</RefSource>
                <PMID Version="1">16272335</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2005 Nov;116(5):1000-6</RefSource>
                <PMID Version="1">16275367</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 2006 Apr 15;107(8):3243-50</RefSource>
                <PMID Version="1">16357326</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochim Biophys Acta. 2006 Nov;1761(11):1289-300</RefSource>
                <PMID Version="1">16952481</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochim Biophys Acta. 2006 Nov;1761(11):1246-59</RefSource>
                <PMID Version="1">16973413</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 2006 Nov 7;45(44):13203-18</RefSource>
                <PMID Version="1">17073442</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Immunol. 2007 Feb;7(2):93-104</RefSource>
                <PMID Version="1">17259966</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 2007 Jul 15;110(2):561-7</RefSource>
                <PMID Version="1">17369491</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 2007 Apr 16;204(4):865-77</RefSource>
                <PMID Version="1">17403936</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2007 Sep;62(9):999-1006</RefSource>
                <PMID Version="1">17578498</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2007 Dec 1;176(11):1072-8</RefSource>
                <PMID Version="1">17901411</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Biochem. 2008;77:495-520</RefSource>
                <PMID Version="1">18405237</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Immunol. 2008 Jun;8(6):478-86</RefSource>
                <PMID Version="1">18483499</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochim Biophys Acta. 2009 Feb;1791(2):92-102</RefSource>
                <PMID Version="1">19130898</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 1994 Jun 15;300 ( Pt 3):619-22</RefSource>
                <PMID Version="1">8010941</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Cell Mol Biol. 1994 Jul;11(1):108-13</RefSource>
                <PMID Version="1">8018333</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1994 Jun 1;152(11):5438-46</RefSource>
                <PMID Version="1">8189063</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 1996 May 1;183(5):2235-45</RefSource>
                <PMID Version="1">8642333</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Exp Lung Res. 1996 May-Jun;22(3):299-315</RefSource>
                <PMID Version="1">8792123</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antibodies, Anti-Idiotypic</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aziridines</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchoalveolar Lavage Fluid</DescriptorName>
                <QualifierName MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Carbamates</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dithiothreitol</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Immunoglobulin E</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Indolizines</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene C4</DescriptorName>
                <QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Lung</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mast Cells</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Naphthoquinones</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Phospholipases A2, Secretory</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
                <QualifierName MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS160499</OtherID>
        <OtherID Source="NLM">PMC2788562</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0091-6749(09)00694-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jaci.2009.04.035</ArticleId>
            <ArticleId IdType="pubmed">19541351</ArticleId>
            <ArticleId IdType="pmc">PMC2788562</ArticleId>
            <ArticleId IdType="mid">NIHMS160499</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19524426</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>07</Month>
            <Day>06</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>03</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-2823</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>81</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Prostaglandins, leukotrienes, and essential fatty acids</Title>
                <ISOAbbreviation>Prostaglandins Leukot. Essent. Fatty Acids</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Leukotriene pathway polymorphisms are associated with altered cysteinyl leukotriene production in children with acute asthma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>9-15</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.plefa.2009.05.022</ELocationID>
            <Abstract>
                <AbstractText>Cysteinyl leukotrienes (cysLTs) are pro-inflammatory mediators with increasing evidence for a role in childhood acute asthma. This study examined the influence of polymorphisms in cysLT pathway genes on urinary leukotriene E(4) (uLTE(4)) levels and clinical status in acute asthmatic children. Children aged 2-16 years were recruited during an asthma attack (n=205). Where possible, asthma severity scores were assigned, ALOX5AP G-336A, ALOX5 G-1708A, LTC4S A-444C and G-1072A, GPX4 C718T, and CYSTLTR1 T927C genotypes were determined and uLTE(4) was measured in acute and convalescent samples. uLTE(4) levels were higher acutely compared with convalescence (acute GM: 115.7pg/mg creatinine; 95% CI 88.6-151.1, convalescence GM: 66.4pg/mg creatinine; 95% CI 51.5-85.6; n=50 paired samples, p=0.003) and paired sample analysis showed genotype-specific effects with significantly increased uLTE(4) for LTC(4)S-444AA (acute GM: 127.9pg/mg creatinine; 95% CI 91.8-178.3, convalescence GM: 68.2pg/mg creatinine; 95% CI 50.5-92.0; n=32, p=0.002), LTC(4)S-1072 GG (acute GM: 126.7pg/mg creatinine; 95% CI 95.4-168.3, convalescence GM: 78.9pg/mg creatinine; 95% CI 59.7-104.1; n=39, p=0.019) and CYSLTR1 927 TT/T_ (acute GM: 96.8pg/mg creatinine; 95% CI 73.8-126.9, convalescence GM: 62.4pg/mg creatinine; 95% CI 46.8-83.3; n=28, p=0.036) but not AC/CC, GA/AA, or TC/CC/C_, respectively. When we compared the allele frequencies of the CYSLTR1 SNP between asthmatics and non-asthmatics, the 927C allele was found to be a risk allele for asthma (OR=2.13, 95% CI: 1.06-4.26, p=0.033). Genotypes were not associated with acute or convalescent uLTE(4) levels alone and neither the SNPs nor uLTE(4) correlated with acute asthma severity. Leukotriene pathway gene polymorphisms may influence the magnitude of cysLT production during an attack, yet their influence alone may not be substantial enough to alter the severity of exacerbations.</AbstractText>
            </Abstract>
            <Affiliation>School of Paediatrics and Child Health, University of Western Australia, GPO Box D184, Perth, WA 6840, Australia.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bizzintino</LastName>
                    <ForeName>Joelene A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khoo</LastName>
                    <ForeName>Siew-Kim</ForeName>
                    <Initials>SK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Guicheng</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martin</LastName>
                    <ForeName>Andrew C</ForeName>
                    <Initials>AC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rueter</LastName>
                    <ForeName>Kristina</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Geelhoed</LastName>
                    <ForeName>Gary C</ForeName>
                    <Initials>GC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goldblatt</LastName>
                    <ForeName>Jack</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Laing</LastName>
                    <ForeName>Ingrid A</ForeName>
                    <Initials>IA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Le Souf</LastName>
                    <ForeName>Peter N</ForeName>
                    <Initials>PN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hayden</LastName>
                    <ForeName>Catherine M</ForeName>
                    <Initials>CM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>06</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Scotland</Country>
            <MedlineTA>Prostaglandins Leukot Essent Fatty Acids</MedlineTA>
            <NlmUniqueID>8802730</NlmUniqueID>
            <ISSNLinking>0952-3278</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Receptors, Leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>cysteinyl-leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>leukotriene D4 receptor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>52-90-4</RegistryNumber>
                <NameOfSubstance>Cysteine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75715-89-8</RegistryNumber>
                <NameOfSubstance>Leukotriene E4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.5.1.18</RegistryNumber>
                <NameOfSubstance>Glutathione Transferase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 4.4.1.20</RegistryNumber>
                <NameOfSubstance>leukotriene-C4 synthase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Acute Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cysteine</DescriptorName>
                <QualifierName MajorTopicYN="Y">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glutathione Transferase</DescriptorName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene E4</DescriptorName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptors, Leukotriene</DescriptorName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>9</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0952-3278(09)00103-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.plefa.2009.05.022</ArticleId>
            <ArticleId IdType="pubmed">19524426</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19494502</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>06</Month>
            <Day>04</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>07</Month>
            <Day>20</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1423-0097</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>149 Suppl 1</Volume>
                    <PubDate>
                        <Year>2009</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International archives of allergy and immunology</Title>
                <ISOAbbreviation>Int. Arch. Allergy Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Eosinophil superoxide anion generation induced by adhesion molecules and leukotriene D4.</ArticleTitle>
            <Pagination>
                <MedlinePgn>31-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000210651</ELocationID>
            <Abstract>
                <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Eosinophils preferentially accumulate at sites of inflammation in the asthmatic airway. Participation of circulating eosinophils in the airway inflammation in asthma involves their interaction with adhesion molecules expressed on the endothelial cell surface and exposure to inflammatory mediators, such as cysteinyl leukotrienes (cysLTs).</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate whether interaction of eosinophils with adhesion molecules modifies the functions of these cells induced by cysLTs. Methods: Eosinophils were isolated from the blood of healthy donors, incubated in the EIA plates coated with adhesion proteins, and then exposed to LTD4. The generation of superoxide anion (O2-), adhesion to the plates, and release of eosinophil-derived neutrotoxin (EDN) were evaluated.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Neither VCAM-1 nor LTD4 (100 nM) independently induced eosinophil O2- generation, however, combined exposure to the two molecules synergistically induced eosinophil O2- generation. ICAM-1 by itself induced eosinophil O2- generation, which was enhanced by LTD4. On the contrary, P-selectin did not induce O2- generation, either in the presence or absence of LTD4. LTD4 significantly enhanced eosinophil adhesion to rh-VCAM-1 and rh-ICAM-1, but not to rh-P-selectin. Finally, we observed that combined exposure of eosinophils to LTD4 and VCAM-1 induced the release of EDN.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Combined exposure to VCAM-1 or ICAM-1 and cysLT effectively induces the effector functions of eosinophils. Eosinophil adhesion to and migration across endothelial cells via these specific adhesion proteins and subsequent exposure to cysLTs may be mechanisms underlying activation of the effector functions of eosinophils in the asthmatic airway.</AbstractText>
                <CopyrightInformation>Copyright 2009 S. Karger AG, Basel.</CopyrightInformation>
            </Abstract>
            <Affiliation>Department of Respiratory Medicine, Saitama Medical University, Saitama 350-0495, Japan.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mori</LastName>
                    <ForeName>Mariko</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takaku</LastName>
                    <ForeName>Yotaro</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kobayashi</LastName>
                    <ForeName>Takehito</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hagiwara</LastName>
                    <ForeName>Koichi</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanazawa</LastName>
                    <ForeName>Minoru</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nagata</LastName>
                    <ForeName>Makoto</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>06</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Int Arch Allergy Immunol</MedlineTA>
            <NlmUniqueID>9211652</NlmUniqueID>
            <ISSNLinking>1018-2438</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Vascular Cell Adhesion Molecule-1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>11062-77-4</RegistryNumber>
                <NameOfSubstance>Superoxides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>126547-89-5</RegistryNumber>
                <NameOfSubstance>Intercellular Adhesion Molecule-1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>73836-78-9</RegistryNumber>
                <NameOfSubstance>Leukotriene D4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.-</RegistryNumber>
                <NameOfSubstance>Eosinophil-Derived Neurotoxin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cell Adhesion</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophil-Derived Neurotoxin</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophils</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Intercellular Adhesion Molecule-1</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene D4</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Superoxides</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Up-Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Vascular Cell Adhesion Molecule-1</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>5</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">000210651</ArticleId>
            <ArticleId IdType="doi">10.1159/000210651</ArticleId>
            <ArticleId IdType="pubmed">19494502</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19505984</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>11</Month>
            <Day>06</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>01</Month>
            <Day>06</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1931-3543</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>136</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Chest</Title>
                <ISOAbbreviation>Chest</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Changes in sputum eicosanoids and inflammatory markers after inhalation challenges with occupational agents.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1308-15</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1378/chest.09-0103</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">An increase in cysteinyl-leukotrienes (LTs) after specific inhalation challenge (SIC) with common allergens in patients with atopic asthma has been shown previously, but there are scarce data with occupational agents. We sought to determine whether there are differences in lower airway inflammatory markers and the production of cytokines and eicosanoids between patients with a positive or negative SIC response to occupational agents.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-six patients with suspected occupational asthma and 13 healthy control subjects were studied. Spirometry, methacholine challenge, and sputum induction were performed at baseline and 24 h after SIC with occupational agents. Several cytokines and inflammatory mediators, including eicosanoids, were measured in sputum.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-six SICs were carried out with high-molecular-weight or low-molecular-weight agents, and the responses were positive in 18 patients. SIC elicited nine early asthmatic responses, two dual asthmatic responses, and seven isolated late asthmatic responses. Significant increments in sputum eosinophil counts were found only in patients with positive SIC responses compared with baseline values. Interleukin-10 levels were decreased in patients with positive and negative SIC responses compared to those in healthy control subjects. A significant increase (p &lt; 0.05) in the LTC(4)/prostaglandin E(2) (PGE(2)) ratio was observed in patients after positive SIC responses compared to those with negative SIC responses.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Overexpression of LTC(4), relative underproduction of PGE(2), and greater airway eosinophilia were observed in patients with positive SIC responses.</AbstractText>
            </Abstract>
            <Affiliation>Allergy Department, Fundacin Jimnez Daz Capio and Centro de Investigacon Biomedica en Red de Enfermedades Respiratorias, Madrid, Spain.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fernndez-Nieto</LastName>
                    <ForeName>Mar</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sastre</LastName>
                    <ForeName>Beatriz</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sastre</LastName>
                    <ForeName>Joaqun</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lahoz</LastName>
                    <ForeName>Carlos</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Quirce</LastName>
                    <ForeName>Santiago</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Madero</LastName>
                    <ForeName>Mauro</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Del Pozo</LastName>
                    <ForeName>Victoria</ForeName>
                    <Initials>V</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>06</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Chest</MedlineTA>
            <NlmUniqueID>0231335</NlmUniqueID>
            <ISSNLinking>0012-3692</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Allergens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Cytokines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Eicosanoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Allergens</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cytokines</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eicosanoids</DescriptorName>
                <QualifierName MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Flow Cytometry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Inflammation</DescriptorName>
                <QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Respiratory Mechanics</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Smoking</DescriptorName>
                <QualifierName MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sputum</DescriptorName>
                <QualifierName MajorTopicYN="N">cytology</QualifierName>
                <QualifierName MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>10</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>10</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">chest.09-0103</ArticleId>
            <ArticleId IdType="doi">10.1378/chest.09-0103</ArticleId>
            <ArticleId IdType="pubmed">19505984</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19501235</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>06</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>06</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1097-6825</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>123</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of allergy and clinical immunology</Title>
                <ISOAbbreviation>J. Allergy Clin. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Body mass index and phenotype in subjects with mild-to-moderate persistent asthma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1328-34.e1</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaci.2009.04.005</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although obesity has been hypothesized to worsen asthma, data from studies of subjects with well-characterized asthma are lacking.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We sought to evaluate the relationship between body mass index (BMI), asthma impairment, and response to therapy.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">BMI (in kilograms per meter squared) and asthma phenotypic and treatment response data were extracted from Asthma Clinical Research Network studies. The cross-sectional relationship between BMI and asthma impairment was analyzed, as was the longitudinal relationship between BMI and response to asthma controller therapies.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">One thousand two hundred sixty-five subjects with mild-to-moderate persistent asthma were evaluated. Analyses of lean versus overweight/obese asthmatic subjects demonstrated small differences in FEV1 (3.05 vs 2.91 L, P = .001), FEV1/forced vital capacity ratio (mean, 83.5% vs 82.4%; P = .01), rescue albuterol use (1.1 vs 1.2 puffs per day, P = .03), and asthma-related quality of life (5.77 vs 5.59, P = .0004). Overweight/obese asthmatic subjects demonstrated a smaller improvement in exhaled nitric oxide levels with inhaled corticosteroid (ICS) treatment than did lean asthmatic subjects (3.6 vs 6.5 ppb, P = .04). With ICS/long-acting beta-agonist treatment, overweight/obese asthmatic subjects demonstrated smaller improvements in lung function than lean asthmatic subjects, with an 80 mL (P = .04) and 1.7% (P = .02) lesser improvement in FEV1 and FEV1/forced vital capacity ratio, respectively. Significant differences in therapeutic response to leukotriene modifiers between BMI categories were not observed.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Increased BMI is not associated with clinically significant worsening of impairment in subjects with mild-to-moderate persistent asthma. There is a modest association between increased BMI and reduced therapeutic effect of ICS-containing regimens in this patient population. Prospective studies evaluating the effect of being overweight or obese on treatment response in asthma are warranted.</AbstractText>
            </Abstract>
            <Affiliation>National Jewish Health, Denver, CO 80206, USA. sutherlande@njhealth.org</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sutherland</LastName>
                    <ForeName>E Rand</ForeName>
                    <Initials>ER</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lehman</LastName>
                    <ForeName>Erik B</ForeName>
                    <Initials>EB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teodorescu</LastName>
                    <ForeName>Mihaela</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wechsler</LastName>
                    <ForeName>Michael E</ForeName>
                    <Initials>ME</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>National Heart, Lung, and Blood Institute's Asthma Clinical Research Network</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>HL074204</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL074206</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL074208</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL51810</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL51823</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL51831</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL51834</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL51843</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL51845</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL56443</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL74073</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL74212</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL74218</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL74225</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL74227</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL74231</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U10 HL051834-07</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U10 HL051834-08</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U10 HL051834-09</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U10 HL051834-10</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U10 HL074073-01</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U10 HL074073-02</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U10 HL074073-03</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U10 HL074073-04</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U10 HL074073-05</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Allergy Clin Immunol</MedlineTA>
            <NlmUniqueID>1275002</NlmUniqueID>
            <ISSNLinking>0091-6749</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Glucocorticoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Intern Med. 1999 Nov 22;159(21):2582-8</RefSource>
                <PMID Version="1">10573048</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Thorax. 2008 Nov;63(11):1018-23</RefSource>
                <PMID Version="1">18984817</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2000 Dec;162(6):2341-51</RefSource>
                <PMID Version="1">11112161</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 2001 May 23-30;285(20):2583-93</RefSource>
                <PMID Version="1">11368732</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 2001 May 23-30;285(20):2594-603</RefSource>
                <PMID Version="1">11368733</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Control Clin Trials. 2001 Dec;22(6 Suppl):207S-21S</RefSource>
                <PMID Version="1">11728625</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2002 Mar;109(3):410-8</RefSource>
                <PMID Version="1">11897984</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2002 May 15;165(10):1377-83</RefSource>
                <PMID Version="1">12016099</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2002 Aug 15;347(7):498-504</RefSource>
                <PMID Version="1">12181405</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Epidemiol. 2003 Jul 15;158(2):165-74</RefSource>
                <PMID Version="1">12851230</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Thorax. 2003 Dec;58(12):1036-41</RefSource>
                <PMID Version="1">14645968</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Allergy Asthma Immunol. 2004 Jan;92(1):32-9</RefSource>
                <PMID Version="1">14756462</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2004 Apr 15;169(8):963-8</RefSource>
                <PMID Version="1">14742299</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2004 Oct 23-29;364(9444):1505-12</RefSource>
                <PMID Version="1">15500895</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am Rev Respir Dis. 1988 Jun;137(6):1502-4</RefSource>
                <PMID Version="1">3059864</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Respir J. 1988 Dec;1(10):902-7</RefSource>
                <PMID Version="1">3066641</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1996 Sep 19;335(12):841-7</RefSource>
                <PMID Version="1">8778601</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Respir J. 1999 Jul;14(1):32-8</RefSource>
                <PMID Version="1">10489826</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Respir J. 2004 Nov;24(5):740-4</RefSource>
                <PMID Version="1">15516666</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Epidemiol. 2004 Nov 15;160(10):969-76</RefSource>
                <PMID Version="1">15522853</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Respir Med. 2005 May;99(5):529-34</RefSource>
                <PMID Version="1">15823448</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2005 Apr 14;352(15):1519-28</RefSource>
                <PMID Version="1">15829533</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2005 May;115(5):897-909; quiz 910</RefSource>
                <PMID Version="1">15867841</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2005 May;115(5):1100-1</RefSource>
                <PMID Version="1">15867878</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Respir J. 2006 Mar;27(3):495-503</RefSource>
                <PMID Version="1">16507848</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2006 Jun 1;354(22):2340-8</RefSource>
                <PMID Version="1">16738270</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Can Respir J. 2006 May-Jun;13(4):203-10</RefSource>
                <PMID Version="1">16779465</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2007 Jan;119(1):3-11; quiz 12-3</RefSource>
                <PMID Version="1">17141853</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2007 Jan;119(1):14-21; quiz 22-3</RefSource>
                <PMID Version="1">17208583</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2007 Jan;119(1):73-80</RefSource>
                <PMID Version="1">17208587</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2007 Feb 1;175(3):228-34</RefSource>
                <PMID Version="1">16973987</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Appl Physiol. 2007 Feb;102(2):516-28</RefSource>
                <PMID Version="1">17053103</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2007 Apr 1;175(7):661-6</RefSource>
                <PMID Version="1">17234901</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Respir Med. 2007 Nov;101(11):2240-7</RefSource>
                <PMID Version="1">17686624</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Thorax. 2008 Aug;63(8):671-6</RefSource>
                <PMID Version="1">18663068</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chest. 2008 Aug;134(2):317-23</RefSource>
                <PMID Version="1">18641097</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2008 Sep 1;178(5):469-75</RefSource>
                <PMID Version="1">18565954</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2008 Oct 1;178(7):682-7</RefSource>
                <PMID Version="1">18635892</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMJ. 2000 Mar 25;320(7238):827-32</RefSource>
                <PMID Version="1">10731173</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Administration, Inhalation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Body Mass Index</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glucocorticoids</DescriptorName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Longitudinal Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Overweight</DescriptorName>
                <QualifierName MajorTopicYN="N">complications</QualifierName>
                <QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Respiratory Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Vital Capacity</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS122659</OtherID>
        <OtherID Source="NLM">PMC2743451</OtherID>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Deykin</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Drazen</LastName>
                <ForeName>J M</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Israel E</LastName>
                <ForeName>W</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wechsler</LastName>
                <ForeName>M E</ForeName>
                <Initials>ME</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kraft</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Martin</LastName>
                <ForeName>R J</ForeName>
                <Initials>RJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Szefler</LastName>
                <ForeName>S J</ForeName>
                <Initials>SJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lemanske</LastName>
                <ForeName>R F</ForeName>
                <Initials>RF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sorkness</LastName>
                <ForeName>C A</ForeName>
                <Initials>CA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jarjour</LastName>
                <ForeName>N N</ForeName>
                <Initials>NN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fish</LastName>
                <ForeName>J E</ForeName>
                <Initials>JE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Leone</LastName>
                <ForeName>F T</ForeName>
                <Initials>FT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Peters</LastName>
                <ForeName>S P</ForeName>
                <Initials>SP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Boushey</LastName>
                <ForeName>H A</ForeName>
                <Initials>HA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fahy</LastName>
                <ForeName>J V</ForeName>
                <Initials>JV</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lazarus</LastName>
                <ForeName>S C</ForeName>
                <Initials>SC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ford</LastName>
                <ForeName>J G</ForeName>
                <Initials>JG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>DiMango</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pesola</LastName>
                <ForeName>G R</ForeName>
                <Initials>GR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Calhoun</LastName>
                <ForeName>W J</ForeName>
                <Initials>WJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ameredes</LastName>
                <ForeName>B T</ForeName>
                <Initials>BT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Castro</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Walter</LastName>
                <ForeName>M J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ramsdell</LastName>
                <ForeName>J</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wasserman</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bleecker</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Meyers</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Peters</LastName>
                <ForeName>S P</ForeName>
                <Initials>SP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chinchilli</LastName>
                <ForeName>V M</ForeName>
                <Initials>VM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Craig</LastName>
                <ForeName>T J</ForeName>
                <Initials>TJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>King</LastName>
                <ForeName>T S</ForeName>
                <Initials>TS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mauger</LastName>
                <ForeName>E A</ForeName>
                <Initials>EA</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0091-6749(09)00557-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jaci.2009.04.005</ArticleId>
            <ArticleId IdType="pubmed">19501235</ArticleId>
            <ArticleId IdType="pmc">PMC2743451</ArticleId>
            <ArticleId IdType="mid">NIHMS122659</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19486029</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>12</Month>
            <Day>03</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>02</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2222</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</Title>
                <ISOAbbreviation>Clin. Exp. Allergy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1522-31</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2222.2009.03277.x</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Basophil activation has been implicated in the pathogenesis of aspirin-exacerbated respiratory disease (AERD). However, a comprehensive analysis of basophil responses to aspirin in terms of mediator release, cytokine secretion and increased expression of surface activation markers has not been performed.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To study the in vitro effects of aspirin on the concurrent release of histamine, leukotriene C4 (LTC4) and IL-4 from human basophils and to also evaluate changes in surface activation markers (CD63, CD69 and CD203c) expressed by these cells.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Basophil-enriched cell suspensions from 10 patients with AERD and 10 healthy volunteers were incubated with lysine-aspirin for up to 3 h. Cells were analysed for expression of CD63, CD69 and CD203c using flow cytometry. Cell-free supernatants were evaluated for histamine, and LTC4 release and for IL-4 secretion.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Aspirin-induced expression of CD63, CD69 and CD203c yielded 30%, 80% and 70% sensitivity, respectively, but with poor specificity. There was no significant difference in LTC4 synthesis between groups. None of the patients with AERD (or controls) released IL-4 in response to aspirin. A higher dose of 5 mg/mL aspirin-mediated non-specific effects on basophils.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Basophil responses to in vitro aspirin challenge are poor indicators of clinical sensitivity. Aspirin activates some basophils by means of mechanisms that differ from the classical IgE-mediated pathway. Our study also shows that the use of 27 mm of aspirin (5 mg/mL) by previous investigators causes non-specific basophil activation, thereby eliminating its usefulness in a cell-based diagnostic test for AERD. Evaluation of in vitro basophil activation has low clinical value in identifying aspirin-induced respiratory reactions.</AbstractText>
            </Abstract>
            <Affiliation>Ankara University School of Medicine, Division of Allergy, Ankara, Turkey. gulfemcelik@gmail.com</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Celik</LastName>
                    <ForeName>G E</ForeName>
                    <Initials>GE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schroeder</LastName>
                    <ForeName>J T</ForeName>
                    <Initials>JT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamilton</LastName>
                    <ForeName>R G</ForeName>
                    <Initials>RG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saini</LastName>
                    <ForeName>S S</ForeName>
                    <Initials>SS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adkinson</LastName>
                    <ForeName>N F</ForeName>
                    <Initials>NF</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>AI143654F</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AI042221</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AI042221-10</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01A142221</GrantID>
                    <Agency>PHS HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>05</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Clin Exp Allergy</MedlineTA>
            <NlmUniqueID>8906443</NlmUniqueID>
            <ISSNLinking>0954-7894</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antigens, CD</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>IL4 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>207137-56-2</RegistryNumber>
                <NameOfSubstance>Interleukin-4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>50-78-2</RegistryNumber>
                <NameOfSubstance>Aspirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>51-45-6</RegistryNumber>
                <NameOfSubstance>Histamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>72025-60-6</RegistryNumber>
                <NameOfSubstance>Leukotriene C4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2006 Aug;61(8):935-9</RefSource>
                <PMID Version="1">16867045</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Pharmacol. 2006 Mar 8;533(1-3):145-55</RefSource>
                <PMID Version="1">16457808</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2006 Sep;61(9):1084-5</RefSource>
                <PMID Version="1">16918511</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 2000 Dec;30(12):1785-91</RefSource>
                <PMID Version="1">11122218</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2001 Jul;56(7):688-92</RefSource>
                <PMID Version="1">11421930</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 2001 Sep;31(9):1369-77</RefSource>
                <PMID Version="1">11591186</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 2001 Oct;31(10):1615-22</RefSource>
                <PMID Version="1">11678863</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2002 May;109(5):817-23</RefSource>
                <PMID Version="1">11994706</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy Asthma Proc. 2002 Mar-Apr;23(2):117-24</RefSource>
                <PMID Version="1">12001790</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2002 Aug 1;166(3):301-6</RefSource>
                <PMID Version="1">12153961</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Thorax. 2003 Jan;58(1):23-9</RefSource>
                <PMID Version="1">12511714</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2002 Nov;110(5 Suppl):S141-219</RefSource>
                <PMID Version="1">12542074</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 2003 Feb;33(2):259-65</RefSource>
                <PMID Version="1">12580920</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2003 Apr;111(4):743-9</RefSource>
                <PMID Version="1">12704352</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2003 Apr;58(4):312-7</RefSource>
                <PMID Version="1">12708979</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2006 Oct;118(4):773-86; quiz 787-8</RefSource>
                <PMID Version="1">17030227</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Allergy Immunol. 2007;19:147-75</RefSource>
                <PMID Version="1">17153012</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Allergy Asthma Immunol. 2006 Nov;97(5):715-6</RefSource>
                <PMID Version="1">17165288</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Immunol. 2007 Jan;147(1):99-105</RefSource>
                <PMID Version="1">17177968</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int Arch Allergy Immunol. 2007;142(1):59-63</RefSource>
                <PMID Version="1">17016058</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Pulm Med. 2004 Jan;10(1):51-6</RefSource>
                <PMID Version="1">14749606</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2003 May;111(5):1041-8</RefSource>
                <PMID Version="1">12743569</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int Arch Allergy Immunol. 2006;141(1):79-90</RefSource>
                <PMID Version="1">16837789</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Allergy Clin Immunol. 2004 Feb;113(2):277-83</RefSource>
                <PMID Version="1">14767442</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 2004 Sep;34(9):1448-57</RefSource>
                <PMID Version="1">15347380</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2004 Oct;59(10):1110-7</RefSource>
                <PMID Version="1">15355471</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 1994 Jan;49(1):43-9</RefSource>
                <PMID Version="1">8198239</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol Methods. 1995 Dec 15;188(1):117-28</RefSource>
                <PMID Version="1">8551029</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):87-9</RefSource>
                <PMID Version="1">10224347</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Respir J. 1999 Mar;13(3):638-46</RefSource>
                <PMID Version="1">10232440</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Allergy. 1999 Oct;29(10):1402-11</RefSource>
                <PMID Version="1">10520062</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int Arch Allergy Immunol. 2005 Jan;136(1):53-7</RefSource>
                <PMID Version="1">15591814</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int Arch Allergy Immunol. 2005 Jan;136(1):58-72</RefSource>
                <PMID Version="1">15608437</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anaesthesia. 2005 Mar;60(3):251-6</RefSource>
                <PMID Version="1">15710010</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int Arch Allergy Immunol. 2005 Mar;136(3):230-8</RefSource>
                <PMID Version="1">15713985</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2005 Sep;60(9):1139-45</RefSource>
                <PMID Version="1">16076298</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Med. 2005 Jul;5(2):43-9</RefSource>
                <PMID Version="1">16096852</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunity. 2005 Aug;23(2):191-202</RefSource>
                <PMID Version="1">16111637</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Allergy. 2006 Mar;61(3):311-5</RefSource>
                <PMID Version="1">16436139</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Clin Exp Allergy. 2010 Mar;40(3):520; author reply 520-1</RefSource>
                <PMID Version="1">20082616</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antigens, CD</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aspirin</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma, Aspirin-Induced</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Basophils</DescriptorName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
                <QualifierName MajorTopicYN="Y">secretion</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Histamine</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Histamine Release</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Interleukin-4</DescriptorName>
                <QualifierName MajorTopicYN="Y">secretion</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene C4</DescriptorName>
                <QualifierName MajorTopicYN="Y">secretion</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS125987</OtherID>
        <OtherID Source="NLM">PMC2788679</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>3</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>3</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>2</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">CEA3277</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1365-2222.2009.03277.x</ArticleId>
            <ArticleId IdType="pubmed">19486029</ArticleId>
            <ArticleId IdType="pmc">PMC2788679</ArticleId>
            <ArticleId IdType="mid">NIHMS125987</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19482346</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>28</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-6825</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>124</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of allergy and clinical immunology</Title>
                <ISOAbbreviation>J. Allergy Clin. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Leukotriene E4: perspective on the forgotten mediator.</ArticleTitle>
            <Pagination>
                <MedlinePgn>417-21</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaci.2009.04.020</ELocationID>
            <Abstract>
                <AbstractText>Leukotriene (LT) E(4) mediates many of the principal features of bronchial asthma, such as bronchial constriction, hyperresponsiveness, eosinophilia, and increased vascular permeability. Furthermore, it is the most stable of the cysteinyl leukotrienes (CysLTs) and can be active at the site of release for a prolonged time after its synthesis. There might be several reasons why LTE(4) has been forgotten. LTE(4) demonstrated low affinity for CysLT(1) and CysLT(2) receptors in equilibrium competition assays. It was less potent than other CysLTs in functional assays, such as calcium flux, in cells transfected with CysLT(1) and CysLT(2). The introduction of CysLT(1) antagonists into clinical practice diverted interest into CysLT(1)-related mechanisms, which were mediated mainly by LTD(4). However, experiments with animal models and human studies have revealed that LTE(4) has unique characteristics that cannot be explained by the current knowledge of CysLT(1) and CysLT(2). These activities include its potency relative to other CysLTs to increase airway responsiveness to histamine, to enhance eosinophilic recruitment, and to increase vascular permeability. Asthmatic airways also demonstrate marked in vivo relative hyperresponsiveness to LTE(4), especially in patients with aspirin-sensitive respiratory disease. This has stimulated a search for additional LT receptors that would respond preferentially to LTE(4) stimulation.</AbstractText>
            </Abstract>
            <Affiliation>MRC &amp; Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, London, United Kingdom. tak.lee@kcl.ac.uk</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Tak H</ForeName>
                    <Initials>TH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Woszczek</LastName>
                    <ForeName>Grzegorz</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Farooque</LastName>
                    <ForeName>Sophie P</ForeName>
                    <Initials>SP</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>05</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Allergy Clin Immunol</MedlineTA>
            <NlmUniqueID>1275002</NlmUniqueID>
            <ISSNLinking>0091-6749</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Receptors, Leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>50-78-2</RegistryNumber>
                <NameOfSubstance>Aspirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>51-45-6</RegistryNumber>
                <NameOfSubstance>Histamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>62-51-1</RegistryNumber>
                <NameOfSubstance>Methacholine Chloride</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>72025-60-6</RegistryNumber>
                <NameOfSubstance>Leukotriene C4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>73836-78-9</RegistryNumber>
                <NameOfSubstance>Leukotriene D4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75715-89-8</RegistryNumber>
                <NameOfSubstance>Leukotriene E4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aspirin</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchial Hyperreactivity</DescriptorName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Hypersensitivity</DescriptorName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Histamine</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnostic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene C4</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene D4</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene E4</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Methacholine Chloride</DescriptorName>
                <QualifierName MajorTopicYN="N">diagnostic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptors, Leukotriene</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Skin</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>45</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0091-6749(09)00660-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jaci.2009.04.020</ArticleId>
            <ArticleId IdType="pubmed">19482346</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19418204</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>08</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2012</Year>
            <Month>12</Month>
            <Day>31</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1420-908X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>58</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Inflammation research : official journal of the European Histamine Research Society ... [et al.]</Title>
                <ISOAbbreviation>Inflamm. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Lovastatin inhibits antigen-induced airway eosinophilia without affecting the production of inflammatory mediators in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>363-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00011-009-0043-5</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE AND DESIGN" NlmCategory="OBJECTIVE">Statins have been proposed as a novel treatment of respiratory diseases. To determine the beneficial effects of statins on allergic bronchial asthma, the effect of systemic treatment with lovastatin on antigen-induced airway inflammation was investigated.</AbstractText>
                <AbstractText Label="SUBJECTS" NlmCategory="METHODS">Male BALB/c mice were used.</AbstractText>
                <AbstractText Label="TREATMENTS" NlmCategory="METHODS">Mice were sensitized and repeatedly challenged with ovalbumin (OA) antigen to induce asthmatic response. Animals were also treated with lovastatin (4 mg/kg/day, i.p.) once a day prior to and during the antigen inhalation period.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Inflammatory cell counts and levels of interleukin (IL)-4, IL-13, eotaxin, thymus and activation-regulated chemokine and leukotriene B(4) (LTB(4)) in bronchoalveolar lavage (BAL) fluids were measured.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Significant increases in eosinophils and levels of the T helper 2 cytokines, chemokines and LTB(4) in BAL fluids in association with the increments of total and OA-specific immunoglobulin E (IgE) in sera were observed in the repeatedly antigen-challenged mice. The airway eosinophilia was ameliorated by lovastatin, whereas it had no significant effect on the levels of these inflammatory mediators or IgE.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Lovastatin may be beneficial for the treatment of allergic inflammatory diseases in the airways, such as allergic bronchial asthma.</AbstractText>
            </Abstract>
            <Affiliation>Department of Pharmacology, School of Pharmacy, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan. chiba@hoshi.ac.jp</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chiba</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sato</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Misawa</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>05</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Inflamm Res</MedlineTA>
            <NlmUniqueID>9508160</NlmUniqueID>
            <ISSNLinking>1023-3830</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Inflammatory Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antigens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Cytokines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Inflammation Mediators</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>37341-29-0</RegistryNumber>
                <NameOfSubstance>Immunoglobulin E</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>71160-24-2</RegistryNumber>
                <NameOfSubstance>Leukotriene B4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75330-75-5</RegistryNumber>
                <NameOfSubstance>Lovastatin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9006-59-1</RegistryNumber>
                <NameOfSubstance>Ovalbumin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antigens</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchoalveolar Lavage Fluid</DescriptorName>
                <QualifierName MajorTopicYN="N">cytology</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cell Count</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cytokines</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophilia</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Immunoglobulin E</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Inflammation Mediators</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene B4</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Lovastatin</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Ovalbumin</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pneumonia</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00011-009-0043-5</ArticleId>
            <ArticleId IdType="pubmed">19418204</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19416143</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>06</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2010</Year>
            <Month>11</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1398-9995</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>64</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Allergy</Title>
                <ISOAbbreviation>Allergy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Leukotriene pathway genetics and pharmacogenetics in allergy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>823-39</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1398-9995.2009.02015.x</ELocationID>
            <Abstract>
                <AbstractText>Leukotrienes (LT) are biologically active lipid mediators known to be involved in allergic inflammation. Leukotrienes have been shown to mediate diverse features of allergic conditions including inflammatory cell chemotaxis/activation and smooth muscle contraction. Cysteinyl leukotrienes (LTC(4), LTD(4) and, LTE(4)) and the dihydroxy leukotriene LTB(4) are generated by a series of enzymes/proteins constituting the LT synthetic pathway or 5-lipoxygenase (5-LO) pathway. Their function is mediated by interacting with multiple receptors. Leukotriene receptor antagonists (LTRA) and LT synthesis inhibitors (LTSI) have shown clinical efficacy in asthma and more recently in allergic rhinitis. Despite growing knowledge of leukotriene biology, the molecular regulation of these inflammatory mediators remains to be fully understood. Genes encoding enzymes of the 5-LO pathway (i.e. ALOX5, LTC4S and LTA4H) and encoding for LT receptors (CYSLTR1/2 and LTB4R1/2) provide excellent candidates for disease susceptibility and severity; however, their role remains unclear. Preliminary data also suggest that 5-LO pathway/receptor gene polymorphism can predict patient responses to LTSI and LTRA; however, the exact mechanisms require elucidation. The aim of this review was to summarize the recent advances in the knowledge of these important mediators, focusing on genetic and pharmacogenetic aspects in the context of allergic phenotypes.</AbstractText>
            </Abstract>
            <Affiliation>Division of Therapeutics and Molecular Medicine, University of Nottingham, Nottingham, UK.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Duroudier</LastName>
                    <ForeName>N P</ForeName>
                    <Initials>NP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tulah</LastName>
                    <ForeName>A S</ForeName>
                    <Initials>AS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sayers</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>03</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Denmark</Country>
            <MedlineTA>Allergy</MedlineTA>
            <NlmUniqueID>7804028</NlmUniqueID>
            <ISSNLinking>0105-4538</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>5-Lipoxygenase-Activating Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>ALOX5AP protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Carrier Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotriene Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Membrane Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Receptors, Leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Receptors, Leukotriene B4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>leukotriene D4 receptor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.13.11.34</RegistryNumber>
                <NameOfSubstance>Arachidonate 5-Lipoxygenase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.5.1.18</RegistryNumber>
                <NameOfSubstance>Glutathione Transferase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.3.2.-</RegistryNumber>
                <NameOfSubstance>Epoxide Hydrolases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.3.2.-</RegistryNumber>
                <NameOfSubstance>leukotriene A4 hydrolase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 4.4.1.20</RegistryNumber>
                <NameOfSubstance>leukotriene-C4 synthase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">5-Lipoxygenase-Activating Proteins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Arachidonate 5-Lipoxygenase</DescriptorName>
                <QualifierName MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Carrier Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Epoxide Hydrolases</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glutathione Transferase</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hypersensitivity</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Membrane Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Pharmacogenetics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptors, Leukotriene</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptors, Leukotriene B4</DescriptorName>
                <QualifierName MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Signal Transduction</DescriptorName>
                <QualifierName MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>149</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>24</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ALL2015</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1398-9995.2009.02015.x</ArticleId>
            <ArticleId IdType="pubmed">19416143</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19355919</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>04</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>26</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1566-5240</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>9</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Current molecular medicine</Title>
                <ISOAbbreviation>Curr. Mol. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The role of leukotrienes in airway remodeling.</ArticleTitle>
            <Pagination>
                <MedlinePgn>383-91</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Asthma is an inflammatory disorder of the airways that has been typified by its bronchospastic component. New attention has been directed to the long-term changes in asthmatic airways as indicated by the accelerated rate of lung function decline occurring in these patients despite therapy with inhaled corticosteroids. These structural changes in the airway wall, termed airway remodeling, are now thought to be a key component in the pathophysiology of asthma. Airway remodeling is characterized by thickening of the lamina reticularis with deposition of collagen and other extracellular matrix proteins leading to subepithelial fibrosis and increased airway goblet cells causing mucus hypersecretion. Of note, there is myofibroblast proliferation and increased airway smooth muscle mass caused by both hyperplasia and hypertrophy of smooth muscle cells. While an important role for cysteinyl leukotrienes (CysLTs) in the pathogenesis of airway inflammation and bronchoconstriction in asthma has been well-established, the specific role of CysLTs in airway remodeling is less clear. This aim of this review is to summarize the data from mouse models of asthma as well as limited human studies that demonstrate a key role for CysLTs in allergen-induced mucus hypersecretion, thickening of the lamina reticularis, and subepithelial fibrosis in the lungs. We will also focus on the interaction between CysLTs and cytokines/growth factors that mediate these changes in epithelial cells, smooth muscle cells, vasculature, and other structural components of the lungs in patients with asthma.</AbstractText>
            </Abstract>
            <Affiliation>Center for Allergy and Inflammation, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98109, USA.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mehrotra</LastName>
                    <ForeName>Anjuli K</ForeName>
                    <Initials>AK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Henderson</LastName>
                    <ForeName>William R</ForeName>
                    <Initials>WR</Initials>
                    <Suffix>Jr</Suffix>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>AI42989</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Curr Mol Med</MedlineTA>
            <NlmUniqueID>101093076</NlmUniqueID>
            <ISSNLinking>1566-5240</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Adrenal Cortex Hormones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Immunologic Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>cysteinyl-leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>52-90-4</RegistryNumber>
                <NameOfSubstance>Cysteine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">pathology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cysteine</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Epithelial Cells</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Extracellular Matrix</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Fibroblasts</DescriptorName>
                <QualifierName MajorTopicYN="N">cytology</QualifierName>
                <QualifierName MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Immunologic Factors</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Muscle, Smooth</DescriptorName>
                <QualifierName MajorTopicYN="N">cytology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Respiratory System</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">pathology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>83</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>10</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>10</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19355919</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19354073</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>04</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>04</Month>
            <Day>24</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1081-1206</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>102</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of allergy, asthma &amp; immunology : official publication of the American College of Allergy, Asthma, &amp; Immunology</Title>
                <ISOAbbreviation>Ann. Allergy Asthma Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Does exhaled nitric oxide measurement have a role in asthma care?</ArticleTitle>
            <Pagination>
                <MedlinePgn>253-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S1081-1206(10)60089-0</ELocationID>
            <Affiliation>Pulmonary and Allergy Associates, New Jersey Medical School, Cedar Knolls, New Jersey 07927, USA. nallopp@optonline.net</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Oppenheimer</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sorkness</LastName>
                    <ForeName>Christine A</ForeName>
                    <Initials>CA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ann Allergy Asthma Immunol</MedlineTA>
            <NlmUniqueID>9503580</NlmUniqueID>
            <ISSNLinking>1081-1206</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Biological Markers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>10102-43-9</RegistryNumber>
                <NameOfSubstance>Nitric Oxide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Biological Markers</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Breath Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchial Hyperreactivity</DescriptorName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophils</DescriptorName>
                <QualifierName MajorTopicYN="N">cytology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Nitric Oxide</DescriptorName>
                <QualifierName MajorTopicYN="Y">analysis</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Primary Health Care</DescriptorName>
                <QualifierName MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sputum</DescriptorName>
                <QualifierName MajorTopicYN="N">cytology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>10</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>10</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>25</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19354073</ArticleId>
            <ArticleId IdType="pii">S1081-1206(10)60089-0</ArticleId>
            <ArticleId IdType="doi">10.1016/S1081-1206(10)60089-0</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19294813</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>03</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>20</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1744-8042</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacogenomics</Title>
                <ISOAbbreviation>Pharmacogenomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Understanding clinical variability in response to asthma treatment.</ArticleTitle>
            <Pagination>
                <MedlinePgn>327-30</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kukreti</LastName>
                    <ForeName>Ritushree</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guleria</LastName>
                    <ForeName>Randeep</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Editorial</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Pharmacogenomics</MedlineTA>
            <NlmUniqueID>100897350</NlmUniqueID>
            <ISSNLinking>1462-2416</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Adrenergic beta-Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Bronchodilator Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>CRF receptor type 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Glucocorticoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Receptors, Corticotropin-Releasing Hormone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Receptors, Muscarinic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>T-Box Domain Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>T-box transcription factor TBX21</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>58-55-9</RegistryNumber>
                <NameOfSubstance>Theophylline</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adrenergic beta-Agonists</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchodilator Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Genetic Variation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Glucocorticoids</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptors, Corticotropin-Releasing Hormone</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptors, Muscarinic</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Severity of Illness Index</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">T-Box Domain Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Theophylline</DescriptorName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>30</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>20</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>20</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19294813</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19291727</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>03</Month>
            <Day>31</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>04</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1096-8652</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>84</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of hematology</Title>
                <ISOAbbreviation>Am. J. Hematol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Urinary cysteinyl leukotriene E4 significantly increases during pain in children and adults with sickle cell disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>231-3</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ajh.21370</ELocationID>
            <Abstract>
                <AbstractText>Baseline level of the cysteinyl leukotriene (CysLT), leukotriene E4 (LTE4), is associated with an increased pain rate in children and adults with sickle cell disease (SCD). To provide additional evidence for a role of CysLTs in the pathogenesis of vaso-occlusion, we tested the hypothesis that LTE4 levels will increase within an individual during painful episodes compared to baseline. In a cohort of 19 children and adults with SCD, median LTE4 levels increased from 82.36 pg/mg creatinine at baseline to 162.81 pg/mg creatinine during a painful episode (P &lt; 0.001). These data further support a contribution of CysLTs to the process of vaso-occlusion.</AbstractText>
                <CopyrightInformation>Copyright 2009 Wiley-Liss, Inc.</CopyrightInformation>
            </Abstract>
            <Affiliation>Division of Hematology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA. jfield@dom.wustl.edu</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Field</LastName>
                    <ForeName>Joshua J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Strunk</LastName>
                    <ForeName>Robert C</ForeName>
                    <Initials>RC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Knight-Perry</LastName>
                    <ForeName>Jessica E</ForeName>
                    <Initials>JE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blinder</LastName>
                    <ForeName>Morey A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Townsend</LastName>
                    <ForeName>R Reid</ForeName>
                    <Initials>RR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>DeBaun</LastName>
                    <ForeName>Michael R</ForeName>
                    <Initials>MR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>K12 HL08710</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Hematol</MedlineTA>
            <NlmUniqueID>7610369</NlmUniqueID>
            <ISSNLinking>0361-8609</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Acetates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Asthmatic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Biological Markers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotriene Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Quinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75715-89-8</RegistryNumber>
                <NameOfSubstance>Leukotriene E4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9034-63-3</RegistryNumber>
                <NameOfSubstance>Fetal Hemoglobin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>MHM278SD3E</RegistryNumber>
                <NameOfSubstance>montelukast</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Acetates</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anemia, Sickle Cell</DescriptorName>
                <QualifierName MajorTopicYN="N">complications</QualifierName>
                <QualifierName MajorTopicYN="Y">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Asthmatic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">complications</QualifierName>
                <QualifierName MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Biological Markers</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Fetal Hemoglobin</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hemoglobin C Disease</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Heterozygote</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hospitalization</DescriptorName>
                <QualifierName MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Ischemia</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene E4</DescriptorName>
                <QualifierName MajorTopicYN="Y">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pain</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Quinolines</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sickle Cell Trait</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">beta-Thalassemia</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.21370</ArticleId>
            <ArticleId IdType="pubmed">19291727</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19233745</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>04</Month>
            <Day>13</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>11</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-376X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>877</Volume>
                    <Issue>13</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>May</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</Title>
                <ISOAbbreviation>J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>LC/MS/MS analysis of leukotriene B4 and other eicosanoids in exhaled breath condensate for assessing lung inflammation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1272-80</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jchromb.2009.01.036</ELocationID>
            <Abstract>
                <AbstractText>Leukotriene (LT) B(4) is a potent inflammatory lipid mediator that has been involved in the pathophysiology of respiratory diseases including asthma. Exhaled breath condensate (EBC) is a non-invasive method to sample secretions from the airways. LC/MS/MS techniques for measuring LTB(4) concentrations in EBC have been developed and are suitable for an accurate quantitative assessment of its concentrations in EBC. LC/MS/MS for other eicosanoids including 8-isoprostane, a marker of oxidative stress, and cysteinyl-LTs have been developed. This article, mainly focused on LTB(4), presents the analytical aspects of the LC/MS/MS techniques for measuring LTB(4) and 8-isoprostane in EBC, provides examples of their application to the assessment of airway inflammation in patients with asthma and other respiratory diseases, and discusses their potential utility for non-invasive monitoring of drug therapy.</AbstractText>
            </Abstract>
            <Affiliation>Department of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Largo Francesco Vito 1, Rome 00168, Italy. pmontuschi@rm.unicatt.it</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Montuschi</LastName>
                    <ForeName>Paolo</ForeName>
                    <Initials>P</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>02</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>J Chromatogr B Analyt Technol Biomed Life Sci</MedlineTA>
            <NlmUniqueID>101139554</NlmUniqueID>
            <ISSNLinking>1570-0232</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Eicosanoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>71160-24-2</RegistryNumber>
                <NameOfSubstance>Leukotriene B4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Breath Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Chromatography, Liquid</DescriptorName>
                <QualifierName MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Monitoring</DescriptorName>
                <QualifierName MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eicosanoids</DescriptorName>
                <QualifierName MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene B4</DescriptorName>
                <QualifierName MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Spectrometry, Mass, Electrospray Ionization</DescriptorName>
                <QualifierName MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName>
                <QualifierName MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>25</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1570-0232(09)00061-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jchromb.2009.01.036</ArticleId>
            <ArticleId IdType="pubmed">19233745</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19230459</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>02</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>03</Month>
            <Day>10</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1081-1206</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>102</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of allergy, asthma &amp; immunology : official publication of the American College of Allergy, Asthma, &amp; Immunology</Title>
                <ISOAbbreviation>Ann. Allergy Asthma Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Exhaled leukotrienes and bronchial responsiveness to methacholine in patients with seasonal allergic rhinitis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>103-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S1081-1206(10)60238-4</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Allergic rhinitis and bronchial asthma can coexist and affect each other.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the relationship between the postseasonal increase in the concentration of leukotriene (LT) B4 and LTE4 in exhaled breath condensate (EBC) and bronchial responsiveness to methacholine (BRM) in patients with seasonal allergic rhinitis (SAR).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">In 28 patients with SAR and 50 healthy study patients, the leukotrienes were measured in EBC during and after the pollen season by gas chromatography/mass spectrometry. The BRM was determined after the pollen season.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In 7 patients with SAR, significantly increased concentrations of both the leukotrienes were found in EBC during and 5 months after the pollen season. The following seasonal and postseasonal median values were measured in patients with SAR in comparison with control patients: LTB4: 131 and 90 pg/mL vs 80 and 79 pg/mL, P &lt; .001 and P = .03, respectively; LTE4: 122 and 86 pg/mL vs 76 and 74 pg/mL, P &lt; .001 and P = .02, respectively. Five months after the pollen season, the concentrations of LTB4 and LTE4 decreased with respect to their seasonal values (90 and 86 pg/mL, respectively, P &lt; .001, for both leukotrienes). In 7 patients with SAR and leukotriene levels exceeding the reference limits, significantly increased BRM was also found (LTB4: P = .02; LTE4: P = .002).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The seasonal and postseasonal increases in LTB4 and LTE4 concentrations in EBC of the patients with SAR correlated significantly with the later increase in BMR. This relationship could provide a useful predictive parameter for early inflammatory processes in the lower airways of patients with allergic rhinitis.</AbstractText>
            </Abstract>
            <Affiliation>Department of Allergology and Clinical Immunology, &quot;Na Homolce&quot; Hospital, Institute for Postgraduate Medical Education, Prague, Czech Republic. petr.cap@homolka.cz</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cap</LastName>
                    <ForeName>Petr</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maly</LastName>
                    <ForeName>Marek</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pehal</LastName>
                    <ForeName>Frantisek</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pelikan</LastName>
                    <ForeName>Zdenek</ForeName>
                    <Initials>Z</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ann Allergy Asthma Immunol</MedlineTA>
            <NlmUniqueID>9503580</NlmUniqueID>
            <ISSNLinking>1081-1206</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Asthmatic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>62-51-1</RegistryNumber>
                <NameOfSubstance>Methacholine Chloride</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>71160-24-2</RegistryNumber>
                <NameOfSubstance>Leukotriene B4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75715-89-8</RegistryNumber>
                <NameOfSubstance>Leukotriene E4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Asthmatic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchi</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Exhalation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene B4</DescriptorName>
                <QualifierName MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene E4</DescriptorName>
                <QualifierName MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Methacholine Chloride</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Reference Standards</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rhinitis, Allergic, Seasonal</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>11</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19230459</ArticleId>
            <ArticleId IdType="pii">S1081-1206(10)60238-4</ArticleId>
            <ArticleId IdType="doi">10.1016/S1081-1206(10)60238-4</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19226274</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>26</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2222</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</Title>
                <ISOAbbreviation>Clin. Exp. Allergy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Chemokine CC-ligand 5 production and eosinophil activation into the upper airways of aspirin-sensitive patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>491-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2222.2008.03190.x</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Airway eosinophilia is a hallmark of aspirin-sensitive asthma/rhinitis.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We have investigated chemokine CC-ligand 5 (CCL5) production and its association with eosinophil activation in the upper airways of aspirin-sensitive patients both in vivo and in vitro.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Twenty aspirin-sensitive asthma/rhinosinusitis patients, 18 atopic-tolerant asthma/rhinosinusitis patients and 15 healthy control subjects took part in the study. All subjects were challenged with saline and lysine-acetylsalicylic acid (L-asa) on separate occasions. Nasal lavages were obtained at baseline and 120 min after challenge and analysed for mediators' release.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">When compared with control subjects, the baseline levels of CCL5 were significantly increased in both sensitive and tolerant patients (there was no significant difference in CCL5 concentrations between these two groups, P&gt;0.05). However, L-asa nasal challenge induced significantly increased levels of CCL5 in the sensitive patients but not in the tolerant subjects (median: 380 vs. 140 pg/mL, P&lt;0.0001). Similarly, the concentrations of both eosinophil cationic protein (ECP) and cysteinil leukotriene (cys-LTs) were increased significantly in the aspirin-sensitive but not in the tolerant patients. There was a trend towards a significant correlation between CCL5 and ECP concentrations in the sensitive patients following L-ASA challenge. On incubation with aspirin, nasal tissue derived from aspirin-sensitive but not that derived from tolerant subjects released increased CCL5 levels in culture. As determined by immunohistochemistry, CCL5 was predominantly localized to the nasal airway epithelium.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Altogether, these findings suggest that CCL5 is released in aspirin-sensitive asthma/rhinosinusitis.</AbstractText>
            </Abstract>
            <Affiliation>Department of Immunogenetics and Allergy, Instituto Nacional de Enfermedades Respiratorias, Calzada Tlalpan, Mxico.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fuentes-Beltrn</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Montes-Vizuet</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valencia-Maqueda</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Negrete-Garca</LastName>
                    <ForeName>M C</ForeName>
                    <Initials>MC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garca-Cruz</LastName>
                    <ForeName>M de L</ForeName>
                    <Initials>Mde L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teran</LastName>
                    <ForeName>L M</ForeName>
                    <Initials>LM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>02</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Clin Exp Allergy</MedlineTA>
            <NlmUniqueID>8906443</NlmUniqueID>
            <ISSNLinking>0954-7894</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>CCL5 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Chemokine CCL5</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>50-78-2</RegistryNumber>
                <NameOfSubstance>Aspirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.27.-</RegistryNumber>
                <NameOfSubstance>Eosinophil Cationic Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.27.-</RegistryNumber>
                <NameOfSubstance>RNASE3 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Administration, Intranasal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aspirin</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Chemokine CCL5</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
                <QualifierName MajorTopicYN="Y">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Hypersensitivity</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophil Cationic Protein</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophils</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Nasal Lavage Fluid</DescriptorName>
                <QualifierName MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rhinitis, Allergic, Perennial</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sinusitis</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>20</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>20</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">CEA3190</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1365-2222.2008.03190.x</ArticleId>
            <ArticleId IdType="pubmed">19226274</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19205280</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>02</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>03</Month>
            <Day>03</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1081-1206</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>102</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of allergy, asthma &amp; immunology : official publication of the American College of Allergy, Asthma, &amp; Immunology</Title>
                <ISOAbbreviation>Ann. Allergy Asthma Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cysteinyl-leukotrienes in asthmatic airway smooth muscle cell hyperplasia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>16-21</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S1081-1206(10)60102-0</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To present a historic perspective and an up-to-date understanding of the involvement of cysteinyl-leukotrienes (cys-LTs) in asthmatic airway smooth muscle (ASM) cell hyperplasia.</AbstractText>
                <AbstractText Label="DATA SOURCES" NlmCategory="METHODS">Data collected from human tissues, from animal models of airway inflammation, and from ASM cells cultured in vitro are included.</AbstractText>
                <AbstractText Label="STUDY SELECTION" NlmCategory="METHODS">All studies regarding the potential contribution of cys-LTs on ASM cell hyperplasia are reviewed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Whereas in vivo observations are consistent and seem to attribute an important role for cys-LTs in ASM cell hyperplasia, the observations made in cultured ASM cells are inconsistent, with studies documenting a mitogenic potential only reporting marginal effects.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This dichotomy between in vitro and in vivo results led to the elaboration of a hypothesis suggesting that the mitogenic effect of cys-LTs on ASM cells may be indirect and mediated by a paracrine loop involving transforming growth factor beta1 production by airway resident and inflammatory cells.</AbstractText>
            </Abstract>
            <Affiliation>The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, Providence Health Care/St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. ybosse@mrl.ubc.ca</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Boss</LastName>
                    <ForeName>Ynuk</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stankova</LastName>
                    <ForeName>Jana</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rola-Pleszczynski</LastName>
                    <ForeName>Marek</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ann Allergy Asthma Immunol</MedlineTA>
            <NlmUniqueID>9503580</NlmUniqueID>
            <ISSNLinking>1081-1206</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Receptors, Leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Transforming Growth Factor beta1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>cysteinyl-leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>leukotriene D4 receptor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>103107-01-3</RegistryNumber>
                <NameOfSubstance>Fibroblast Growth Factor 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>52-90-4</RegistryNumber>
                <NameOfSubstance>Cysteine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cysteine</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophils</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Epithelial Cells</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Fibroblast Growth Factor 2</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hyperplasia</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Myocytes, Smooth Muscle</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rabbits</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptors, Leukotriene</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>50</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19205280</ArticleId>
            <ArticleId IdType="pii">S1081-1206(10)60102-0</ArticleId>
            <ArticleId IdType="doi">10.1016/S1081-1206(10)60102-0</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19153534</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>02</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>07</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1323-8930</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>58</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Allergology international : official journal of the Japanese Society of Allergology</Title>
                <ISOAbbreviation>Allergol Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Molecular mechanism of the additive effects of leukotriene modifier in asthmatic patients receiving steroid therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>89-96</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2332/allergolint.08-OA-0014</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The addition of leukotriene modifier (LM) may be a useful approach for uncontrollable asthma despite treatment with inhaled corticosteroid (ICS), especially in asthmatics comorbid with allergic rhinitis (AR), although little is known about its molecular mechanism. We evaluated the additive effects of LM with ICS on pulmonary function and airway inflammation in asthmatics with or without AR.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Eighteen uncontrolled steroid-treated asthmatics, nine with and nine without AR, were enrolled. Spirometry, peak expiratory flow (PEF) measurements, and exhaled breath condensate sampling were performed before and 8 weeks after LM administration. The lowest PEF over the course of one week, expressed as a percentage of the highest PEF (Min%Max PEF), was used as an index of fluctuation of the airway caliber. Airway cytokine expression was analyzed with a protein array.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A significant improvement in forced expiratory volume in one second as a percentage of the predicted value (%FEV(1)) and Min%Max PEF was seen in the subgroup of asthma with AR. Although there was no significant difference in the baseline cytokine values between the groups, the exhaled RANTES level was significantly reduced by LM in the asthma with AR group. The changes in the RANTES level were significantly related to the changes in the %FEV(1) and Min%Max PEF values.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">LM caused a greater improvement in pulmonary function and airway inflammation in asthmatics with AR. The RANTES-mediated pathway may be involved in the improvement of the airflow limitation and airway lability by LM additive therapy in asthmatics receiving steroid therapy.</AbstractText>
            </Abstract>
            <Affiliation>Third Department of Internal Medicine, Wakayama Medical University, School of Medicine, Wakayama, Japan.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Matsunaga</LastName>
                    <ForeName>Kazuto</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yanagisawa</LastName>
                    <ForeName>Satoru</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ichikawa</LastName>
                    <ForeName>Tomohiro</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akamatsu</LastName>
                    <ForeName>Keiichiro</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koarai</LastName>
                    <ForeName>Akira</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hirano</LastName>
                    <ForeName>Tsunahiko</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sugiura</LastName>
                    <ForeName>Hisatoshi</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Minakata</LastName>
                    <ForeName>Yoshiaki</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ichinose</LastName>
                    <ForeName>Masakazu</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>01</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Allergol Int</MedlineTA>
            <NlmUniqueID>9616296</NlmUniqueID>
            <ISSNLinking>1323-8930</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Acetates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Adrenal Cortex Hormones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>CCL5 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Chemokine CCL5</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Chromones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Cytokines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotriene Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Quinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>cysteinyl-leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>pranlukast</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>52-90-4</RegistryNumber>
                <NameOfSubstance>Cysteine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>MHM278SD3E</RegistryNumber>
                <NameOfSubstance>montelukast</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Acetates</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Administration, Inhalation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
                <QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Chemokine CCL5</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
                <QualifierName MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Chromones</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cysteine</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cytokines</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Synergism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Forced Expiratory Volume</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Quinolines</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>6</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>8</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">058010089</ArticleId>
            <ArticleId IdType="doi">10.2332/allergolint.08-OA-0014</ArticleId>
            <ArticleId IdType="pubmed">19153534</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19144047</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>01</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>08</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1440-1843</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>14</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Respirology (Carlton, Vic.)</Title>
                <ISOAbbreviation>Respirology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Changes in the proteome of human bronchial epithelial cells following stimulation with leucotriene E4 and transforming growth factor-beta1.</ArticleTitle>
            <Pagination>
                <MedlinePgn>39-45</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1440-1843.2008.01414.x</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">Activated bronchial epithelial cells exert considerable potential to maintain a microenvironment in the airway wall that promotes airway inflammation and remodelling. Cysteinyl leucotrienes (CysLT) and transforming growth factor-beta(1) (TGF-beta(1)) are both increased in asthmatic airways and may influence the pathophysiology of disease. However, the consequences of activation of bronchial epithelial cells by these mediators are not fully understood. A proteomic-based approach was used to characterize the inflammatory pathways in bronchial epithelial cells after stimulation with CysLT and TGF-beta(1).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Human bronchial epithelial cells (BEAS-2B) were stimulated with 1 ng/mL TGF-beta(1) and 50 nmol/L leucotriene E(4) (LTE(4)) for 48 h and whole-cell lysates were subjected to two-dimensional gel electrophoresis. Proteins showing statistically significant differential expression were identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and database searching.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Stimulation with LTE(4) increased the expression of three proteins and five proteins showed decreased expression. Of the latter group, two were definitively identified as heat shock protein (Hsp90 alpha) and stress-70 protein. Hsp90 alpha forms a heterocomplex with the glucocorticoid receptor (GR) and a significant decrease in GR following LTE(4) stimulation was confirmed. TGF-beta(1) downregulated 18 intracellular proteins, including lamin A/C, glyceraldehyde-3-phosphate dehydrogenase, protein DJ-1, voltage-dependent calcium channel gamma-7 subunit, heterogeneous nuclear ribonucleoprotein A2/B1 and stress-70 protein.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The current findings suggest that by downregulating GR and Hsp90 alpha, CysLT may interfere with the action of glucocorticoids. Overall, the results confirm the complex role of bronchial epithelium in aspects of airway inflammation and remodelling.</AbstractText>
            </Abstract>
            <Affiliation>Department of Pulmonary Medicine, Institute of General and Molecular Pathology, University of Tartu, Tartu, Estonia. alan@kliinikum.ee</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Altraja</LastName>
                    <ForeName>Siiri</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jaama</LastName>
                    <ForeName>Juta</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valk</LastName>
                    <ForeName>Ervin</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Altraja</LastName>
                    <ForeName>Alan</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Australia</Country>
            <MedlineTA>Respirology</MedlineTA>
            <NlmUniqueID>9616368</NlmUniqueID>
            <ISSNLinking>1323-7799</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Heat-Shock Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Proteome</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Receptors, Glucocorticoid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Transforming Growth Factor beta1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75715-89-8</RegistryNumber>
                <NameOfSubstance>Leukotriene E4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchi</DescriptorName>
                <QualifierName MajorTopicYN="Y">cytology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Down-Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Electrophoresis, Gel, Two-Dimensional</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Heat-Shock Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene E4</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Proteome</DescriptorName>
                <QualifierName MajorTopicYN="Y">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Proteomics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptors, Glucocorticoid</DescriptorName>
                <QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Respiratory Mucosa</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">RES1414</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1440-1843.2008.01414.x</ArticleId>
            <ArticleId IdType="pubmed">19144047</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19130894</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>12</Month>
            <Day>15</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1098-8823</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>89</Volume>
                    <Issue>3-4</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Prostaglandins &amp; other lipid mediators</Title>
                <ISOAbbreviation>Prostaglandins Other Lipid Mediat.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>On the biosynthesis and biological role of eoxins and 15-lipoxygenase-1 in airway inflammation and Hodgkin lymphoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>120-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.prostaglandins.2008.12.003</ELocationID>
            <Abstract>
                <AbstractText>This mini-review is focused on the enzyme 15-lipoxygenase-1 (15-LO-1) and eoxins in airway inflammatory diseases and Hodgkin lymphoma. Several studies have demonstrated increased expression and activity of 15-LO-1 in the respiratory tissue from asthma patients , indicating a pathophysiological role of this enzyme in airway inflammation. Eoxins were recently identified as pro-inflammatory metabolites of arachidonic acid, formed through the 15-LO-1 pathway, in human eosinophils, mast cells, airway epithelial cells and Hodgkin lymphoma. Mice deficient of 12/15-LO, the ortholog to human 15-LO-1, had an attenuated allergic airway inflammation compared to wild type controls, also indicating a pathophysiological role of this enzyme in respiratory inflammation. The putative therapeutic implications of 15-LO-1 inhibitors in the treatment of asthma, chronic obstructive pulmonary disorder and Hodgkin lymphoma are discussed.</AbstractText>
            </Abstract>
            <Affiliation>Department of Medical Biochemistry and Biophysics, Division of Physiological Chemistry II, Karolinska Institutet, Stockholm and Orexo AB, Uppsala, Sweden. hans-erik.claesson@ki.se</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Claesson</LastName>
                    <ForeName>Hans-Erik</ForeName>
                    <Initials>HE</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Prostaglandins Other Lipid Mediat</MedlineTA>
            <NlmUniqueID>9808648</NlmUniqueID>
            <ISSNLinking>1098-8823</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>12-15-lipoxygenase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>73836-78-9</RegistryNumber>
                <NameOfSubstance>Leukotriene D4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.13.11.31</RegistryNumber>
                <NameOfSubstance>Arachidonate 12-Lipoxygenase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.13.11.33</RegistryNumber>
                <NameOfSubstance>Arachidonate 15-Lipoxygenase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Arachidonate 12-Lipoxygenase</DescriptorName>
                <QualifierName MajorTopicYN="N">deficiency</QualifierName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Arachidonate 15-Lipoxygenase</DescriptorName>
                <QualifierName MajorTopicYN="N">deficiency</QualifierName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophils</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hodgkin Disease</DescriptorName>
                <QualifierName MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Inflammation</DescriptorName>
                <QualifierName MajorTopicYN="N">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene D4</DescriptorName>
                <QualifierName MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Lung</DescriptorName>
                <QualifierName MajorTopicYN="N">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Organ Specificity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Pulmonary Disease, Chronic Obstructive</DescriptorName>
                <QualifierName MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Reed-Sternberg Cells</DescriptorName>
                <QualifierName MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>58</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>10</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>10</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1098-8823(08)00091-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.prostaglandins.2008.12.003</ArticleId>
            <ArticleId IdType="pubmed">19130894</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19128354</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>01</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>02</Month>
            <Day>13</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1365-2222</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</Title>
                <ISOAbbreviation>Clin. Exp. Allergy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>72-80</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2222.2008.03104.x</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Anaphylaxis is a life-threatening syndrome resulting from the sudden release of mast cell- and basophil-derived mediators into the circulation. However, pathological evidence of the association between inflammatory mediators and human anaphylaxis is insufficient.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to better understand the relationship between in vivo production of inflammatory mediators and the pathogenesis of anaphylaxis. We also sought to evaluate mast cell activation in anaphylaxis.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We measured the concentrations of various inflammatory mediators in urine samples, which were collected from 32 anaphylactic patients during the onset of anaphylaxis and during clinical remission, 21 patients with asthma on acute exacerbation and 15 healthy control subjects. Blood and urine specimens were collected from the patients after provocation test. Urinary leukotriene E4 (LTE4), 9alpha, 11beta-prostaglandin F2 (9alpha, 11beta-PGF2), eosinophil-derived neurotoxin (EDN) and leukotriene B4 glucuronide (LTBG) concentrations were determined by enzyme immunoassay, and the activity of plasma platelet-activating factor acetylhydrolase and serum tryptase concentration were measured using commercially available kits.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Significantly higher concentrations of urinary LTE4 and 9alpha, 11beta-PGF2, which immediately decreased during clinical remission, were observed in the anaphylactic patients than in asthmatic patients on acute exacerbation and healthy control subjects. Concentrations of EDN and LTBG were not significantly different among the anaphylactic patients, asthmatic patients on acute exacerbation and healthy subjects. There was a significant correlation between urinary LTE4 and 9alpha, 11beta-PGF2 concentrations in the anaphylactic patients (r=0.672, P=0.005, n=32). In addition, LTE4 concentration in patients with anaphylactic shock is significantly elevated compared with that in patients without anaphylactic shock.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This is a report on the significant increase in urinary LTE4 and 9alpha, 11beta-PGF2 concentrations during anaphylaxis. Urinary LTE4 and 9alpha, 11beta-PGF2 concentrations may be a reliable marker of endogenous production of inflammatory mediators associated with anaphylaxis.</AbstractText>
            </Abstract>
            <Affiliation>Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Sagamihara, Kanagawa, Japan. e-ono@sagamihara-hosp.gr.jp</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ono</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taniguchi</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mita</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fukutomi</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Higashi</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miyazaki</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kumamoto</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akiyama</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Clin Exp Allergy</MedlineTA>
            <NlmUniqueID>8906443</NlmUniqueID>
            <ISSNLinking>0954-7894</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Inflammation Mediators</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>cysteinyl-leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>41598-07-6</RegistryNumber>
                <NameOfSubstance>Prostaglandin D2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>52-90-4</RegistryNumber>
                <NameOfSubstance>Cysteine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>551-11-1</RegistryNumber>
                <NameOfSubstance>Dinoprost</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75715-89-8</RegistryNumber>
                <NameOfSubstance>Leukotriene E4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Clin Exp Allergy. 2009 Jan;39(1):5-7</RefSource>
                <PMID Version="1">19032357</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anaphylaxis</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cysteine</DescriptorName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dinoprost</DescriptorName>
                <QualifierName MajorTopicYN="Y">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Inflammation Mediators</DescriptorName>
                <QualifierName MajorTopicYN="Y">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene E4</DescriptorName>
                <QualifierName MajorTopicYN="Y">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mast Cells</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Prostaglandin D2</DescriptorName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">CEA3104</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1365-2222.2008.03104.x</ArticleId>
            <ArticleId IdType="pubmed">19128354</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19127069</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>14</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>06</Month>
            <Day>09</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1423-0097</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>149</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2009</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International archives of allergy and immunology</Title>
                <ISOAbbreviation>Int. Arch. Allergy Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Increases in urinary 9alpha,11beta-prostaglandin f2 indicate mast cell activation in wine-induced asthma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>127-32</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000189195</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Wine-induced asthmatic symptoms may be caused by sulphite additives. Prostaglandin (PG)D2 and cysteinyl leukotrienes (cysLT) are important mediators of asthmatic responses. To determine whether the sulphite additives in wine alter the production of PGD2 and cysLT, asthmatic patients with compelling histories of wine sensitivity were challenged with high- and low-sulphite wines; the urinary metabolites of PGD2 and cysLT were measured before and after challenge.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Eight self-reporting wine-sensitive asthmatic patients completed double-blind challenges with high- and low-sulphite wines on separate days. Urine samples were collected before and after consumption of 150 ml of wine. Urinary concentrations of 9alpha,11beta-PGF2 and leukotriene (LT)E4 were measured by enzyme immunoassay.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Urinary 9alpha,11beta-PGF2 concentrations increased in all subjects following challenge with high-sulphite wine, and the median concentration increased 1.6-fold (p &lt; 0.01). Urinary 9alpha,11beta-PGF2 also increased 1.5-fold after low-sulphite wine challenge, although this did not reach statistical significance (p = 0.08). The median difference in 9alpha,11beta-PGF2 concentration after high-sulphite wine challenge was not significantly different compared with that after low-sulphite wine challenge. Median urinary LTE4 concentrations did not change significantly after either wine challenge.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Increased urinary 9alpha,11beta-PGF2 concentrations following wine challenge suggest mast cell activation as a possible mechanism for wine-induced asthma, although this did not appear to be related to the sulphite additives in wine. Urinary 9alpha,11beta-PGF2 may warrant further assessment as a potential biomarker of reactivity to wine in asthmatic subjects.</AbstractText>
                <CopyrightInformation>Copyright 2009 S. Karger AG, Basel.</CopyrightInformation>
            </Abstract>
            <Affiliation>Lung Institute of Western Australia Inc., Centre for Asthma, Allergy and Respiratory Research, Ground Floor, E Block, Sir Charles Gairdner Hospital, Verdun Street, Nedlands, W.A. 6009, Australia. nmisso@liwa.uwa.edu.au</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Misso</LastName>
                    <ForeName>Neil L A</ForeName>
                    <Initials>NL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aggarwal</LastName>
                    <ForeName>Shashi</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thompson</LastName>
                    <ForeName>Philip J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vally</LastName>
                    <ForeName>Hassan</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Randomized Controlled Trial</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>01</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Int Arch Allergy Immunol</MedlineTA>
            <NlmUniqueID>9211652</NlmUniqueID>
            <ISSNLinking>1018-2438</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Allergens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Sulfites</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>551-11-1</RegistryNumber>
                <NameOfSubstance>Dinoprost</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75715-89-8</RegistryNumber>
                <NameOfSubstance>Leukotriene E4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Allergens</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">etiology</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cross-Over Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dinoprost</DescriptorName>
                <QualifierName MajorTopicYN="Y">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene E4</DescriptorName>
                <QualifierName MajorTopicYN="Y">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Mast Cells</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Skin Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sulfites</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Wine</DescriptorName>
                <QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>8</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>8</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>10</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">000189195</ArticleId>
            <ArticleId IdType="doi">10.1159/000189195</ArticleId>
            <ArticleId IdType="pubmed">19127069</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19110408</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>03</Month>
            <Day>31</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>03</Month>
            <Day>15</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-3064</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>103</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Respiratory medicine</Title>
                <ISOAbbreviation>Respir Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Exhaled cysteinyl-leukotrienes and 8-isoprostane in patients with asthma and their relation to clinical severity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>750-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rmed.2008.11.009</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Collection of exhaled breath condensate (EBC) is a safe, non-invasive method to collect droplets of the airway surface liquid and measure mediators of airway inflammation and oxidative stress, such as cysteinyl-leukotrienes (cys-LTs) and 8-isoprostane.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of our study was to investigate baseline values of inflammatory lipid mediators in EBC and their relation to asthma severity.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Nineteen healthy subjects, 16 mild, 12 moderate and 15 severe asthmatics were studied. All subjects attended a clinic visit for spirometry and EBC collection. The concentrations of exhaled cys-LTs and 8-isoprostane were measured by means of specific enzyme immunoassays.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">8-isoprostane levels were significantly increased in mild (49.1+/-5.2 pg/mL, p&lt;0.001), moderate (49.7+/-5.2 pg/mL, p&lt;0.001) and severe asthmatics (77.7+/-7.3 pg/mL, p&lt;0.001), compared to healthy controls (16.4+/-1.6 pg/mL). Moreover, 8-isoprostane levels were significantly higher in severe compared to mild and moderate asthmatics (p&lt;0.01). Cys-LT levels were significantly higher in moderate (34.6+/-4.4 pg/mL, p&lt;0.05) and severe asthmatics (47.9+/-6.0 pg/mL, p&lt;0.001), while no significant difference was found between healthy controls and mild asthmatics. 8-isoprostane levels in EBC of asthmatics strongly correlated with cys-LT levels (r=0.61, p&lt;0.0001).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">8-isoprostane and cys-LT are detectable in EBC of healthy subjects and their levels progressively increase in asthmatic patients according to disease severity. The correlation found between these two lipid mediators indicating a link between oxidative stress and airway inflammation.</AbstractText>
            </Abstract>
            <Affiliation>7th Department of Respiratory Medicine, Sotiria General Hospital, Athens, Greece.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Samitas</LastName>
                    <ForeName>Konstantinos</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chorianopoulos</LastName>
                    <ForeName>Dimitrios</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vittorakis</LastName>
                    <ForeName>Stelios</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zervas</LastName>
                    <ForeName>Eleftherios</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Economidou</LastName>
                    <ForeName>Erasmia</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Papatheodorou</LastName>
                    <ForeName>George</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loukides</LastName>
                    <ForeName>Stelios</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gaga</LastName>
                    <ForeName>Mina</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Comparative Study</PublicationType>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Respir Med</MedlineTA>
            <NlmUniqueID>8908438</NlmUniqueID>
            <ISSNLinking>0954-6111</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>cysteinyl-leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>27415-26-5</RegistryNumber>
                <NameOfSubstance>8-epi-prostaglandin F2alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>52-90-4</RegistryNumber>
                <NameOfSubstance>Cysteine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>551-11-1</RegistryNumber>
                <NameOfSubstance>Dinoprost</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Breath Tests</DescriptorName>
                <QualifierName MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cysteine</DescriptorName>
                <QualifierName MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dinoprost</DescriptorName>
                <QualifierName MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Forced Expiratory Volume</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic">Greece</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Oxidative Stress</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Spirometry</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2008</Year>
                <Month>9</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>3</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0954-6111(08)00403-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.rmed.2008.11.009</ArticleId>
            <ArticleId IdType="pubmed">19110408</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19077700</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>12</Month>
            <Day>16</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>02</Month>
            <Day>27</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1531-6971</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>15</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Current opinion in pulmonary medicine</Title>
                <ISOAbbreviation>Curr Opin Pulm Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Biomarkers in asthma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>12-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MCP.0b013e32831de235</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">The purpose of this review is to highlight seminal and current literature that informs our understanding of the clinical and investigative utility of biomarkers in asthma. Biomarkers derive from a variety of sources [bronchiolar lavage (BAL), sputum, exhaled breath, and blood], and have widely variant performance characteristics, and applicability.</AbstractText>
                <AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Increasing attention is given to biomarkers in exhaled breath, both gaseous (exhaled nitric oxide) and higher molecular weight moieties [in exhaled breath condensate (EBC)]. Current research in EBC analysis has focused on validation, standardization, and technical considerations, whereas research on exhaled nitric oxide (ENO) has moved to testing its predictive value in clinical situations. The use of advanced biostatistical techniques, and combinatorial analyses has led to additional advances in the utility of biomarkers.</AbstractText>
                <AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">To date, the best validated, and best performing biomarkers for clinical asthma appear to be measures of inflammation in induced sputum, and measures of ENO. Some trials using ENO appear particularly promising for early clinical use. EBC metrics are at present too inchoate for clinical purposes. However, not all important clinical and research questions can be addressed with sputum, EBC, or ENO metrics, leaving an important place for BAL, bronchial biopsy, and perhaps EBC measurements in the research arena.</AbstractText>
            </Abstract>
            <Affiliation>Pulmonary and Critical Care Medicine, University of Texas Medical Branch, Galveston, Texas 77555-0568, USA.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Murugan</LastName>
                    <ForeName>Anandhi</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Prys-Picard</LastName>
                    <ForeName>Curig</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Calhoun</LastName>
                    <ForeName>William J</ForeName>
                    <Initials>WJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Curr Opin Pulm Med</MedlineTA>
            <NlmUniqueID>9503765</NlmUniqueID>
            <ISSNLinking>1070-5287</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Biological Markers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>10102-43-9</RegistryNumber>
                <NameOfSubstance>Nitric Oxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75715-89-8</RegistryNumber>
                <NameOfSubstance>Leukotriene E4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Biological Markers</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Breath Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchoalveolar Lavage</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Exhalation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene E4</DescriptorName>
                <QualifierName MajorTopicYN="N">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Nitric Oxide</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sputum</DescriptorName>
                <QualifierName MajorTopicYN="N">cytology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>74</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>17</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>17</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>28</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MCP.0b013e32831de235</ArticleId>
            <ArticleId IdType="pii">00063198-200901000-00004</ArticleId>
            <ArticleId IdType="pubmed">19077700</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19063820</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>12</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1534-6315</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Current allergy and asthma reports</Title>
                <ISOAbbreviation>Curr Allergy Asthma Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Role of leukotrienes in exercise-induced bronchoconstriction.</ArticleTitle>
            <Pagination>
                <MedlinePgn>18-25</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Exercise-induced bronchoconstriction (EIB) refers to acute airflow obstruction that is triggered by a period of physical exertion. EIB occurs mainly in individuals with other features of asthma but is especially prominent in a subset of asthmatics with pronounced indirect airway hyperresponsiveness. Leukotrienes (LTs) play a critical role in the pathophysiology of EIB. Asthmatics who are susceptible to EIB have increased levels of cysteinyl LTs (cysLTs [ie, LTs C4, D4, and E4]) in induced sputum and exhaled breath condensate. Exercise challenge in individuals susceptible to this disorder initiates the sustained increase in cysLTs in the airways and an increase in the ratio of cysLTs to prostaglandin E(2). The effects of cysLTs leading to secreted mucin release and smooth muscle constriction may be mediated in part through activation of sensory nerves. Therapies that block cysLT production or the cysLT(1) receptor effectively reduce the severity of EIB.</AbstractText>
            </Abstract>
            <Affiliation>Division of Pulmonary and Critical Care, University of Washington, Seattle, WA 98195, USA. tealh@u.washington.edu</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hallstrand</LastName>
                    <ForeName>Teal S</ForeName>
                    <Initials>TS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Henderson</LastName>
                    <ForeName>William R</ForeName>
                    <Initials>WR</Initials>
                    <Suffix>Jr</Suffix>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>AI42989</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL089215</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Curr Allergy Asthma Rep</MedlineTA>
            <NlmUniqueID>101096440</NlmUniqueID>
            <ISSNLinking>1529-7322</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Asthmatic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotriene Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>363-24-6</RegistryNumber>
                <NameOfSubstance>Dinoprostone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Asthmatic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma, Exercise-Induced</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y">Bronchoconstriction</DescriptorName>
                <QualifierName MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Constriction, Pathologic</DescriptorName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dinoprostone</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sputum</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>10</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>10</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19063820</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19054597</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>02</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>26</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-1983</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>28</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical nutrition (Edinburgh, Scotland)</Title>
                <ISOAbbreviation>Clin Nutr</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Eicosapentaenoic acid is more effective than docosahexaenoic acid in inhibiting proinflammatory mediator production and transcription from LPS-induced human asthmatic alveolar macrophage cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>71-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clnu.2008.10.012</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">The purpose of the study was to determine which of the active constituents of fish oil, eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), is most effective in suppressing proinflammatory mediator generation and cytokine expression from LPS-stimulated human asthmatic alveolar macrophages (AMphi).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The AMphi were obtained from twenty-one asthmatic adults using fiberoptic bronchoscopy. Cells were pretreated with DMEM, pure EPA, an EPA-rich media (45% EPA/10% DHA), pure DHA, a DHA-rich media (10% EPA/50% DHA) or Lipovenos (n-6 PUFA), and then exposed to Dulbecco's Modified Eagle's Medium (DMEM) (-) or LPS (+). Supernatants were analyzed for leukotriene (LT)B(4), prostaglandin (PG)D(2), tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta production. Detection of TNF-alpha and IL-1beta mRNA expression levels was quantified by reverse transcriptase polymerase chain reaction.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">120 microM pure EPA and EPA-rich media significantly (p&lt;0.05) suppressed TNF-alpha and IL-1beta mRNA expression and the production of LTB(4), PGD(2) and TNF-alpha and IL-1beta in LPS-stimulated primary AMphi cells obtained from asthmatic patients to a much greater extent than 120 microM pure DHA and DHA-rich media respectively.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study has shown for the first time that EPA is a more potent inhibitor than DHA of inflammatory responses in human asthmatic AMphi cells.</AbstractText>
            </Abstract>
            <Affiliation>Exercise Biochemistry Laboratory, Department of Kinesiology, Indiana University, Bloomington, IN 47401, USA. tmickleb@indiana.edu</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mickleborough</LastName>
                    <ForeName>Timothy D</ForeName>
                    <Initials>TD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tecklenburg</LastName>
                    <ForeName>Sandra L</ForeName>
                    <Initials>SL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Montgomery</LastName>
                    <ForeName>Gregory S</ForeName>
                    <Initials>GS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lindley</LastName>
                    <ForeName>Martin R</ForeName>
                    <Initials>MR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Clin Nutr</MedlineTA>
            <NlmUniqueID>8309603</NlmUniqueID>
            <ISSNLinking>0261-5614</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Interleukin-1beta</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Lipopolysaccharides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Tumor Necrosis Factor-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1553-41-9</RegistryNumber>
                <NameOfSubstance>Eicosapentaenoic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>25167-62-8</RegistryNumber>
                <NameOfSubstance>Docosahexaenoic Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>41598-07-6</RegistryNumber>
                <NameOfSubstance>Prostaglandin D2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>71160-24-2</RegistryNumber>
                <NameOfSubstance>Leukotriene B4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Docosahexaenoic Acids</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eicosapentaenoic Acid</DescriptorName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Inflammation</DescriptorName>
                <QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Interleukin-1beta</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotriene B4</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Macrophages, Alveolar</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Prostaglandin D2</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2008</Year>
                <Month>9</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>10</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>5</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>12</Month>
                <Day>5</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0261-5614(08)00204-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.clnu.2008.10.012</ArticleId>
            <ArticleId IdType="pubmed">19054597</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19038786</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>02</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>04</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2009</Year>
            <Month>11</Month>
            <Day>19</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1938-3673</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>85</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of leukocyte biology</Title>
                <ISOAbbreviation>J. Leukoc. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Expression of kinin receptors on eosinophils: comparison of asthmatic patients and healthy subjects.</ArticleTitle>
            <Pagination>
                <MedlinePgn>544-52</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1189/jlb.0508283</ELocationID>
            <Abstract>
                <AbstractText>Eosinophils contribute to asthmatic airway inflammation by releasing cysteinyl leukotrienes (cysLT) and other inflammatory mediators, and bradykinin (BK) induces bronchoconstriction in asthmatic patients. The aims of this study were to investigate kinin receptor expression on eosinophils of asthmatic and healthy subjects and to assess the effects of kinin stimulation on eosinophils, which were isolated from peripheral blood of asthmatic (n=27) and healthy subjects (n=14). Kinin B(1) and B(2) receptors (B(1)R and B(2)R, respectively) and mRNA expression were investigated by quantitative confocal microscopy, flow cytometry, and RT-PCR. Intracellular Ca(2+) was assessed by live-cell fluorescence confocal microscopy. Production of cysLT and eosinophil migration in response to BK and Lys-des[Arg(9)]-BK were assessed. Eosinophils expressed kinin B(1)R and B(2)R mRNA and proteins. Quantitative immunofluorescence analysis indicated that expression of B(1)R and B(2)R proteins was significantly greater in eosinophils of asthmatic patients compared with those of nonasthmatic subjects. However, kinin B(1)R and B(2)R mRNA expression did not differ significantly between these groups. Expression of kinin B(1)R and mRNA was decreased in patients using high doses of inhaled corticosteroids and in eosinophils treated with a corticosteroid in vitro. Kinin B(1) and B(2) agonists up-regulated expression of their respective receptors but did not increase intracellular Ca(2+) or the production of cysLT or enhance eosinophil migration significantly. Up-regulation of kinin receptor expression in eosinophils of asthmatic patients may be a consequence of inflammation, whereby enhanced release of kinin peptides has a positive-feedback effect on kinin receptor expression. Importantly, anti-inflammatory corticosteroids down-regulated the expression of the kinin B(1)R.</AbstractText>
            </Abstract>
            <Affiliation>Lung Institute of Western Australia, Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Australia.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bertram</LastName>
                    <ForeName>Cornelia M</ForeName>
                    <Initials>CM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Misso</LastName>
                    <ForeName>Neil L</ForeName>
                    <Initials>NL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fogel-Petrovic</LastName>
                    <ForeName>Mirjana</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Figueroa</LastName>
                    <ForeName>Carlos D</ForeName>
                    <Initials>CD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Foster</LastName>
                    <ForeName>Paul S</ForeName>
                    <Initials>PS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thompson</LastName>
                    <ForeName>Philip J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bhoola</LastName>
                    <ForeName>Kanti D</ForeName>
                    <Initials>KD</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Leukoc Biol</MedlineTA>
            <NlmUniqueID>8405628</NlmUniqueID>
            <ISSNLinking>0741-5400</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Adrenal Cortex Hormones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Kinins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Receptor, Bradykinin B1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Receptor, Bradykinin B2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7440-70-2</RegistryNumber>
                <NameOfSubstance>Calcium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Calcium</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Chemotaxis, Leukocyte</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophils</DescriptorName>
                <QualifierName MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Feedback, Physiological</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Kinins</DescriptorName>
                <QualifierName MajorTopicYN="N">agonists</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptor, Bradykinin B1</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Receptor, Bradykinin B2</DescriptorName>
                <QualifierName MajorTopicYN="N">analysis</QualifierName>
                <QualifierName MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>29</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>29</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jlb.0508283</ArticleId>
            <ArticleId IdType="doi">10.1189/jlb.0508283</ArticleId>
            <ArticleId IdType="pubmed">19038786</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19033733</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>04</Month>
            <Day>17</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>11</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1423-0097</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>149</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2009</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International archives of allergy and immunology</Title>
                <ISOAbbreviation>Int. Arch. Allergy Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cellular allergen stimulation test with acetylsalicylic acid-lysine is not a useful test to discriminate between asthmatic patients with and without acetylsalicylic acid sensitivity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>58-64</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000176307</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aspirin provocation test, considered to be the gold standard in the diagnosis of aspirin sensitivity, may be associated with severe adverse reactions; thus, alternative procedures with a higher safety profile are highly desirable. Although the cellular antigen stimulation test (CAST) has been proposed to be such an alternative, there is limited information about its clinical usefulness.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">It was the aim of our study to evaluate the clinical usefulness of CAST in the diagnosis of aspirin sensitivity.</AbstractText>
                <AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Patients with aspirin-sensitive asthma and/or nasal polyps (n = 40), patients with aspirin-tolerant asthma and/or nasal polyps (n = 13) and healthy volunteers (n = 26) were included. A 2-day, single-blind placebo-controlled oral aspirin provocation test was performed. In vitro release of cysteinyl leukotrienes (Cys-LTs) by peripheral blood leukocytes was measured after stimulation with both stimulation buffer and lysine aspirin (2.5 mg/ml) by CAST.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline Cys-LT levels were similar among the 3 groups. After lysine aspirin stimulation, the net increase in Cys-LTs was significantly higher in patients with aspirin sensitivity (median 91 pg/ml, interquartile range 22-206) compared with aspirin-tolerant patients (20 pg/ml, range 0-46) and healthy controls (23 pg/ml, range 0-71; p = 0.004). The assay had a sensitivity of 25%, a specificity of 92.3%, and positive and negative predictive values of 28.7 and 90.7%, respectively.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although the leukocytes of patients with aspirin sensitivity produce higher amounts of Cys-LTs as measured by CAST, the low sensitivity and predictive values limit the clinical usefulness of this test in the diagnosis of aspirin sensitivity.</AbstractText>
                <CopyrightInformation>2008 S. Karger AG, Basel.</CopyrightInformation>
            </Abstract>
            <Affiliation>Department of Allergy, Ankara University, Turkey. bavbek@medicine.ankara.edu.tr</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bavbek</LastName>
                    <ForeName>Sevim</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dursun</LastName>
                    <ForeName>A Berna</ForeName>
                    <Initials>AB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Birben</LastName>
                    <ForeName>Esra</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kalayci</LastName>
                    <ForeName>Omer</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Misirligil</LastName>
                    <ForeName>Zeynep</ForeName>
                    <Initials>Z</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Evaluation Studies</PublicationType>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Int Arch Allergy Immunol</MedlineTA>
            <NlmUniqueID>9211652</NlmUniqueID>
            <ISSNLinking>1018-2438</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Allergens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>37933-78-1</RegistryNumber>
                <NameOfSubstance>acetylsalicylic acid lysinate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>50-78-2</RegistryNumber>
                <NameOfSubstance>Aspirin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>56-87-1</RegistryNumber>
                <NameOfSubstance>Lysine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Allergens</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aspirin</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">complications</QualifierName>
                <QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Hypersensitivity</DescriptorName>
                <QualifierName MajorTopicYN="N">complications</QualifierName>
                <QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Immunologic Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukocytes</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="Y">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Lysine</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">000176307</ArticleId>
            <ArticleId IdType="doi">10.1159/000176307</ArticleId>
            <ArticleId IdType="pubmed">19033733</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19001792</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>03</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>04</Month>
            <Day>16</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1423-0097</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>148</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2009</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International archives of allergy and immunology</Title>
                <ISOAbbreviation>Int. Arch. Allergy Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of n-3 polyunsaturated fatty acids in asthma after low-dose allergen challenge.</ArticleTitle>
            <Pagination>
                <MedlinePgn>321-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000170386</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We investigated the anti-inflammatory potential of n-3 polyunsaturated fatty acids (PUFA) on specific bronchial inflammation. Allergic asthmatics were challenged using a low-dose allergen provocation model.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Our parallel double-blinded study randomly assigned 23 house dust mite-allergic asthmatics (aged 22-29 years; 13 females, 10 males) to dietary supplementation with either an n-3 PUFA-enriched fat blend (0.69 g/day) or placebo for 5 weeks. After 3 weeks, the patients were challenged daily with low doses of mite allergen for 2 weeks. Primary outcome parameters were effects on lung function (forced expiratory volume in 1 s, FEV(1)) and exhaled nitric oxide (eNO) as a marker of bronchial inflammation.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Even before the bronchial challenge, eNO was significantly lower in the n-3 PUFA group (p=0.014). Levels of eNO increased during allergen exposure in both groups, but differences in means were significantly lower in the n-3 PUFA group (p=0.022). During the low-dose allergen challenge, there were no differences between the groups with regard to symptoms, FEV(1) or the allergen dose required to induce deterioration of lung function (PD(20)). Numbers of sputum eosinophils did not differ significantly, while serum eosinophils (10.1+/-0.1.84 vs. 5.79+/-0.69%) as well as changes in eosinophilic cationic protein (20.5+/-9.93 vs. -1.68+/-4.36 ng/ml) and in vitro cysteinyl leukotriene release (2,889+/-872 vs. 1,120+/-173 ng/ml) were significantly lower in the n-3 PUFA group (p&lt;0.05 each).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results provide evidence that dietary supplementation with n-3 PUFA is able to reduce bronchial inflammation even after low-dose allergen challenge.</AbstractText>
                <CopyrightInformation>Copyright 2008 S. Karger AG, Basel.</CopyrightInformation>
            </Abstract>
            <Affiliation>Department of Pediatrics/ZAFES, J.W. Goethe University, Frankfurt/Main, Germany.</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Schubert</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kitz</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beermann</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rose</LastName>
                    <ForeName>M A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lieb</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sommerer</LastName>
                    <ForeName>P C</ForeName>
                    <Initials>PC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moskovits</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alberternst</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bhles</LastName>
                    <ForeName>H J</ForeName>
                    <Initials>HJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schulze</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zielen</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Randomized Controlled Trial</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Int Arch Allergy Immunol</MedlineTA>
            <NlmUniqueID>9211652</NlmUniqueID>
            <ISSNLinking>1018-2438</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antigens, Dermatophagoides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Fatty Acids, Omega-3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>cysteinyl-leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>10102-43-9</RegistryNumber>
                <NameOfSubstance>Nitric Oxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>52-90-4</RegistryNumber>
                <NameOfSubstance>Cysteine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antigens, Dermatophagoides</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y">diet therapy</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Breath Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Bronchial Provocation Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cell Count</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cysteine</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophils</DescriptorName>
                <QualifierName MajorTopicYN="N">cytology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Erythrocytes</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Forced Expiratory Volume</DescriptorName>
                <QualifierName MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukocyte Count</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukocytes</DescriptorName>
                <QualifierName MajorTopicYN="N">cytology</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Nitric Oxide</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Sputum</DescriptorName>
                <QualifierName MajorTopicYN="N">cytology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>3</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>6</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>17</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">000170386</ArticleId>
            <ArticleId IdType="doi">10.1159/000170386</ArticleId>
            <ArticleId IdType="pubmed">19001792</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18849616</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>02</Month>
            <Day>16</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>03</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2011</Year>
            <Month>11</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1423-0097</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>148</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International archives of allergy and immunology</Title>
                <ISOAbbreviation>Int. Arch. Allergy Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>251-60</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000161585</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cluster specific immunotherapy (SIT) is a modern form of allergen immunotherapy allowing safe administration of high allergen doses in a short time interval compared to classic SIT. In the current study, we investigated the safety profile and immunological effect of cluster SIT in children with allergic asthma due to house dust mite allergy.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 34 children (6-18 years) with allergic asthma were assigned to cluster (n = 22) or classic SIT (n = 12). To achieve a maintenance dose of allergen extract, cluster patients received 14 injections of house dust mite allergen within 6 weeks, whereas the classic SIT group received 14 injections within 14 weeks. Safety was monitored by recording adverse events. Immunogenicity was measured by specific IgG(Mite) and IgG4(Mite), by antibody-blocking properties on basophil activation, and by the T cell subset transcription factors Foxp3, T-bet, and GATA-3.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no significant differences in local and systemic side effects between the two groups. In the cluster group, serum levels of specific IgG(Mite) (p &lt; 0.001) and specific IgG4(Mite) (p &lt; 0.001) significantly increased after 8 weeks, while it took 12 weeks in the classic SIT group. These data were confirmed by blocking CD63 expression as well as release of cysteinyl leukotrienes after in vitro basophil stimulation. No differences in transcription factor expression were found in the two groups.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Cluster SIT is safe in children. Additionally, our data demonstrated an even more rapid induction of specific immune tolerance. Cluster SIT is an attractive alternative to conventional up-dosing schedules with fewer consultations for the patients.</AbstractText>
                <CopyrightInformation>(c) 2008 S. Karger AG, Basel.</CopyrightInformation>
            </Abstract>
            <Affiliation>Paediatric Pulmonology and Allergology, Department of Internal Medicine III, J.W. Goethe University, Frankfurt am Main, Germany. ralf.schubert@kgu.de</Affiliation>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Schubert</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eickmeier</LastName>
                    <ForeName>O</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garn</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baer</LastName>
                    <ForeName>P C</ForeName>
                    <Initials>PC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mueller</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schulze</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rose</LastName>
                    <ForeName>M A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosewich</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Renz</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zielen</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>10</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Int Arch Allergy Immunol</MedlineTA>
            <NlmUniqueID>9211652</NlmUniqueID>
            <ISSNLinking>1018-2438</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antigens, CD</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antigens, CD63</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Antigens, Dermatophagoides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Arthropod Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>CD63 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>FOXP3 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Forkhead Transcription Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>GATA3 Transcription Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>GATA3 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Immunoglobulin G</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Platelet Membrane Glycoproteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>T-Box Domain Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>T-box transcription factor TBX21</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>10102-43-9</RegistryNumber>
                <NameOfSubstance>Nitric Oxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>37341-29-0</RegistryNumber>
                <NameOfSubstance>Immunoglobulin E</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.27.-</RegistryNumber>
                <NameOfSubstance>Eosinophil Cationic Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.27.-</RegistryNumber>
                <NameOfSubstance>RNASE3 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.22.-</RegistryNumber>
                <NameOfSubstance>Cysteine Endopeptidases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.22.-</RegistryNumber>
                <NameOfSubstance>Dermatophagoides pteronyssinus antigen p 1</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antigens, CD</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antigens, CD63</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Antigens, Dermatophagoides</DescriptorName>
                <QualifierName MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Arthropod Proteins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Basophils</DescriptorName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Breath Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Desensitization, Immunologic</DescriptorName>
                <QualifierName MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Eosinophil Cationic Protein</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Forkhead Transcription Factors</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">GATA3 Transcription Factor</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Gene Expression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Hypersensitivity</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
                <QualifierName MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Immunoglobulin E</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Immunoglobulin G</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
                <QualifierName MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Nitric Oxide</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Platelet Membrane Glycoproteins</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">T-Box Domain Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">T-Lymphocytes</DescriptorName>
                <QualifierName MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>6</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>10</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>10</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>10</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>10</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">000161585</ArticleId>
            <ArticleId IdType="doi">10.1159/000161585</ArticleId>
            <ArticleId IdType="pubmed">18849616</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
